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ABSTRACT
Background: Inflammation plays a pivotal role in pancreatic cancer etiology and
can be modulated by diet. We aimed to examine the association between inflammatory
potential of diet, assessed with the Dietary Inflammatory Index (DIITM), and pancreatic
cancer risk in two prospective cohorts, the Prostate, Lung, Colorectal and Ovarian
(PLCO) Cancer Screening Trial and the National Institutes of Health American
Association of Retired Persons (NIH-AARP) Diet and Health Study. We explored effect
modification by important inflammation-related lifestyle factors, and investigated
whether type-2 diabetes mediated the association in a pooled analysis of both studies.
Methods: A total of 101,449 and 533,286 participants aged between 50 to 78 years at
baseline were included in the analytical cohort of PLCO and NIH-AARP, respectively.
Energy-adjusted DII (E-DII) scores were computed based on food and supplement intake.
Multivariable-adjusted Cox proportional hazards models were used to estimate hazard
ratios (HRs) and 95% confidence intervals (CIs) for pancreatic cancer by E-DII quintiles
with participants in the lowest E-DII quintile (most anti-inflammatory scores) as the
referent. We estimated natural direct effect, natural indirect effect, and marginal total
effect of both categorical and continuous E-DII scores on pancreatic cancer with type-2
diabetes as a mediator using causal mediation approach. Results: A total of 328 and
3,338 pancreatic cancer cases were identified in the PLCO and NIH-AARP, respectively.
There was no significant association between dietary inflammatory potential and
pancreatic cancer risk in either the PLCO or NIH-AARP. However, time significantly
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modified the association in PLCO (P-interaction=0.02). An inverse association in the first
four years of follow up was observed (HRQ5vsQ1=0.55; 95% CI=0.32-0.95; P-trend=0.15),
while there was a positive trend among those with ≥4 years of follow-up (HRQ5vsQ1
=1.36; 95% CI=0.85-2.17; P-trend=0.03). Type-2 diabetes significantly mediated the EDII and pancreatic cancer association (P<0.05). Conclusion: Findings from these two
large prospective cohorts did not support the association between inflammatory potential
of diet and pancreatic cancer risk. Reverse causality owing to undetected disease may
account for the inverse association observed in the first four years of follow-up in the
PLCO. Type-2 diabetes explained an underlying mechanism through dietary
inflammatory potential to pancreatic cancer development.
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CHAPTER 1
INTRODUCTION
1.1

Statement of the problem
Pancreatic cancer is the fourth leading cause of cancer mortality in the United

States among both men and women and has the highest case-fatality rate among major
cancers with 7% 5-year survival rate for all stages combined.1,2 Most pancreatic cancer
(95%) are cancers of the exocrine pancreas, which produces enzymes to digest food.
Neuroendocrine tumors (5%) are much rarer, and have a younger median age at diagnosis
and better prognosis than exocrine pancreatic cancer.1 Because there is so far no reliable
screening method for early detection, pancreatic cancer is often diagnosed at an advanced
stage when survival statistics are even worse (2% 5-year survival for patients diagnosed
at distant stage).1 Thus, identifying modifiable risk factors for pancreatic cancer is an
important strategy for reducing the burden of this disease.3 The main risk factors include
age, cigarette smoking, diabetes, family history, obesity, and chronic pancreatitis, though
taken together these risk factors do not explain all of the risk for this malignancy.4 There
is biologic evidence showing chronic inflammation is related to pancreatic cancer
development, and substantial amount of studies support that some dietary factors could
increase cancer incidence or mortality risk through modulating inflammation.5 Thus,
understanding the effect of dietary inflammatory potential on pancreatic cancer
development may help guide dietary intervention strategies and clinical guidelines for
preventing this cancer.
1

Many dietary factors, such as saturated fat and fruits and vegetables, have been
shown to affect inflammation through pro-inflammatory or anti-inflammatory
mechanisms. A Western style diet characterized by greater intake of pro-inflammatory
foods which are high in sugar, refined grains, red and processed meats, and fried foods
can increase pro-inflammatory biomarkers such as C-reactive protein (CRP), interleukin6 (IL-6) and tumor necrosis factor alpha (TNF-α).6 In contrast, the Mediterranean diet,
high in whole-grains, fruit, green vegetables, and fish, and low in red meat and butter,
with moderate alcohol and olive oil intake, has been associated with reduced chronic
inflammation.7-9 However, most often nutrients or dietary components have been studied
separately for their potential association with pancreatic cancer and inconsistent results
have been found.10-12 A dietary pattern approach, which takes into account the complex
interactions among dietary components, has advantages over individual foods or nutrients
when being studied for associations with disease risk.13 Given the fact that no nutrient is
consumed alone but in conjunction with other nutrients or non-nutrient components of
food, several dietary patterns or indices such as the Healthy Eating Index (HEI)14 have
been studied in relation to PanC.15-21 However, these dietary indices are limited by the
relatively small numbers of dietary components and lack of focus on specific biologic
pathways for explaining their mechanism. Until the dietary inflammatory index (DII™)
was developed based on extensive review of research articles published through 2010 on
the effect of dietary parameters on six well established inflammatory markers (IL-1β, IL4, IL-6, IL-10, TNF- α and CRP),22 none of these a priori indices had focused on
inflammation as a main mechanism explaining diet’s effects on disease. The DII
calculated with dietary data from different dietary assessment tools has been construct-

2

validated where higher DII scores (representing more pro-inflammatory diets) were found
to be positively associated with higher inflammatory biomarker levels.23-30 Higher DII
scores also have been associated with increased risk of different types of cancer in
multiple studies.31-33,34-37
Given the role of inflammation in pancreatic carcinogenesis, a dietary index with
inflammation as the underlying biological mechanism and which assesses the
inflammatory potential of the entire diet, has advantages for its potential association with
pancreatic cancer compared to other dietary patterns focused solely on a specific food
item or more general dietary guidelines. Among the literature, only two case-control
studies have examined the association between the DII and pancreatic cancer. One study
conducted in Italy between 1991 and 2008 with 326 incident cases and 652 controls
reported a positive association between the DII and pancreatic cancer.38 Another casecontrol study with 817 cases and 1,756 controls in the US by Antwi et al. reported a 2.54fold excess odds of pancreatic cancer among subjects in the highest quintile of DII
compared to those in the first quintile (odds ratio (OR)Q5vsQ1=2.54, 95% confidence
interval (CI)=1.87-3.46, P-trend<0.0001).39 Given the possibility of selection bias and
inextricable recall bias of diet measurement in case-control studies, a prospective cohort
study design may be a more appropriate study design compared to case-control design on
this research topic.
Although two case-control studies found a significant positive association
between dietary inflammatory potential and pancreatic cancer, little is known about the
mechanism underlying the pathway from dietary inflammatory potential to pancreatic
cancer development. Type-2 diabetes has been shown to have a positive relationship with
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pancreatic cancer. Recent data from pooled analyses reported concordant findings,
showing that diabetics had 40% to 90% increased pancreatic risk compared to nondiabetics.40,41 Given the strong positive association between type-2 diabetes and
pancreatic cancer and the inflammatory nature of diabetes,42 type-2 diabetes may play a
role as a mediator linking the dietary inflammatory potential to pancreatic cancer
development.
1.2

Purpose and objectives
We used data from two large, nationally representative, prospective cohort studies

[i.e. the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and the
National Institutes of Health American Association of Retired Persons (NIH-AARP) Diet
and Health Study] with rich dietary and other comprehensive covariate information to
examine the inflammatory potential of diet and pancreatic cancer association in a
prospective manner. We also investigated effect modification by inflammation-related
lifestyle factors including body mass index (BMI), cigarette smoking, alcohol drinking,
diabetes history, and non-steroidal anti-inflammatory drug (NSAIDs) use. As it is unclear
whether diets with high inflammatory potential increase the risk of pancreatic cancer
through occurrence of type-2 diabetes mellitus, we also conducted a causal mediation
analysis with combined PLCO and NIH-AARP data to examine whether incident type-2
diabetes was playing a role as a mediator in the causal pathway between dietary
inflammatory potential and pancreatic cancer and if so, what was the mediation
proportion of diabetes. Our three specific aims were as follows:
Aim 1: Examine the association between inflammatory potential of diet and
pancreatic cancer in the PLCO and examine effect modification by sex and BMI.
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PLCO is a randomized controlled trial with the aim to assess if cancer screening tests can
reduce cancer mortality.43 Briefly, a total of 154,897 eligible participants (76,682 men
and 78,215 women), aged 55–74 years, were enrolled into the trial from 1993 to 2001
from ten centers across the US and randomized based on sex and age group into either a
control arm (77,453 participants) where usual care was received, or an intervention arm
(77,444 participants) where screening exams for prostate, lung, colorectal or ovarian
cancers were received.44 In general, a majority of recruited participants were nonHispanic white, married or living as married, had higher education level than some
college, were overweight at baseline, and above 85% of female participants were
postmenopausal.45 We calculated the energy-adjusted DII (E-DII) score for each subject
using dietary data from the Diet History Questionnaire (DHQ) and calculated BMI at
baseline to examine its effect modification on the E-DII and pancreatic cancer
relationship. We hypothesized that higher E-DII scores were associated with higher risk
of developing pancreatic cancer and that associations were stronger among males and
overweight or obese subjects.
Aim 2: Examine the association between inflammatory potential of diet and
pancreatic cancer in the NIH-AARP and examine effect modification by sex and
inflammation-related lifestyle factors including BMI, cigarette smoking, alcohol
drinking, diabetes history, and NSAIDs use. The NIH-AARP Diet and Health Study
was initiated to examine a number of important diet and cancer hypotheses. The initial
study population of this cohort was 567,169 eligible study participants (340,148 men and
227,021 women) after excluding respondents whose responses on the questionnaire were
not reliable. Participants were 50 to 71 years old with mean age of 62 years at baseline
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and lived in one of six states (California, Florida, Pennsylvania, New Jersey, North
Carolina, or Louisiana) or two metropolitan areas (Atlanta, Georgia or Detroit,
Michigan).46 Participants are predominantly white and have higher education level than
the general US population. The percentage of current smokers in the NIH-AARP are
lower than national estimates.47,48 We hypothesized that a pro-inflammatory diet (i.e.,
higher E-DII score) was associated with increased risk of pancreatic cancer. As more
pancreatic cancer cases were available in the NIH-AARP dataset than the PLCO, we a
priori proposed to examine more effect modifiers in these analyses than in Aim 1,
including sex, BMI, cigarette smoking, alcohol drinking, diabetes history, and NSAIDs
use. We hypothesized that males, overweight or obese individuals, individuals with
previous smoking history, high level of alcohol drinking, those who had presence of
diabetes history, or less frequent NSAIDs use would have an enhanced effect of E-DII on
pancreatic cancer risk compared to their counterparts.
Aim 3: Investigate causal mediation by type-2 diabetes in the association
between inflammatory potential of diet and pancreatic cancer in PLCO and NIHAARP pooled analysis. We first conducted a causal mediation analysis to investigate the
causal mediated effect of type-2 diabetes on the pathway from E-DII to pancreatic cancer
risk in PLCO and NIH-AARP studies separately. Given that PLCO and NIH-AARP
studies had very similar food frequency questionnaire (FFQ) and other covariate
information as well as study population demographics, and for the purpose of increasing
pancreatic cancer cases and incident type-2 diabetes cases, we combined primary data
from these two cohorts into a single dataset after demonstrating that there was no
significant heterogeneity between two studies. We hypothesized that incident type-2
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diabetes played a role as a mediator in the DII and pancreatic cancer association in both
cohorts and the pooled analyses.
1.3

Significance and relevance of the dissertation research

1.3.1

Public health and clinical impact

Pancreatic cancer is a highly malignant cancer with low survival chance and no reliable
screening method. Findings from this dissertation had both clinical and public health
significance. Quantifying the effect of inflammatory potential of diet on pancreatic cancer
risk and the interactive effects of important inflammation-related lifestyle factors is
crucial, not only for healthy people who may reduce their chance of developing
pancreatic cancer through modulating dietary inflammation, but also important for those
who are already at risk of this malignancy such as obese or diabetic individuals. By
elucidating the role that type-2 diabetes may play in the pathway of DII and pancreatic
cancer, we may better understand the mechanism through which dietary inflammatory
potential could lead to development of pancreatic cancer. Findings of mediation analyses
also may provide clinical evidence and guidance to identify possible intermediate
biomarkers to screen high risk population of developing pancreatic cancer, especially for
those who consume more pro-inflammatory diets. In addition, it could help with the
design and guidance of an effective dietary intervention to reduce risk of pancreatic
cancer through intervening on type-2 diabetes.
1.3.2

Scientific relevance or significance
This dissertation work was significant in the following aspects: (1) Use of data

from two large, well-characterized prospective cohorts minimized the recall and selection
bias that may exist in a typical case-control study. Aims 1 and 2 were the first two studies
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to investigate the inflammatory potential of diet and pancreatic cancer association in a
prospective manner with adequate number of pancreatic cancer cases and with
comprehensive dietary factors and covariates assessed before pancreatic cancer onset; (2)
the joint effect of E-DII and other common inflammation-related lifestyle factors on
pancreatic risk was examined in a prospective study for the first time, and (3) this was the
first mediation analysis with the method of pooling studies to examine the mediated
effect of type-2 diabetes on the pathway from DII to a cancer endpoint.
1.4

Dissertation outline
Chapter 1 provides a brief overview of the problem of interest with an

introduction to the relationships between diet/dietary patterns and inflammation, and
between inflammation and pancreatic cancer. We also present the tentative scope of the
dissertation: three aims with respective hypothesis. Chapter 1 concludes with the clinical
and public health relevance of the dissertation as well as scientific significance. Chapter 2
provides a detailed overview of the previous literature with aspects related to the
dissertation work including the biological mechanisms of chronic inflammation and
pancreatic cancer; biological and epidemiological perspectives of the association between
dietary factors and inflammation; an overview of dietary patterns research and
introduction to a few a priori dietary patterns; and current evidence of risk factors for
pancreatic cancer as well as summary of study results related to diet and pancreatic
cancer risk in the PLCO and NIH-AARP. Chapter 3 provides a description of the
methods used for each aim which includes study population description, variable
information, and statistical analysis methods. Chapters 4 to 6 include detailed
manuscripts for each aim. Chapter 7 is the synthesis and discussion for my overall
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dissertation.
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CHAPTER 2
2

2
BACKGROUND

2.1

Relationship between chronic inflammation and pancreatic cancer

2.1.1

Biological mechanism for chronic inflammation and cancer
Inflammation, a crucial function of the innate immune system, protects against

pathogens and initiates specific immunity.49 Acute inflammation is a rapid and selflimiting process during which chemical mediators are induced in a tightly regulated
sequence, and immune cells move in and out of the affected area, destroying infectious
agents, repairing damaged tissue, and initiating a specific and long-term response to the
pathogen.49 Acute inflammation is not regarded as a risk factor for the development of
neoplasia, although many of the same molecular mediators are generated in both acute
and chronic inflammation.50 Frequent acute inflammation results in unresolved wound
healing with consequent chronic inflammation. Chronic inflammation could be caused by
a variety of factors, including bacterial, viral, and parasitic infections, chemical irritants,
and non-digestible particles. Chronic exposure to inflammatory mediators including
metabolites of arachidonic acid, cytokines, chemokines, and free radicals leads to
increased cell proliferation, mutagenesis, oncogene activation, and angiogenesis. The
ultimate result is the proliferation of cells that have lost normal growth control.50 Several
lines of evidence, including general or cell-specific gene inactivation and populationbased studies, support the view that inflammation plays an important role in cancer
causation which include the following: (1) many cancers arise at sites of chronic
10

inflammation, and chronic inflammation increases cancer risk, (2) immune cells with the
function to mediate chronic inflammation are found in cancers and they promote growth
of tumor, (3) cancers could produce chemical mediators that regulate inflammation, (4)
development of experimental cancers are inhibited after deletion or inhibition of
inflammatory mediators, (5) genetic variation of inflammatory genes can alter
susceptibility to and severity of cancer, and (6) the long term use of NSAIDs reduces the
risk of some cancers.49 The types of chronic inflammation that lead to cancer are varied.
In some cases, the inflammation initiation factors are known which may include chronic
bacterial and parasitic infections, chemical irritants, and non-digestible particles. In
animal cancer models, these cells and mediators of chronic inflammation act as tumor
promoters for malignant progression of Barrett’s esophagus and esophageal cancer,51
inflammatory bowel disease,52 gastric cancer,53 liver cancer54 and colon cancer.55 In other
cases, the underlying cause of the chronic inflammation is complex due to the diversity of
inflammatory reactions that is dictated by the primary stimulus as well as by exogenous
and endogenous modifying signals.49 At one end of the spectrum, type 1 inflammation,
characterized by granuloma formation, is elicited by intracellular pathogens. At the other
extreme, inflammatory reactions to parasites are characterized by eosinophil and mast
cell infiltration and by extensive tissue remodeling (type 2 inflammation).49
More recently, the role of inflammation in cancer development was highlighted
by Brucher and Jamall who proposed a new paradigm for the epistemology of the origin
of cancer.56 They stated that less than 10% of all cancers are hereditary. According to
their view, the origin of cancer follows a sequence of events beginning with (1) a
pathogenic stimulus which can be biologic or non-biologic (including diet), (2) followed
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by chronic inflammation from which fibrosis develops, with associated changes in the
cellular microenvironment if the inflammation does not resolve, (3) a pre-cancerous niche
then develops which triggers a chronic stress escape strategy that transforms a normal
cell to a cancer cell if the chronic stress does not resolve.56 Based on this hypothesis, we
have a better chance to reduce cancer burden in the nation should we intervene to reduce
chronic inflammation which may be triggered by potentially modifiable risk factors such
as diet.
2.1.2

Relationship between chronic inflammation and pancreatic cancer

development
Inflammation has been identified as a significant factor in the development of
solid tumor malignancies including pancreatic cancer. Both hereditary and sporadic
forms of chronic pancreatitis are associated with an increased risk of developing
pancreatic cancer.57 The combined increase in genomic damage and cellular proliferation,
both of which are involved with inflammation, transform normal pancreatic cells to a
malignancy. Cytokines, reactive oxygen species, and mediators of the inflammatory
pathway (e.g., nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2)) have been
shown to increase cell cycling, cause loss of tumor suppressor function, and stimulate
oncogene expression, all of which may lead to pancreatic malignancy.57 Like other tumor
types, pancreatic cancer has been shown to overexpress COX-2, a modulatory molecule
in inflammation and carcinogenesis which has been implicated in the positive regulation
of growth and tumorigenesis.58 Systemic low-grade chronic inflammation in addition to
local inflammation in the pancreas is involved in the pathogenesis of pancreatic
cancer.57,59,60 Using laser-capture microdissection (LCM), gene array, and
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immunohistochemistry, some researchers found the potential inflammatory components
in epithelial and stromal cells that may contribute to both chronic pancreatitis and
pancreatic cancer, illustrated as follows: (1) increased expression of IL-8, an activator of
the inflammatory factor NF-κB, (2) decreased expression of IκB (an inhibitor of NF-κB)
in chronic pancreatitis ductal cells compared with normal ducts, (3) increased expression
of tumor related genes including S100A4, cyclin E1, and epidermal growth factor (EGF)
receptor, and (4) expression of matrix metalloproteinase 2, a pro-invasive factor for
tumor cells.61
Epidemiology studies have reported associations between certain chronic
inflammatory biomarkers and pancreatic cancer risk with inconsistent results. Several
hospital-based case–control studies showed that CRP levels, an acute phase protein
produced in the liver which is part of the systemic inflammatory response to the tumor,
were significantly higher in pancreatic cancer cases compared with controls.62-64 In
addition, serum levels of IL-6 and TNF-α have been repeatedly reported in several casecontrol studies to be significantly higher among pancreatic cancer patients than healthy
controls. 62-66 One study also found significantly higher levels of IL-8 and macrophage
inflammatory protein-3α in sera of pancreatic adenocarcinoma patients compared to
healthy controls.67 However, two nested case-control and two prospective cohort studies
reported no association or weak inverse associations between pre-diagnostic CRP and
pancreatic cancer,68-71 while three studies have reported positive point estimates.69-71 Only
one study examined pre-diagnostic IL-6 and TNF-α receptor levels in relation to
pancreatic risk, and neither biomarker was reported to be significantly associated with
pancreatic cancer.69 The inconsistent results across studies may be due to differences in

13

study designs, populations, different confounding factors, or statistical power.
Other evidence that supports a relationship between inflammation and pancreatic
cancer is demonstrated by NSAID’s effect to reduce its risk. One meta-analysis involving
7,252 pancreatic cancer cases and more than 120,0000 healthy control subjects showed
that high-dose aspirin intake was marginally associated with decreased risk for pancreatic
cancer in the overall analysis (OR=0.88, 95% CI=0.76-1.01) and stratified analysis for
Americans showed a similar result (OR=0.82, 95% CI=0.65-1.02).72
2.2

Relationship between diet and chronic inflammation

2.2.1

Biological mechanisms linking diet and chronic inflammation
Dietary factors have consistently been shown to affect inflammation, through both

pro-inflammatory and anti-inflammatory mechanisms. Dietary components that are
beneficial against carcinogens seem to have multiple mechanisms of action and many
share a common mechanism of reducing inflammation, often via the NF-κB pathway.73
NF-κB is a transcription factor that activates expression of multiple genes related to
inflammation and is also upregulated in response to oxidative stress.74 Another wellaccepted mechanism for a protective effect of diet against inflammation is that healthy
diets can reduce obesity and insulin resistance75 which are factors likely to initiate
inflammation,76,77 and decrease oxidative damage78 and change gene expression.79 Many
dietary components in mammals including folate, vitamin B6, vitamin B12, betaine,
methionine and choline can induce changes in deoxyribonucleic acid (DNA) methylation.
79

A lot of dietary factors including fruits and vegetables,80,81 isoflavones (such as

genistein and diadzein),82,83 flavonols (such as kaempferol and quercetin),84 stilbenes,85
curcumin,86 isothiocyanates,87 and omega-3 fatty acids88 have been shown to have anti-
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cancer ability though decreasing pro-inflammatory cytokines, suppressing the activity of
NF-κB, or promoting antioxidant defense.
2.2.2

Relationship between individual dietary factors and chronic inflammation
Several studies have investigated the association between an individual dietary

factor and inflammatory biomarkers. Factors that were reported to be associated with
lower inflammation levels included fruits and vegetables,89-91 omega-3 polyunsaturated
fatty acids (PUFAs),92-94 fiber,95,96 whole grains,97-99 moderate alcohol intake,100,101
vitamin E,102,103 vitamin C,102,104 β-carotene,102,105,106 anthocyanin and flavonols.107 On
the contrary, some dietary factors were observed to be related to higher inflammation
levels which included saturated fat,108,109 high daily intake of carbohydrate from honey,
sucrose, or high-fructose corn syrup,110 high dietary glycemic index (GI) and/or glycemic
load (GL),111-113 animal protein and meat protein, as well as total protein intake within an
energy-restricted diet.114
2.2.3

Relationship between dietary patterns and chronic inflammation

2.2.3.1 An overview of dietary pattern research and different types of dietary
patterns
The traditional nutritional epidemiological studies usually focused on the relation
between specific nutrients, food items, or food groups and disease, but people consume a
wide variety of food items, not isolated nutrients or foods. Additionally, impacted by
different living environmental conditions, religions, personal preferences, food
availability, economical statuses and many other cultural factors, people may have
culture-specific dietary patterns. Dietary pattern research thus provides a more
comprehensive scope to examine diet-disease associations than an individual food or
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nutrient approach. The dietary pattern approach has several advantages over the
traditional individual food/nutrient approach which have been discussed as follows:115-120
(1) biologically, nutrients may interact with each other via impacting bioavailability and
absorption; single nutrient-based research does not consider the complex interactions
among nutrients; (2) increased consumption of one food item may be always associated
with reduced consumption of other food items since the total energy intake is considered
to be stable; (3) many nutrients, especially macronutrients such as fat, and total energy
are highly correlated and studying their separate effects may produce a collinearity issue
in the statistical model; (4) the effect of a single nutrient may be too small to be detected
but the cumulative effects of multiple nutrients in a dietary pattern may be sufficiently
large to be identified; (5) analysis of individual nutrients may be confounded by dietary
patterns; and (6) analysis of a large number of individual nutrients or food groups may
produce significant associations simply by chance.
There are basically two broad categories of dietary pattern approach: the a priori
dietary pattern which is also known as index-based or score-based dietary pattern, and the
a posteriori dietary pattern which is also known as a data-driven approach. Both indexbased and data-driven dietary patterns take into account the whole diet instead of a single
nutrient, thus overcoming most limitations of single nutrient research, and results are
more meaningful and interpretable. There are both strengths and limitations of each
approach. The index-based approach is analytically simple to compute, and easily
reproducible and can be comparable across different studies because it provides a
standardized assessment of a set of recommendations which allows researchers to define
criteria exactly the same way.13 However, scores that dichotomize components (met or
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not met) do not consider the full range of amount of foods consumed. Those that include
a range of points for each component do consider variability in intake of foods but not
amounts at the extremes. The scoring algorithm of the index is based on the underlying
dietary guidelines, which are generally not targeted at certain type of disease. Subjectivity
may be introduced during index construction in terms of the selection of foods for
inclusion, number of foods or nutrients being selected, scoring algorithm, and
interpretation of the result. Also, the equally weighted diet components implies that each
component is equally related to health, which may not be the case.115
The data-driven methods can be broadly grouped into two categories: data-driven,
outcome independent and data-driven, outcome dependent.13 Factor analysis and cluster
analysis are two data-driven, outcome independent methods to identify dietary patterns,
because both are derived from analysis of dietary data (factor analysis examines
correlations between food group variables and finds linear combinations of those
variables that explain overall variance in the data so it is a continuous variable; and
cluster analysis identifies clusters of individuals with similar dietary patterns according to
food groups defined by investigator so it is a categorical variable) and both are derived
independent of their potential relationship to a health outcome. Therefore, the resulting
factors or clusters may be significantly associated with a health outcome, but the
interpretation does not mean that this factor or cluster necessarily represents the dietary
pattern most associated with disease. Another limitation of factor analysis is subjectivity
introduced at multiple levels including food groups determination, the number of factors,
names of the factors (often called patterns), and treatment of input items (e.g., whether to
use grams, servings, percent energy or standardized intake). Unless methods of collecting
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the data are comparable and food group construction is standardized, results are not
comparable across studies.13 In addition, factors are not mutually exclusive and therefore
do not represent the entire eating pattern for a group of individuals. Another challenge
both factor and cluster analysis face is that the population under study can dramatically
affect results because patterns are derived based on data variability under the study
population. It is almost unlikely that the exact same pattern could be identified by using
another population, therefore generalizability of the results and reproducibility is
necessarily limited.13 Reduced rank regression (RRR) and classification and regression
tree analysis (CART) are two data-driven, outcome dependent methods. RRR is typically
used to identify combinations of food that explain the most variation in a set of
intermediate health biomarkers and in subsequent confirmatory analysis it links the
pattern to the outcome of interest. CART is an emerging method and it makes
determinations in stepwise fashion, first determining which dietary component explains
the most variation in the health outcome and then determining which component explains
the next most variation based on value for the initial component, until the last component
is reached. Results from RRR and CART are reproducible across studies to the extent
that study population exhibit the same relationship between diet and health outcome.13
Regarding the relationship of dietary patterns and inflammation, the Western-type
diet, which is typically defined as high in refined grains, red and processed meat, high-fat
dairy, sweets and desserts, fries and soft drinks has been associated with higher levels of
CRP and IL-6.6,121-124 In a cross-sectional study with 486 healthy Iranian women, higher
Western pattern score was associated with elevated CRP (beta=0.08, P<0.001), serum
amyloid A (SAA) (beta =0.11, P<0.05), and IL-6 (P<0.001).124 In contrast, the
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Mediterranean diet, which is high in whole-grains, fruit and green vegetables, fish, low in
red meat and butter, with moderate alcohol and olive oil intake, has been associated with
lower levels of inflammatory biomarkers, such as CRP,125-127 IL-6,128, IL-8,127 and IL10.129
As my dissertation focuses on an a priori dietary pattern as exposure, I mainly
describe in the following sub-sections a few selected well-established a priori dietary
patterns including introduction of each dietary pattern’s scoring algorithm and its
association with inflammatory biomarkers and some disease outcomes.
2.2.3.2 Healthy Eating Index
The HEI was developed by the US Department of Agriculture (USDA) to
measure concordance with the Dietary Guidelines for Americans (DGA) and the Food
Guide Pyramid.130 The overall structure of HEI included 10 components: five food
groups (grains, vegetables, fruits, milk and meat), four nutrients (percent energy from
total fat, percent energy from saturated fat, cholesterol intake, sodium intake), and the
number of different kinds of foods in person’s diet over a 3-day period.131 Recipe
ingredients of mixed food item were allocated to appropriate food groups. The exact
score assigned to a person in every component of HEI was determined by the number of
servings the individual consumed per day for a given energy intake. For example, the
recommended dietary allowance (RDA) for total energy for a 40-year-old woman is
2,200 kcal and the USDA food guide pyramid indicated that four servings of vegetables
per day are recommended at this energy level. Thus, a woman of 40-year-old should have
at least four servings of vegetables per day to obtain the maximum score of 10 in this
category.131 Each of the 10 components has a score ranging from 0 to 10, so the total
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index score is 100. If an individual consumed the recommended number of servings for
each food component or met the recommended guidance for nutrient intake, then this
individual would receive a score of 10 for this component. A score of 0 was assigned to
people who had no serving within a food group or below the criteria for minimum score
of 0 for nutrients intake. Between 0 and 10, the score of each component was calculated
proportionately.131
Some studies have investigated the association of the HEI score and inflammation
with the main findings showing that the HEI score was not associated with systemic
inflammation biomarkers such as CRP,7,132,133 SAA133 and IL-6.7,132,133 Only one crosssectional study using data from the Third National Health and Nutrition Examination
Survey (NHANES III) showed that higher HEI score predicted lower CRP level among
8719 disease-free adults (P-trend=0.04).134 HEI only weakly predicted major chronic
disease risk in men but not in women and it generally did not predict cancer risk in men
or women.135,136 The HEI’s low predictive ability for chronic inflammation and chronic
disease outcomes could be improved had it distinguished between unsaturated and
saturated fats, the form of carbohydrates, or protein sources.137 These limitations were
addressed by the development of an alternate HEI (AHEI) with the goal to capture
specific dietary pattern and eating behavior consistently associated with lower chronic
disease risk in clinical and epidemiological investigations. AHEI has 9 components, and
compared to the original HEI, the AHEI removed potato and potato products from the
vegetable component; whereas HEI considered all types of meat, AHEI gave more credit
for consuming white over red meat (included a component: white to red meat ratio).
AHEI also included a separate component for beneficial non-meat protein sources which
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were nuts and soy products and gave credit for higher cereal fiber intake in the grain
category. The ratio of polyunsaturated to saturated fat was included in AHEI to capture
beneficial effects of unsaturated oils which was not considered in HEI; moderate alcohol
consumption and a long-term multivitamin use were also added into the AHEI. Except
for the multivitamin use (contributing either 7.5 points for regular use >5 years and 2.5
points for all others), the other 8 components of AHEI were assigned a score from 0 to
10. All individual component scores were summed for a total AHEI score ranging from
2.5 (worst) to 87.5 (best).135,137 A study comparing the disease predictive ability of the
HEI and AHEI using same study population and during same follow up periods found
that the AHEI was nearly twice as predictive of overall chronic disease risk as was the
HEI and most of additional reduction of risk resulted from reduction in cardiovascular
disease (CVD) risk.138 However, AHEI was more predictive of CVD risk than cancer
risk, perhaps because CVD outcome is more homogeneous than is cancer outcome.138
The association between AHEI and plasma concentrations of inflammation biomarkers
was assessed in two studies with main findings showing higher AHEI scores were
associated with lower inflammatory biomarker levels such as IL-6 and TNF-α.7, 139
Since DGA are issued every 5 years by the USDA and U.S. Department of Health
and Human Services, the HEI-200514 and HEI-2010140 reflected the dietary
recommendations from 2005 edition of the Dietary Guidelines and the 2010 edition,
respectively. The HEI-2010 keeps several features of the 2005 version: (1) it has 12
components, many unchanged, including 9 adequacy (adequacy items are those higher
intake indicate higher score) and 3 moderation components (those reverse scored food
items); (2) it uses an energy density approach to set standards, e.g., nutrients are adjusted
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for total energy as a percent of calories; and (3) the standards for the maximum scores are
the least-restrictive (easiest to achieve) recommendations among those that vary by
energy level, sex, and/or age. Changes to the HEI-2010 include: (1) Greens and Beans
replaces Dark Green and Orange Vegetables and Legumes because Greens and Beans are
considered as the subgroups for which intakes are furthest from recommended levels; (2)
Seafood and Plant Proteins has been added to capture specific choices from the protein
group; (3) Fatty Acids, a ratio of poly- and mono-unsaturated to saturated fatty acids,
replaces Oils and Saturated Fat to acknowledge the recommended beneficial effect of
replacing saturated fat with mono-and polyunsaturated fatty acids; and (4) a moderation
component, Refined Grains, replaces the adequacy component, Total Grains, to reflect
the recommendation of restricting the over-consumption of refined grains.140 The HEI2010 allows for flexibility in food choices and lack of any one commodity does not
prevent from having a perfect HEI-2010 score. In contrast to the adequacy components of
the HEI-2010 where assigning the minimum score of zero was determined by no intake,
the 85th percentile of the 2001–2002 population distribution of 1-day intakes is used for
the minimum score of zero for those moderate components because these components are
reverse-scored and there is no clear scientific evidence to specify how high of an intake
deserves a score of zero.140 Although the suitability of the HEI-2010 for ethnic and
cultural groups has not yet been determined, the index would be expected to be useful for
assessing the diets for subpopulations for which the DGA are appropriate.
HEI-2005 was found to have an inverse association with CRP.141,142 The higher
HEI-2005 score was found to be related to lower risk of colorectal cancer,143 reduced
symptoms of depression,144 lower risk of cardiovascular risk factors,145 reduced risk of
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overall chronic diseases,146 and lower risk of stroke.147 HEI-2010 was also found to be
related to lower risks of all-disease mortality, cardiovascular disease mortality, and
cancer mortality in the low-income Southeast US population.148 Among specific cancer
types, an inverse association was found for HEI-2010 with risk of melanoma,149 lung
cancer,150 and colorectal cancer.151
2.2.3.3 Dietary Approaches to Stop Hypertension (DASH)
The DASH-style diet was initially developed in the middle 1990s to lower blood
pressure and prevent hypertension in the US. It is a healthy dietary pattern that contains 8
components: fruits, vegetables, whole grains, low-fat dairy products, legumes and nuts,
sodium, red and processed meat, and sugar-sweetened beverages.152 There are several
versions of DASH scoring algorithms: one version assigns scores from 1 to 5 to each
quintile of component intake (higher quintile of recommended food items intake receive
higher point while higher quintile of undesired food items intake was assigned lower
score)153 with total score ranging from 8 to 40; a second version has minimum and
maximum component scores between 0 and 10 with total score from 0 to 80;154 while a
third version has 11 components with scores from 0 to 1 assigned to each component
thus making total DASH score from 0 to 11.155 A recent meta-analysis of twenty-two
randomized clinical trials that investigated the effect of DASH diet intervention on CVD
risk factors reported that compared to control, DASH diet significantly decreased systolic
blood pressure (BP), diastolic BP, the concentrations of total cholesterol and low-density
lipoprotein.156 Importantly, the beneficial effects of the DASH diet are not limited to BP
and CVD risk factors, some studies have reported significant improvements in weight
loss,157 insulin sensitivity,158,159 inflammation,160,161 and oxidative stress.159 The DASH
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diet has been shown to be associated with reduced risk of several inflammation-related
chronic diseases such as type-2 diabetes,154,162,163, colorectal cancer,164 all cancer
mortality,165 heart disease and stroke,153,166 and all-cause mortality.165 In a NIH-AARP
study followed from 1995 to 2006, Miller et al. compared four DASH indices defined by
Dixon (7 food groups, saturated fat, and alcohol), Mellen (9 nutrients), Fung (7 food
groups and sodium), and Günther (8 food groups) with regard to their associations with
colorectal cancer risk.167 They concluded that higher scores of all four indices were
consistently associated with reduced risk of colorectal cancer in men and higher scores on
three of the indices (except the Dixon defined index) were associated with reduced risk
among women.167
2.2.3.4 Mediterranean Diet Score (MDS)
The Mediterranean diet score (MDS) was originally developed by Trichopoulou
et al.168 to measure the degree of adherence to the traditional Mediterranean diet. It
includes eight components and a score of 1 is assigned to beneficial food items including
vegetables, legumes, fruits, cereal and ratio of monounsaturated fat to saturated fat for
which the consumption is at or above the sex-specific median, and 0 is assigned to
consumption of these foods below sex-specific median. For components presumed to be
unhealthy (meat and meat products, milk and dairy products), people whose consumption
is at or above the sex-specific median are assigned 0, and people with consumption below
the sex-specific median are assigned a score of 1. For ethanol consumption, a score of 1
is assigned for moderate ethanol consumption and 0 is assigned to heavy drinkers. The
total score ranged from 0 (minimal adherence) to 8 (maximal adherence). Trichopoulou
et al. later updated the original version of MDS to include fish intake and defined

24

moderate ethanol consumption as 10 to 50 grams per day for men and 5 to 25 grams for
women, which made the total score between 0 to 9.169 Different definitions of moderate
ethanol consumption were included in other studies.170,171 There were several
Mediterranean dietary indices constructed based on the original MDS and used to
evaluate their associations with health outcomes, such as the adapted composite
Mediterranean diet score (MED) considering different health effects of cereal and grain
products,172 the alternate MED (aMED) which was adapted to the American
population,173 and the Mediterranean style-dietary pattern score (MSDPS).174,175
Increasing evidence suggests that bioactive and nutrient-dense components contained in
the Mediterranean diet are modulators of insulin resistance, can exert beneficial effects
on blood pressure, improve atherogenic dyslipidemia, beneficially influence metabolic
pathways or attenuate the inflammatory burden.176,177 The Mediterranean diet could
protect against diseases associated with chronic inflammation, including metabolic
syndrome,178,179 atherosclerosis and CVD, 180,181 cancers,182 diabetes,177 and obesity.183,184
The MDS has been associated with lower chronic systemic inflammation markers, such
as IL-6 and CRP. 7,185,186 A study to compare and evaluate the reliability of ten
Mediterranean diet indices showed these indices had acceptable performance in
measuring the adherence to the Mediterranean diet.187 The components that had strongest
correlation with the core of Mediterranean diet were monounsaturated-to-saturated fatty
acid ratio, fruit, and vegetables. In order to improve the concordance between the indices,
further research was suggested to standardize the number of components and the scoring
criteria.187
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2.2.3.5 Dietary inflammatory index (DII)
The development and construct validation of the DII have been described
previously.22-24,26,27,29,30,188 In short, the 45 food parameters (i.e., DII components) were
assigned inflammatory effect scores based on research summarizing findings from 1,943
articles published through 2010 describing the relationship between the food parameters
and six inflammatory markers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP). A
representative world database (i.e., dietary intake from 11 populations around the world)
was created that provided a mean intake and standard deviation for each food parameter.
To calculate an E-DII score, this global mean dietary intake after energy adjustment was
subtracted from the actual food intake value from a specific study, and divided by its
standard deviation. This z-score is then converted to a percentile (in order to minimize
the effect of outliers or right-skewing) and centered by doubling the value and subtracting
1. The product of the transformed z-score and inflammatory effect score for each DII
component was calculated and summed across all components to create the overall E-DII
score for an individual. The E-DII score characterizes an individual’s diet on a continuum
from maximally anti-inflammatory to maximally pro-inflammatory, with a higher E-DII
score indicating a more pro-inflammatory diet and a lower E-DII score indicating a more
anti-inflammatory diet.
The DII has been construct validated with dietary data from different dietary
assessment tools, where higher DII scores were found to be positively associated with
higher inflammatory biomarkers levels.23-27,29,30 Higher DII scores have previously been
associated with some inflammation-related diseases such as colorectal cancer reported in
the Iowa Women’s Health Study,33 NIH-AARP study,34 the Women’s Health Initiative,31
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and the Bellvitge Colorectal Cancer Study;32 prostate cancer among French middle-aged
adults189 and Jamaican men190 as well as Italian men;191 prostate cancer mortality among
patients with aggressive cancer,192 esophageal squamous cell cancer,193,194
gastroesophageal junctional adenocarcinoma,195 endometrial cancer,36 ovary cancer,196
dyspnoea and radiological evidence of emphysema among heavy smokers,197 breast
cancer death198 and incidence,193 myocardial infarction,199 ulcerative colitis,200 previously
diagnosed circulatory conditions,201 hepatocellular cancer,202 metabolic syndrome and
associated traits including higher blood pressure and triglycerides and lower HDLcholesterol,26,203 depression,204 asthma.205 Higher DII scores were more likely to be
observed among shift workers especially rotating shift workers.206 The higher DII was
also associated with larger BMI, waist circumference and waist to height ratio in a
population sample at high CVD risk,207 lower scores on other dietary indices,208
decreased cognitive functioning,196 lower fetal growth and breast feeding failure,209 lower
bone mineral density,210 lower lung function,205 higher risk of incident cardiovascular
diseases,211,212 higher CVD mortality,193,213,214 and higher cancer mortality and all-cause
mortality.213-216 As mentioned previously, the DII has been associated with pancreatic
cancer in two case-control studies.38,39
2.3

Other inflammation-related lifestyle factors: Obesity, type-2 diabetes,

smoking, NSAIDs use
Obesity is an inflammatory condition, often associated with the development of
adipose tissue inflammation, resulting in metabolic dysfunction and an increased risk for
developing multiple chronic diseases.217 In addition to excess fat storage in adipose
tissue, obesity is also associated with fat storage in other tissues including liver and
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skeletal muscle, which may lead to insulin resistance and stimulate inflammation.218 On
the other hand, obesity changes the type of chemicals that fat cells secrete which include
several pro-inflammatory mediators, produced by macrophages resident in the adipose
tissue.218 It has been demonstrated that healthy obese subjects have increased circulating
levels of pro-inflammatory cytokines such as IL-6, TNF-α and CRP.219,220 Weight loss by
hypocaloric diets or surgery reduced CRP levels in healthy middle-aged221 and
postmenopausal obese women222 and obese men.223
Chronic diabetic wounds are trapped in a persistent inflammatory state with
elevated levels of pro-inflammatory cytokines and proteases together with impaired
expression of growth factors.224 Recent data have demonstrated that the plasma
concentration of inflammatory mediators, such as TNF-α and IL-6, are increased in the
insulin-resistant states of obesity and type-2 diabetes. The first molecular link between
inflammation and insulin resistance was established by observing the insulin resistance in
obese mouse can be reduced through neutralization of TNF-α by soluble TNF- α
receptors.225 In the Women’s Health Study, elevated CRP levels were associated with a
four-fold increased risk to develop diabetes among healthy middle-aged women after
follow up of 4 years.226 In addition, Dandona et al. demonstrated that insulin has an antiinflammatory effect that may inhibit atherogenesis in the long term.227
Cigarette smoking has been shown to augment the production of proinflammatory cytokines such as IL-1, IL-6 and IL-8 and to decrease the levels of antiinflammatory cytokines such as IL-10.228 One of the key mechanisms behind smokinginduced inflammation activation is through the NF-kB pathway. In response to
environmental stimuli including tobacco exposure, the inactive complex of NF-kB/
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intracellular inhibitor (IkB) is activated by phosphorylation of IkB, which leads to the
poly-ubiquitination and subsequent degradation of IkB. Degradation of IkB induces
transcription of various genes involved in immune regulation and inflammation.229 The
pro-inflammatory impact of smoking on increased level of various inflammatory
cytokines was confirmed in several epidemiological studies. The associations between
cigarette smoking, years since quitting smoking and inflammatory markers were
investigated among 2,920 British men and the result showed that current smokers had
higher levels of the acute phase CRP compared to never smokers.230 Reduced levels of
inflammatory markers were found in subjects who quit smoking for 5 years, and the
levels of inflammatory markers were reverted to those found in never smokers only in
subjects who quit smoking for 20 years or more.230 Serum levels of the key proinflammatory mediator TNF-α were found to be highest among healthy subjects who
smoked more than one pack of cigarettes per day, followed by smokers who smoked less
than one pack per day and lowest in healthy nonsmokers, demonstrating a positive
relationship between cigarette smoke and serum level of TNF-α.231 Also, significantly
higher serum levels of IL-1β was found in healthy active smokers compared with
nonsmokers.232 In a recent multi-ethnic study of atherosclerosis cohort of 6814 adults
without prior CDV, a monotonic association was found between higher pack-year
quartiles and increasing inflammatory markers including high sensitivity CRP (hsCRP),
IL-6 and fibrinogen.233
NSAIDs which include aspirin, indomethacin, piroxicam, sulindac, ibuprofen and
other COX-2 inhibitors, are a diverse group of similarly acting compounds that are used
to treat the signs and symptoms of inflammation by primarily inhibiting the activity of the
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COX enzymes and thereby affecting the synthesis of the prostaglandin signaling
molecules, which are involved in a wide range of inflammation-related process.234
NSAIDs have shown the ability to alter systemic inflammation, reduce tumor recurrence
and improve moderate cancer cachexia (a multifactorial syndrome affecting almost 50%
of all cancer patients, characterized by skeletal muscle wasting with or without loss of fat
mass and is often associated with psychological distress and fatigue).235 A large body of
evidence supports aspirin’s protective effect of reducing cancer incidence and cancer
mortality. The beneficial effects are particularly large and consistent for colorectal,
esophageal and gastric cancers, with smaller reductions seen on breast, prostate and lung
cancer. 236 Data from 51 randomized controlled trials (RCTs) showed that aspirin use at
doses between 75 and 100 mg/day reduced overall cancer incidence by 12%. This benefit
was only noted apparently with a 24% reduction observed after 3 years of follow-up and
beneficial effect became larger with increasing follow-up. The benefit was most evident
in patients with a scheduled treatment duration of 5 years or longer.237 Reductions in
cancer incidence were similar in men and women.237 Data from multiple RCTs showed
that aspirin use can reduce total cancer death by 20% and the protective effect was only
observed after 5 years of use. The magnitude of benefit became larger with longer
duration of aspirin use, and it had similar benefit in men and women.238
2.4

Risk factors for pancreatic cancer

2.4.1

Selected individual dietary factors
The following selected dietary factors and associated evidence are summarized

based on the World Cancer Research Fund/American Institute for Cancer Research 2012
Continuous Update Project (CUP) summary report for pancreatic cancer, which serves as
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the most updated authoritative scientific resource generating evidence on food, nutrition
and physical activity relating to the prevention of pancreatic cancer.239 This summary
report updates the pancreatic cancer section of the Second Expert Report of Food,
Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective.
Conclusions from the report were made based on the findings of the 2011 systematic
literature review and the CUP Expert Panel discussion in June 2012. Evidence of this
report was summarized based on literature review restricted to Medline and included only
randomized controlled trials, cohort and case-control studies published up to September
2011. Given that there is very little difference between pancreatic cancer incidence and
mortality rates due to low survival rate, study results on incidence and mortality have
been presented and analyzed together in the current report, unless there is large number
of papers reporting pancreatic cancer incidence and mortality separately. I additionally
include evidence from literature published after CUP.
2.4.1.1 Red and processed meat intake
High intake of red meat may result in more absorption of heme iron, greater
oxidative stress, and potential for DNA damage.240 It is also associated with the
formation of N-nitroso compounds, which shares the same mechanisms for increasing
risk with processed meat. Previous studies found inconsistent association for red meat
and pancreatic cancer.241,242 CUP found three of seven studies on pancreatic cancer
incidence that reported an increased risk when comparing the highest red meat intake
group to the lowest, two of which were statistically significant. For pancreatic cancer
mortality, two of three studies reported an increased risk and only one reached statistical
significance. The dose–response meta-analysis showed a non-significant positive
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association between red meat intake and pancreatic cancer risk [incidence and mortality
combined, relative risk (RR)=1.19, 95% CI=0.98-1.45 per 100g/day with moderate
heterogeneity (I2= 52%)] and the association was significant in men (RR=1.43, 95%
CI=1.10-1.86) but not in women (RR=1.06, 95% CI=0.86-1.30). Results from two later
published meta-analysis were similar to the CUP findings, both meta-analysis (one
included 11 prospective studies through November 2011243 and the other included 10
cohort studies and 11 case-control studies up to the end of 2010 244) reported a positive
relationship. One meta-analysis reported an overall non-significant dose-response
relationship (RR=1.13, 95% CI=0.93-1.39) and the association was significant in men
although not in women.243 The other meta-analysis found a significant association in
case-control studies (RR=1.48, 95% CI=1.25-1.76) but not in cohort studies (RR=1.14,
95%CI=0.94-1.38).244 Five individual studies (two case-control studies245,246 and three
prospective cohort studies247-249) reported on the red meat and pancreatic cancer
relationship after the CUP summary report. All five studies reported positive associations
between red meat and pancreatic cancer risk, among which three studies reported
significant increased risk for the highest compared with the lowest group, one study
reported significant association only in men, and one observed a non-significant positive
dose-response relationship. A case-control study reported consumption of barbecuing red
meat versus no consumption was associated with 67 % increased risk of pancreatic
cancer risk.245 Results from the NIH-AARP study showed pancreatic cancer risk
significantly increased with intake of high-temperature cooked meat, grilled/barbequed
meat, or well/very well done meat, which suggested that meat cooking methods may be
important in the association between red meat and risk of developing pancreatic
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cancer.248
Similarly, the association between processed meat and pancreatic risk was
inconsistent. Overall, the CUP found four of six studies on pancreatic cancer incidence
reported an increased risk comparing the highest intake group to the lowest, one of which
was statistically significant. For mortality, one of two studies reported a non-significant
increased risk and the other reported a non-significant decreased risk. Dose-response
meta-analyses which included seven studies (incidence and mortality combined) found a
17% increased risk associated with each 50g increase of processed meat per day, and this
was statistically significant (RR=1.17, 95% CI=1.01-1.34) with no heterogeneity (I2=0).
When stratified by sex, the effect was significant in men (RR= 1.21, 95% CI=1.01-1.45)
but not in women (RR=1.09, 95% CI=0.69-1.73). The dose-response finding from CUP
was consistent with a recent meta-analysis of prospective cohorts which also reported
significantly positive associations.243 Two recent individual studies examining processed
meat and pancreatic cancer risk both showed no associations.247,248 Limited evidence for
nitrate/nitrite intake from processed meat in association with pancreatic cancer has been
published but with inconsistent results.250-252 In summary, CUP concluded there was
limited and inconsistent but suggestive evidence to implicate red and processed meat in
pancreatic cancer etiology.
2.4.1.2 Fat intake
It is well established in animal models that total dietary fat plays a role in
pancreatic carcinogenesis: long-term exposure to free fatty acids could result in
pancreatic hypertrophy or hyperplasia, which in turn leads to uncontrolled growth of
abnormal cells in the pancreas.253 Large amounts of fat intake may stimulate bile acid
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secretion into the pancreatic duct and in turn stimulate the tumor promotor COX-2.254 In
addition, the insulin resistance caused by high fat intake is another mechanism to increase
pancreatic cancer risk through metabolic, immunological and hormonal alterations in the
body.253 Several studies examined the association between total fat intake and pancreatic
cancer risk with results being inconsistent. In a recent meta-analysis including 6 cohort
and 13 case-control studies published up to February 2014 with total of 6,159 pancreatic
canc cases, Shen et al. found a non-significant increased risk for the highest total fat
intake group compared to the lowest group (pooled RR=1.04, 95%=0.90-1.20, I2=57.3%),
with similar effects among case-control and cohort studies. Furthermore, no significant
associations were observed when stratifying by fat source.255 The CUP meta-analysis for
total fat intake included 8 studies and showed a marginally significant positive
association (RR=1.05, 95%CI=1.00-1.12) for the highest versus the lowest intake group,
with no evidence of heterogeneity. In terms of saturated fatty acids, the CUP performed a
dose-response meta-analysis including five studies and found an 11% statistically
significant increased pancreatic cancer risk for each 10g saturated fatty acids intake per
day (RR=1.11, 95% CI=1.01-1.21) with moderate heterogeneity observed. However, the
evidence among individual studies is limited and inconsistent, with four of seven studies
reporting a non-significant decreased risk and three reporting an increased risk (two of
which were significant). In a recently published PLCO study with 411 pancreatic cancer
cases, Arem et al. observed an inverse association between saturated fat, total fat intake
and pancreatic cancer risk among subjects with less than four years of follow-up, and
associations became weaker and nonsignificant after excluding these subjects, whereas
intakes of monounsaturated and polyunsaturated fats and fats from animal or plant
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sources showed no associations with pancreatic cancer.256 In another large cohort study
(the NIH-AARP), researchers found that higher intake of total fat, saturated fat and
monounsaturated fat all significantly increase pancreatic cancer risk, but there was no
association with polyunsaturated fat and associations were strongest for saturated fat
from animal food sources. The authors also examined individual fatty acids and found
increased intake of two types of saturated fatty acids (SFA) (palmitic acid and stearic
acid), one monounsaturated fatty acids (MUFA) (palmitoleic acid), one n-6
polyunsaturated fatty acid (PUFA) (arachidonic acid), and two n-3 PUFAs
(eicosapentaenoic acid, docosahexaenoic acid) were associated with increased risk of
pancreatic cancer.257 The trans fatty acids and pancreatic cancer relationship was
examined in three studies, with two studies10,257 yielding non-significant positive
associations and one study258 reporting a non-significant inverse association.
2.4.1.3 Vegetable and fruit intake
A large number of antioxidant vitamins and minerals rich in fruits and vegetables
have been proposed to have many cancer-protective properties, including reducing
oxidative DNA damage/mutations by reducing oxidative stress and inflammation, or
stimulating glucose metabolism and/or insulin sensitivity.259,260 A recent meta-analysis
summarizing available evidence (15 case-control studies, 8 prospective studies, and one
pooled analysis) up to January 2015 found a significant reduction of pancreatic cancer
risk for the highest versus lowest intake of vegetable and fruit combined (RR=0.73, 95%
CI=0.53-1.00), fruit (RR=0.73, 95% CI=0.63-0.84), and vegetable (RR=0.76, 95%
CI=0.69-0.83) with significant between-study heterogeneity (I2=70.5%, 55.7%, and
43.0%, respectively).11 These inverse associations were borderline significant in
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prospective studies.11 In a pooled analysis of 14 prospective cohort studies from North
America, Europe, and Australia where primary data from these studies was used by
standardizing the definitions of fruit and vegetable intake and covariate categories across
studies, Koushik et al. found that for each 100g/day increase in intake of fruits and
vegetables during adulthood there was a non-significant increased risk of pancreatic
cancer with no statistically significant heterogeneity between studies (pooled
multivariable RR=1.01, 95% CI= 0.99-1.03) for total fruits; RR=1.02, 95% CI= 0.991.06 for total vegetables). Associations were similar for men and women.261 This lack of
overall association was consistent regardless of whether intake was examined as a
continuous measure or in categories based on absolute cut-points or study-specific
quartiles. In the analyses of individual foods, statistically significant increased pancreatic
cancer risks were observed for each 3-servings/week increment in intake of strawberries,
fruit juice, brussels sprouts, green peppers, lettuce/salad, and tomatoes, although most of
the positive associations became non-significant after adjustment for total fruit or
vegetables. They also found each 100g/ day increment in intake of green leafy vegetables
was associated with 17% increased risk with no significant between-study
heterogeneity.261 These non-significant positive associations were not expected a priori
and may have been due to chance. Some research has suggested that exposure to
pesticides, which may be present on fruits and vegetables, may increase risk.262 Other
research has suggested that indole-3-carbinol, which is found in cruciferous vegetables
such as Brussels sprouts, may have some cancer-promoting effects, particularly when
administered after carcinogen exposure.263,264 In addition, residual confounding from
measurement error in the included covariates or uncontrolled covariates as well as
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misclassification in estimates of usual consumption due to only one time diet assessment
may also contribute to the unexpected results, as suggested by authors of this paper.261 In
the Multiethnic Cohort (MEC) Study with 529 pancreatic cancer cases, no association
between total vegetable intake and vegetable subgroup intake and pancreatic risk was
observed among the overall population, but an inverse association with total vegetables,
light green vegetables, and legumes was observed in overweight/obese subjects.265 One
case-control study looked at nutrient intake from fruits, vegetables, and supplements in
association with pancreatic cancer incidence, and found a significant inverse association
in a dose-dependent manner for magnesium, potassium, selenium, alpha-carotene, betacarotene, beta-cryptoxanthin, lutein and zeaxanthin, niacin, total alpha-tocopherol, total
vitamin A activity, vitamin B6, and vitamin C.266
2.4.1.4 Carbohydrate intake, glycemic load (GL), glycemic index (GI), dietary
fructose and sucrose
GI is a value assigned to foods based on how slowly or quickly those foods cause
blood glucose levels to increase, while dietary GL, which reflects both the quality and
quantity of carbohydrates ingested, is the product of the dietary GI and total dietary
carbohydrates.267 Fructose can increase postprandial plasma glucose levels, and can
increase risk of insulin resistance, type-2 diabetes and obesity, which may lead to higher
pancreatic cancer risk.268 Results from a recent cohort study meta-analysis including 10
cohort studies searching up to 2011 September revealed a significant increased risk with
fructose intake (RR= 1.22, 95% CI=1.08–1.37, I2 = 0% per 25 g/day increase) but did not
find an association of pancreatic cancer with dietary GI, GL, total carbohydrates and
sucrose.268 Significantly higher risk of pancreatic cancer was reported to be associated
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with higher GL only in a large population-based case-control study conducted in
Canada.269 In the MEC Study, pancreatic cancer risk increased with higher intakes of
total sugars, fructose, and sucrose in overweight or obese participants (RR=1.46, 95%
CI=0.95–2.25; P for trend =0.04), but the association was not significant in normalweight participants.270 CUP conducted a dose-response meta-analyses which included six
studies on dietary fructose and pancreatic cancer incidence and results showed a 22%
statistically significant increased risk for each 25g increased intake of fructose per day
(RR=1.22, 95% CI=1.08-1.37) with no heterogeneity observed and no differences of the
association were observed between men and women. The CUP found that there were no
clear associations between other related exposures (total carbohydrate, sucrose and soft
drinks) and pancreatic cancer risk. Although there was ample consistent evidence, and
some evidence for a dose-response relationship, fructose comes from many sources
making the evidence difficult to interpret, so CUP concluded that the evidence suggesting
that foods and beverages containing fructose are a cause of pancreatic cancer is limited.
Increased carbohydrate intake during adolescence (age 12-13) and midlife could increase
pancreatic cancer risk in later life.271 In a recently published meta-analyses, dietary fiber
intake was found to be inversely associated with pancreatic cancer in case-control studies
but not in cohort studies.12
2.4.1.5 Coffee
There was substantial evidence consistent with low heterogeneity, showing no
effect of coffee intake on the risk of pancreatic cancer. The CUP dose-response metaanalysis of 13 cohort studies found an overall non-significant positive association
between each one cup of coffee increase per day and pancreatic cancer (incidence and
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mortality combined, RR=1.02, 95% CI=0.95-1.09). When stratifying pancreatic cancer
outcomes, meta-analysis of three studies on mortality showed no association (RR=0.99,
95% CI=0.76-1.28), and non-significant positive association for incidence (RR=1.03,
95% CI =0.95-1.11). The CUP finding is generally consistent with the other published
meta-analyses: the Harvard pooing project of 14 prospective cohort studies revealed a
similar pooled RR for each 237g/d of coffee (RR=1.01, 95% CI=0.97-1.04, I2=38);272 an
updated meta-analysis including 20 cohort studies published up to November 2015
reported the summary RR of pancreatic cancer risk for the highest category of coffee
intake compared to lowest category was 1.06 (95% CI= 0.94-1.20, I2 = 38.5%) after
removing one study which caused largest heterogeneity.273 In a large prospective study
including the largest number of pancreatic cancer cases to date (NIH-AARP study), no
associations between total, caffeinated, or decaffeinated coffee intake and pancreatic
cancer risk were observed. 274
2.4.1.6 Alcohol
Heavy alcohol consumption might increase pancreatic cancer risk by promoting
the effects of other risk factors such as tobacco smoking. Heavy alcohol consumption
may also alter metabolic pathways involved in the inflammatory response and
carcinogenesis (i.e. increased production of reactive oxygen species resulting in oxidative
DNA damage and other independent genetic and epigenetic effects).275,276 Furthermore,
alcohol use is the single most common cause of pancreatitis (its attributable risk is
approximately 40%).277 It is thought that ethanol metabolites, such as acetaldehyde,
might be important carcinogens for pancreatic cancer. 275 The dose-response metaanalyses for total alcoholic drinks and pancreatic cancer (incidence and mortality
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combined) conducted by CUP found a nonlinear association with significant risk starting
from consuming 17.6 or more drinks per week. When stratifying analysis by sex for
incidence and mortality combined, there was no clear linear association in women
(RR=1.00, 95% CI: 0.98-1.01), but in men there was a marginally significant increased
risk (RR 1.01, 95% CI= 1.00-1.02). When alcohol (as ethanol) was examined alone, CUP
dose-response meta-analysis showed a nonlinear association. The risk was significant for
those consuming 53.4g ethanol or more a day. Results from a published pooled
analyses278 with a total of 14 cohort studies and a meta-analysis279 on alcohol (as ethanol)
and pancreatic cancer risk consistently showed that daily consumption of 30g of alcohol,
or the equivalent of >3 glasses of any alcoholic beverage per day, is associated with a
22% increased risk of pancreatic cancer. A statistically significant increase was only
observed among men consuming 45 or more grams of alcohol from liquor per day in the
Pancreatic Cancer Cohort Consortium (PanScan).280 CUP concluded that the increased
pancreatic cancer risk was limited to those consuming more than about 3 alcoholic drinks
per day.
2.4.2

Dietary patterns
Eleven published studies have investigated the dietary patterns and pancreatic

cancer relationship, among them five studies examined a priori dietary patterns (HEI2005,281 aMDS,282 MDS17 and DII38,39), and the other six studies focused on a posteriori
dietary patterns.15,16,18-21 Among the five a priori dietary pattern studies, in general, better
dietary quality was associated with lower pancreatic cancer risk. Results were significant
for studies examining HEI-2005281 and MDS score17 as well as DII,38,39 but not
significant when using aMDS282 as the exposure. In the NIH-AARP with 2,383 incident
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exocrine pancreatic cancer cases, Arem et al. found the top quintile of HEI-2005 score
was associated with a 15% decreased risk of pancreatic cancer compared to the lowest
quintile (HRQ5vsQ1=0.85, 95% CI=0.74 -0.97, P-trend=0.003) for the overall study
population, and the association was significant in men but not in women.281 In another
NIH-AARP investigation which used aMDS as criteria to calculate the dietary score and
categorized it to healthy and unhealthy diet, healthy diet was found to be associated with
8% reduction in pancreatic cancer risk compared to unhealthy diet (HR=0.92, 95%
CI=0.81-1.05).282 Based on aggregated primary data from two Italian case-control
studies, Bosetti et al. found a significant reduction in risk with increased MDS score
[(hazard ratio (HR) for a unit increase=0.85, 95% CI =0.80–0.91)] with significant
inverse associations observed in each case-control study. Two case-control studies using
the DII to examine its association with pancreatic cancer risk found subjects in the
highest quintile of DII scores had a 2.48-fold (OR=2.48, 95% CI=1.50-4.10, P
trend=0.002)38 and a 2.54-fold (OR=2.54, 95% CI=1.87-3.46, P trend<0.001)39 elevated
odds of pancreatic cancer compared to those in the first quintile.
The other six a posteriori studies identified food groups/dietary patterns based on
dietary data using statistical analysis method which included the RRR and principal
component analysis (PCA); factor score was calculated and assigned to each subject for
each food item. Nothlings et al. reported in the MEC study that a food group pattern score
which was predictive of flavonol intake (quercetin, kaempferol, and myricetin) was
associated with lower risk, although the result was not significant (HRQ5vsQ1=0.88, 95%
CI=0.67-1.15, P-trend=0.14).19 Three studies looked at Western dietary patterns and
pancreatic cancer relationships,18,20,21 and only one case-control study found a significant
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positive association among men only (ORQ5vsQ1=2.4, 95% CI=1.3-4.2, P-trend=0.008).
This study also found a significant inverse association of a prudent dietary pattern
characterized by greater intake of vegetables, fruit, fish, poultry, whole grains, and lowfat dairy and pancreatic cancer.21 Results from the other two studies with the Western
dietary pattern did not support an association of prudent or Western patterns with
pancreatic cancer risk,18,20 but a significant positive association for prudent dietary
pattern score among men was observed in the Health Professionals Follow-Up Study
(HPFS).18 A population-based, case-control study conducted in Canada between 1994
and 1997 found “fruit and vegetable” dietary pattern was inversely associated with
pancreatic cancer risk for men only (OR Q4vsQ1=0.51, 95% CI=0.29–0.90, P-trend<0.01)
and “drinker” dietary pattern derived from this study had no association with pancreatic
cancer.20 In the Iowa Women’s Health Study, Maki Inoue-Choi et al. used PCA method
to derive several food patterns (“high vegetable”, “low fat”, Mediterranean, “high fiber”
and “high fruit” food patterns) but none of the food patterns was associated with
pancreatic cancer risk in the study.15 Using the same PCA method, another Italian casecontrol study found compared to the lowest quartile of score, the highest quartile of
“animal product” pattern score and “starch rich” pattern score had 2.03 folds and 1.69
folds increased risk of pancreatic cancer, respectively and an inverse association emerged
for the “vitamins and fiber” pattern.16
2.4.3

Smoking
Tobacco is the most well-established risk factor for pancreatic cancer, and with

alcohol, they are cofactors to increase risk.277 Studies have consistently confirmed the
relationship between smoking and pancreatic cancer, with smokers having about 2-fold
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excess risk compared with nonsmokers. This increased risk is smaller for pancreatic
cancer than for lung cancer, which could be because pancreas has indirect exposure to
tobacco carcinogens, though as in lung cancer, the risk is proportional to the duration and
the intensity of smoking.277 Predictably, the deleterious effect of smoking on the
pancreas is caused by the release of or formation of carcinogens from tobacco. Several
genes mediate the degradation of tobacco carcinogens but little is known how they
function to affect risk.277 In a comprehensive meta-analysis of 47 case-control and 35
cohort studies, Iodice et al. concluded that the overall risk of pancreatic cancer for current
and former cigarette smokers was, respectively, 1.74 (95% CI=1.61-1.87) and 1.20 (95%
CI=1.11-1.29) compared to non-smokers. For former cigarette smokers, the risk remains
elevated for a minimum of 10 years after cessation.283 This study also found a linear
increased trend of pancreatic cancer risk with increasing intensity (cigarette smoked per
day), duration and cumulative dose with 1% increased risk per pack-year.283 Data from
12 case-control studies within the International Pancreatic Cancer Case-Control
Consortium (PanC4),284 pooled analysis of 30 cohort studies from the Asia-Pacific
region,285 a meta-analysis of three case-control and four cohort studies conducted in
Japan286 and a pooled analysis from the Pancreatic Cohort Consortium287 confirmed the
positive link, with a summary RR between 1.6 and 2.2 for current cigarette smokers and
between 1.1 and 1.7 for former cigarette smokers, compared to non-smokers. There are
several other forms of tobacco besides cigarette; the PanC4 study found cigar-only users
increased pancreatic cancer risk by 60% (OR=1.6, 95% CI=1.2-2.3) compared with never
tobacco users and had higher risk than cigarette-only smokers, but pipe-smoking and
smokeless tobacco such as chewing tobacco and snuff did not appear to increase the
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risk.288 Some evidence also indicated increased risk with increasing amounts of cigars
smoked per day although no association with duration.288 The recent meta-analysis found
that current pipe and/or cigar smokers had 47% elevated pancreatic cancer risk compared
to non-smokers, however, the association was not significant for former pipe and/or cigar
smokers.283 Exposure to environmental smoking (passive smoking) during childhood or
adulthood at home did not appear to be associated with pancreatic cancer risk.289
Mutations in carcinogen-metabolizing genes, such as glutathione-S-transferase, with
multiple sequence variants may be genetic modifiers for smoking-related pancreatic
cancer.290 Risk more than 15 years after smoking cessation was similar to that for never
smokers. Estimates of excess odds ratio per pack-year declined with increasing intensity,
suggesting greater risk for total exposure delivered at lower intensity for longer duration
than for higher intensity for shorter duration. This finding and the decline in risk
after smoking cessation suggest that smoking has a late-stage effect.287
2.4.4

Adult attained height
The number of cell divisions in fetal life and childhood, health and nutrition status

in childhood, and age of sexual maturity which will largely determine the adult height
play a role in affecting the hormonal microenvironment and circulating levels of growth
factors, insulin, and estrogens. Thus, taller adults are more likely to have error during
DNA replication, which may result in cancer development.291 CUP identified 14 studies
which examined the adult height and pancreatic cancer association, and the result was
generally consistent with eight of 10 studies on incidence showing an increased risk
(three of which were statistically significant) and one study on mortality showing a nonsignificant increased risk when comparing the highest versus lowest groups. The CUP
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meta-analysis showed a 7% statistically significant increased risk (incidence and
mortality combined) per 5cm (RR=1.07, 95% CI=1.03-1.12) with considerable
heterogeneity observed, which was consistent with the finding from most recent
published meta-analysis including 12 cohort studies, showing the pooled RR per 5-cm
increase in height was 1.07 (95 % CI=1.03-1.12, I2 =57%) and the association was
similar among men and women.292
2.4.5

Body fatness/obesity and physical activity
There is an established connection between increasing BMI or body fatness and

insulin resistance, which in turn increase pancreatic cancer risk via hyperinsulinemia.293
Body fat also directly affects levels of a number of hormones and growth factors, such as
insulin, insulin-like growth factor 1 (IGF-1), leptin, and estrogens, creating an
environment that encourages carcinogenesis and discourages apoptosis.294 In addition, fat
cell produces pro-inflammatory factors, which may contribute to the development of
several cancers.295 Body fat is usually reflected by BMI, measures of abdominal girth
such as waist circumstance and waist to hip ratio (WHR), and weight gain. For both
pancreatic cancer incidence and mortality, CUP found a 10% statistically significant
increased risk per 5 BMI units (RR=1.10, 95% CI=1.07-1.14 for incidence and RR=1.10,
95% CI=1.02-1.19 for mortality) with lower between-study heterogeneity (I2=23%) and
no difference between men and women in the dose-response meta-analysis. There was
evidence of a nonlinear dose-response with an increased risk apparent for BMI of 25
kg/m2 or higher. CUP findings on pancreatic cancer incidence are generally consistent
with three large published pooled studies and a recent meta-analysis. The Harvard
pooling project reported a linear increased trend of pancreatic cancer risk for each 5 BMI
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units (RR=1.14, 95% CI=1.07–1.21), and reported a positive association for pancreatic
cancer with higher BMI in early adulthood, and with greater than 10 kg/m2 BMI gain
between early adulthood and baseline compared to individuals whose BMI remained
stable.296 National Cancer Institute’s pooled analysis found that every 5kg/m2 increment
of BMI was associated with a 1.08-fold increased pancreatic cancer risk for all
participants, but the association was only significant for women, and only significant
among never and former smokers, but not among current smokers.297 The PanScan
pooling study reported pancreatic cancer risk increased by 13% for each 5 unit BMI
increase (OR=1.13, 95% CI=1.11-1.14).298 The recent meta-analysis on BMI and PanC
risk found a non-linear association between BMI and pancreatic cancer risk, with the
lowest risk among persons with a BMI around 21 kg/m2 and with the most pronounced
risk among persons with a BMI>35 kg/m2, however, among nonsmokers, there was a
linearly increased risk.299 Data from the NIH-AARP study on lifetime adiposity and
pancreatic cancer risk reported a higher risk for those being overweight or obese at ages
18, 35, 50, or >50 years (baseline BMI) compared to normal weight. A longer duration
of BMI>25 kg/m2 was significantly associated with pancreatic cancer risk, with
individuals who reported diabetes having the greatest risk. They also found that a
substantial gain in adiposity (>10 kg/m2) after age 50 years old was significantly
associated with increased pancreatic cancer risk.300 A recently published pooled analysis
with data combined from 20 prospective cohort studies which focused on pancreatic
cancer mortality showed higher BMI during early adulthood (ages 18-21
years) (HR=1.18, 95% CI=1.11-1.25 per 5 kg/m2) and BMI gain after early adulthood
(HR=1.05, 95% CI=1.01–1.10 per 5 kg/m2) was associated with increased mortality
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risk.301
Five studies included in the CUP all found a non-significant increased pancreatic
cancer incidence for highest waist circumference versus lowest category, and metaanalysis using these five studies showed an 11% statistically significant increased risk per
10cm waist circumference increase (RR=1.11,95% CI=1.05-1.18) with no heterogeneity.
In a stratified analysis, the effect was statistically significant in women, but not in men.
The CUP findings were consistent with findings from two published pooling
studies.296,298 Higher waist circumference was also reported to be associated with
increased pancreatic cancer mortality in a recent pooled analysis of 20 cohort studies
(HR=1.07, 95% CI=1.00–1.14 per 10 cm).301
Higher WHR was consistently associated with increased pancreatic cancer
incidence and mortality.298,299,301 The CUP reported a 19% statistically significant
increased risk of pancreatic cancer for each 0.1unit increase of the ratio. Others have
suggested that overweight and obese individuals develop pancreatic cancer at a younger
age than do patients with a normal weight, and that they also have lower survival rate
once pancreatic cancer is diagnosed.302 Given ample and consistent evidence for the
positive association between various measures of body fatness and pancreatic cancer
incidence and mortality, the CUP concluded that the evidence that greater body fatness,
including abdominal fatness and adult weight gain, was a cause of pancreatic cancer is
convincing.
Physical activity can play a preventive role in pancreatic cancer development by
regulating body weight and reducing insulin resistance, DNA damage, and chronic
inflammation.303 In a recent meta-analysis comprising 30 studies with 10,501 pancreatic
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cancer cases, results from cohort studies were homogeneous and indicated a weak,
statistically significant inverse association between high versus low levels of total PA and
pancreatic cancer (incidence and mortality combined, RR= 0.93, 95 % CI=0.88–0.98).
Sub-analysis in the cohort studies showed that the protective effect appeared to be more
pronounced for consistent PA over time (PA maintained for more than 10 years) (RR=
0.86, 95% CI= 0.76–0.97) than for recent past PA (up to 3 years before baseline) or
distant past PA (>=3 years prior to baseline). Occupational PA in the cohort studies had
statistically significant inverse association with pancreatic cancer risk and appeared to
generate a stronger risk reduction than did recreational activity, and that risk reduction
was driven mainly by consistent activity over time. Stratified analysis on PA intensity
showed null association for vigorous intensity, moderate intensity and low intensity PA
in both case-control and cohort studies. The association was not modified by smoking
status or BMI.303 Another meta-analysis examining leisure time PA and pancreatic
cancer yielded a summary 11% significant reduction in risk comparing highest to lowest
category, but the pooled association was only significant in case-control studies. They
also found leisure time PA appeared to have the strongest effect among young
populations.304
2.4.6

Past medical history
Several medical conditions are associated with pancreatic cancer risk, among

them, diabetes has been investigated in the largest number of studies. Diabetes was
associated with pancreatic cancer at the onset of symptoms in about 40 to 60% of
patients, being a consequence or the cause of the disease, which is not fully known.305
Five recent pooled analyses40,41,306-308 have concordant findings, showing that diabetics
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had 40% to 90% increased pancreatic cancer risk compared to non-diabetics, and the RR
decreased with duration of diabetes, but a significant excess risk was still evident 10
years after diabetes diagnosis. Among diabetics, risk was higher in insulin ever users
compared with nonusers, and insulin use of >10 years was associated with a reduced risk
of pancreatic cancer (OR=0.5, 95% CI=0.3-0.9, P-trend< 0.001).40 Even in the absence of
diabetes mellitus, higher fasting blood sugar and blood glucose or impaired glucose
tolerance are associated with higher pancreatic cancer risk.285,309,310
The lag period between diagnosis of chronic pancreatitis and pancreatic cancer is
usually one or two decades, whereas pancreatitis occurring a year or two before the
diagnosis of pancreatic cancer is often because of tumor-related ductal obstruction.311 A
comprehensive meta-analysis of 22 studies reported a statistically significant increase of
pancreatic cancer risk associated with all types of pancreatitis, with summary RRs
ranging from 5.1 for unspecified pancreatitis to 100 for tropical pancreatitis.311,312 Results
from a pooled analysis of 10 case-control studies revealed ORs ranging from 3.4 (for an
interval >25 years) to 21 (for an interval between pancreatitis and pancreatic cancer
≤1 year) which probably reflected a combination of reverse causation and antecedent
misdiagnosis of pancreas cancer as pancreatitis. The younger (<65 years) pancreatic
cancer cases showed stronger associations with previous (>2 years) pancreatitis than the
older (≥65 years) cases. 313
Individuals with a history of gallstones and cholecystectomy were at 70% and
31% increased risk of pancreatic cancer, respectively, reported by a recent metaanalysis.314 The positive associations were observed among both Asian population and
Whites.314 Diagnosis of gastric or duodenal ulcer within 2 years before pancreatic cancer

49

diagnosis increased cancer risk for 2.43 folds, but the significant positive association
disappeared when ulcer duration persisted more than 2 years. Similarly, individuals with
history of gastrectomy were at elevated pancreatic cancer risk but the excess risk was
only limited to a gastrectomy within 2 years before cancer diagnosis. The increased risk
for short-term history of ulcer and gastrectomy suggested that such association was due
to reverse causality (i.e., underlying diseases) or increased cancer surveillance.315,316 No
overall association was observed between Helicobacter pylori infection and risk
of pancreatic cancer, but cytotoxin-associated gene A (CagA)-negative nonvirulent
strains of Helicobacter pylori has been shown to increase pancreatic cancer risk, with
findings confirmed in three recent published meta-analyses.317-319
A positive association between periodontal disease (PD) and pancreatic cancer
was reported in most studies performed on this topic.320 In a recent large cohort study in
Taiwan, PD was found to be a risk factor for pancreatic cancer (HR=1.55, 95% CI=1.022.33) independent of other comorbidities such as diabetes, and this positive association
occurred predominantly among those aged 65 years or older.321
Venous thromboembolic events (VTE) was found to be associated with increased
risk of pancreatic cancer in a meta-analysis comprising 12 studies but with significant
between-study heterogeneity (RR= 6.1, 95%CI=3.8–9.7, P-heterogeneity<0.001).322
Using the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data of
1.2 million cancer cases and 200,000 controls (66-99 years old, 1992-2005), Marks et al.
found that VTE has been associated with an increased risk of pancreatic cancer among
US elderly adults (OR=1.53, 95% CI=1.43-1.64), with strongest risks observed within 1
year of VTE diagnosis, but risks were still elevated more than 6 years after VTE.323 There
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was consistent evidence showing that history of allergy, especially allergy to animal or
allergy related to atopy and hay fever, reduced pancreatic cancer risk by 20–40%, based
on evidence from PanScan pooling analysis324 and a meta-analysis.325
Finally, recent meta-analyses summarized the association with hepatitis B virus
(HBV) infection.326-330 These reviews consistently reported a significant positive
association between exposure to HBV infection and pancreatic cancer, but past exposure
to HBV with natural immunity (anti-HB surface antibody positive) was not related
to pancreatic cancer development, nor was the HBV active replication (hepatitis B e
antigen positive status).329 Therefore, it is still unclear whether serological pattern of past
exposure to HBV with or without natural immunity is associated with an enhanced risk of
this malignancy. Results from two meta-analyses suggest a positive association between
hepatitis C virus infection and pancreatic cancer risk328,329 but the same uncertainty as the
HBV serological pattern was present for HCV.
2.4.7

Demographic factors
As for other cancers, less than 10% of pancreatic cancer cases occur at age

younger than 55 years old, and the median age of onset is 71 years. In all race/ethnicity
groups, men have higher incidence rates than women.277 Rates of pancreatic cancer are
considerably higher in the African American population than in any other racial groups,
although little is known about the reasons for the racial disparity.331 Males, Jewish
descent and black ethnicity are associated with increased risk compared to their
counterparts.332 No consistent relationship has been confirmed between development of
the disease and socioeconomic status or immigration status. Finally, incidence rates of
pancreatic cancer are highest in Western and industrialized countries and lowest in
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underdeveloped nations.332
2.4.8

Family history and genetic factors
Several hereditary and genetic factors for pancreatic cancer have been identified.

PanScan pooled analysis333 and a meta-analysis which included seven case-control and
two cohort studies334 both observed that a family history of pancreatic cancer in a parent,
sibling or child was associated with about 80% increased risk of developing this
malignancy. A family history of prostate cancer also was identified to increase pancreatic
cancer risk (OR=1.45,95% CI=1.12–1.89).333 The ABO blood group has recently
emerged as an important susceptibility factor for pancreatic cancer. Two recent metaanalyses335,336 and a pooled PanScan analysis337 reported compared with blood type O,
subjects with types A, AB, and B have a 23–53% increased risk of pancreatic cancer. In
addition, compared with OO genotype, subjects with AO, AA, BO, BB genotypes
significantly elevated the risk.337 Both inherited high-penetrant mutations in BRCA2,
ATM, PALB2, BRCA1, STK11, CDKN2A and mismatch repair genes as well as lowpenetrant loci were associated with increased risk, and several previous genome-wide
association study (GWAS) of pancreatic cancer with large numbers of cases and controls
of European or North American populations revealed significant associations with single
nucleotide polymorphisms (SNPs) at locations: 9q34.2(ABO)338, 13q22.1(KLF5)339,
5p15.33 (TERT, CLPTM1)339,340, 13q12.2 (PDX1)340, 1q32.1(NR5A2)339, 7q32.3(LINCPINT)340, 16q23.1(BCAR1)340 and 22q12.1 (ZNRF3)340, 17q25.1 (LINC00673)341, 7p13
(SUGCT)341, and 3q29 (TP63)341, 2p13.3 (ETAA1)341 , with odds ratio from 0.77 to 1.46.
2.4.9

Drugs
Many studies have assessed the effect of common drugs on pancreatic cancer,
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such as NSAIDs (with most reports focusing on aspirin), statins and antidiabetic drugs
such as metformin. Three most recent meta-analyses reported aspirin use was inversely
associated with pancreatic cancer incidence,72,342,343 two of them found only high-dose
aspirin use was associated with reduced pancreatic cancer,72,342only one study among
them343 found risk decreased with increasing cumulative year of use of aspirin. Nonaspirin NSAIDs was not associated with pancreatic cancer risk, supported by two metaanalyses.72,342 A pooled analysis with eight clinical trials reported the latent period before
a protective effect of daily aspirin use on pancreatic cancer death was about 5 years.238
Statin use was not found to be associated with pancreatic cancer risk,344 while the
association between metformin use and pancreatic cancer appeared to be inconsistent 345348

among diabetics. With regard to other anti-diabetic medications (ADMs), exogenous

insulin use was investigated in many studies, with consistent findings that supported an
increased pancreatic cancer risk with insulin use.40,346,349,350Although insulin, itself, can
promote carcinogenesis either directly or indirectly by increasing insulin-like growth
factor-1 activity, resulting in abnormal stimulation of multiple cellular signaling cascades
and affecting cell metabolism,351 understanding the complex relationship between ADMs
and pancreatic cancer risk is particularly difficult. Under a markedly diabetogenic state
(normally found in pancreatic cancer patients), those with previously stable diabetes may
experience worsening of their glycemic control and, hence, are more likely to require
multiple ADMs, or require aggressive insulin therapy. The reverse causality, wherein the
inherent nature of pancreatic cancer may have resulted in overestimation of the apparent
carcinogenic effects of insulin, is difficult to measure.346 In a recent large prospective
randomized trial, use of insulin glargine as compared with standard care was not
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associated with an increased incidence of cancer, though pancreatic cancer was not
independently evaluated in this study.352
2.5

Summary of dietary factors and pancreatic cancer risk in the PLCO and

NIH-AARP Studies
As reported above, several dietary factors have been examined with pancreatic
cancer risk in the two prospective cohorts that are utilized in this dissertation (PLCO and
NIH-AARP studies). Table 1 below summarizes the main findings with regard to
associations between all dietary factors and pancreatic cancer identified from these two
cohorts. Some dietary factors such as red meat which contained mostly pro-inflammatory
components were associated with increased pancreatic cancer risk in the NIH-AARP,248
whereas saturated fat was inversely associated with risk in the PLCO.256 Some antiinflammatory dietary factors such as fruits and vegetables were not associated with
pancreatic cancer risk in the pooled cohort which included the PLCO .261 The different
relationships between inflammation-modulated foods/nutrients and pancreatic cancer
provide further justification for examining whole dietary patterns with regard to
inflammation and pancreatic cancer risk in these two large, prospective cohort studies.
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Table 2.1 Summary table for associations between dietary factors and pancreatic
cancer in the PLCO and NIH-AARP
Dietary
factors
Meat and
associated
products

PLCO
Citation
Anderson KE
et al. (2012)
Pancreatic
cancer risk:
associations
with meatderived
carcinogen
intake in the
Prostate,
Lung,
Colorectal,
and Ovarian
Cancer
Screening
Trial (PLCO)
cohort.
Molecular
carcinogene45

NIH-AARP

Main findings
Pancreatic cancer
risk comparing
exposure Q5 vs
Q1:
Red meat intake
with well to very
well doneness
level
HR=1.6 (95%CI
=1.01-2.54), Ptrend=0.04
Red BBQ meat
with well to very
well doneness
level
HR=1.35 (95%CI
=1.00-1.83)
Mutagenic
Activity Index
(MAI)
HR=1.87
(95%CI=1.16,
3.02), Ptrend=0.08
Meat-derived
mutagen 2-amino3,4,8trimethylimidazo[
4,5-f]quinoxaline
(DiMeIQx)
HR=1.81
(95%CI=1.20,
2.74), Ptrend=0.08
Meat-derived
mutagen 2-amino3,8dimethylimidazo[4
,5-f]quinoxaline
(MeIQx)
HR=1.75
(95%CI=1.11,
2.76), Ptrend=0.08
Other mutagens
including the
benzo(a)pyrene
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Citation
Taunk P et al.
(2016) Are
meat and
heme iron
intake
associated
with
pancreatic
cancer?
Results from
the NIHAARP diet
and health
cohort. Int J
Cancer248

Main findings
Pancreatic cancer risk
comparing exposure Q5 vs
Q1:
Total meat
HR = 1.20, 95%CI=1.021.42, P-trend = 0.03
Red meat
HR=1.22, 95%CI =1.011.48, P- trend = 0.02
High-temperature
cooked meat
HR=1.21, 95%CI=1.00-1.45,
P-trend = 0.02
Grilled/barbequed meat
HR = 1.24, 95% CI=1.031.50, P-trend = 0.007
Well/very well done meat
HR=1.32, 95% CI=1.101.58, P-trend = 0.005
Heme iron from red
meat (Q4vsQ1)
HR=1.21, 95% CI=1.011.45, P- trend = 0.04
All these significant
associations above were
observed among all
population and among men
only, but not among women.
Meat types: White meat and
processed meat were not
associated with pancreatic
cancer among all, but
women had a significant
association of white meat
and pancreatic cancer
HR=1.33, 95% CI=1.021.74, P- trend =0.04
Meat cooking methods:
pan-fried meat, oven-broiled
meat, sautéed, baked or
microwaved meat were not
risk factors for pancreatic
cancer, but rare/medium
done cooked meat was

(BaP) and one
hydroxycitric acid
[2-amino-1methyl-6phenylimidazo[4,5
-b]pyridine
(PhIP)] were not
associated with
pancreatic cancer
risk

borderline associated with
pancreatic cancer among all
population
Heme iron intake and meatderived mutagens were not
found to be related to
pancreatic cancer

Jiao L et al.
(2015)
Dietary
consumption
of advanced
glycation end
products and
pancreatic
cancer in the
prospective
NIH-AARP
Diet and
Health Study.
Am J Clin
Nutr249

StolzenbergSolomon RZ
et al. (2007)
Meat and
meatmutagen
intake and
pancreatic
cancer risk in
the NIHAARP
cohort.
Cancer
epidemiology
, biomarkers
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Pancreatic cancer risk
comparing exposure Q5 vs
Q1:
Red meat
Men: HR=1.35,
95%CI=1.07-1.70, Ptrend=0.05
Red meat cooked at high
temperature
Men: HR=1.29,
95%CI=1.04-1.59, P
trend=0.005
Processed meat
Men: HR=1.15, 95%
CI=0.95-1.40, P trend=0.19
N(ϵ)-(carboxymethyl)lysine
(CML) Advanced glycation
end products (AGEs):
Men: HR=1.43, 95%
CI=1.06-1.93, P trend =
0.003
Women: HR=1.14, 95%
CI=0.76-1.72, P-trend = 0.42
Meat consumption was not
associated with risk of
pancreatic cancer in women
Pancreatic cancer risk
comparing exposure Q5 vs
Q1:
Total meat
Men: HR=1.41,
95%CI=1.08-1.83, P
trend=0.001
Red meat
Men: HR=1.42,
95%CI=1.05-1.91, P
trend=0.01
High-temperature
cooked meat
Men: HR=1.52,
95%CI=1.12-2.06, P
trend=0.005

&
prevention353

Grilled or barbecued meat
Men: HR=1.46,
95%CI=1.06-2.00, P
trend=0.02
Oven-broiled meat
Men:HR=1.45 ,95%=1.121.89, P trend=0.006
Overall mutagenic activity
(revertant colonies/1,000
kcal)
Men: HR=2.32,95%=1.523.56, P trend=0.001
Total DiMeIQx among all:
HR=1.29 ,95%=1.01-1.64, P
trend=0.006
White meat and processed
meat and other cooking
methods and meat doneness
were not associated with
pancreatic cancer in men. No
associations between meat
and cooking methods among
women were detected.

AschebrookKilfoy B et
al. (2011)
Pancreatic
cancer and
exposure to
dietary nitrate
and nitrite in
the NIHAARP Diet
and Health
Study.
American
journal of
epidemiology
250
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No association between total
nitrate or nitrite intake
and pancreatic cancer in men
or women.
Processed meat sources of
dietary nitrate and nitrite
Men: HR=1.18, 95% CI=
0.95-1.47, P-trend=0.11
Women: No association
Nitrate/nitrite intake from
processed meat at ages 1213 years
Men: HR= 1.32, 95%CI=
0.99-1.76; P-trend = 0.11
Women: no association with
adult or
adolescent nitrate or nitrite i
ntake from processed meats

Fat and
fatty acids

Arem H et al
(2013).
Dietary fat
intake and
risk of
pancreatic
cancer in the
Prostate,
Lung,
Colorectal
and Ovarian
Cancer
Screening
Trial. Annals
of
epidemiology
256

Total fat
HRQ5VSQ1=0.64,
95% CI=0.39–
1.06, Ptrend=0.015 (<4
years);
HRQ5VSQ1=0.76,
95% CI=0.51–
1.15, P-trend=0.35
(>=4 years)

Thiebaut AC
et al. (2009)
Dietary fatty
acids and
pancreatic
cancer in the
NIH-AARP
diet and
health study.
J Natl Cancer
Inst257

Saturated fat
intake
HRQ5VSQ1=0.37,
95% CI=0.21–
0.63, Ptrend<0.001 (<4
years);
HRQ5VSQ1=0.88,
95% CI=0.58–
1.33, P-trend=0.49
(>=4 years)
Intakes of MUFA
and PUFA and fats
from animal or
plant sources
showed no
associations with
risk. Dietary
changes due to
undetected disease
may explain the
observed inverse
associations

Carbohydr
ate intake,
GL, GI,
dietary
fructose
and
sucrose

Meinhold CL
et al. (2010)
Available
carbohydrates
, glycemic
load, and
pancreatic
cancer: is

Pancreatic cancer
risk comparing
exposure 90th
versus 10th
percentile
GL
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Pancreatic cancer risk
comparing exposure Q5 vs
Q1:
Total fat
HR=1.23,95% CI=1.03-1.46,
P-trend=0.03
Saturated fat
HR=1.36, 95%CI=1.14-1.62,
P-trend<0.001
Monounsaturated fat
HR=1.22, 95%CI=1.02-1.46,
P-trend=0.05
Polyunsaturated fat
HR=1.00, 95% CI=0.841.18, P-trend=0.68
food sources of fat:
the positive association of
total, saturated, and
monounsaturated fat with
pancreatic cancer was seen
from food sources from
animal foods
(HR=1.23,1.19,1,22,
respectively), especially red
meat and dairy products and
was not determined by
vegetable food sources
Individual fatty acids:
Increased intake of two
types of saturated fatty acids
(palmitic acid and stearic
acid), one MUFAPalmitoleic acid, one n-6
PUFA-Arachidonic acid, and
two n-3 PUFAs
(Eicosapentaenoic acid,
Docosahexaenoic acid) were
associated with increased
risk of pancreatic cancer
with HR from 1.19 to 1.34.

Jiao L et al.
(2009)
Glycemic
index,
carbohydrates
, glycemic
load, and the
risk of

Total trans fatty acids:
HR=0.99, 95% CI=0.83 to
1.17, P-trend>0.99
There were no associations
between GI, total or
available carbohydrates, GL,
and pancreatic cancer risk.
In terms of individual
available carbohydrate
constituents, only fructose

there a link?
American
journal of
epidemiology
354

HR=1.45, 95%
CI=1.05-2.00
GI
HR=1.08, 95%
CI=0.78-1.49
Available
carbohydrate
HR=1.47, 95%
CI=1.05-2.06
Sucrose HR=1.37,
95% CI= 0.991.89
GI and intakes of
starch and fructose
were not
associated with
pancreatic cancer.

Fruit and
vegetable

Koushik A et
al. (2012)
Intake of
fruits and
vegetables
and risk of
pancreatic
cancer in a
pooled
analysis of 14
cohort
studies.
American
journal of
epidemiology
261

The positive
association for
available
carbohydrate
intake, glycemic
load, sucrose,
fructose, and
inverse association
with saturated fat,
and total fat were
strongest in the
first 2 years and
attenuated with
subsequent followup.
Pancreatic cancer
risk comparing
exposure of each
100g/day
increment in
intake
Total fruits and
vegetables
combined
RR=1.01 (95%
CI=0.99-1.03)
Total vegetables
RR=1.02 (95%
CI=0.99-1.06)
Total fruits
RR=1.01 (95%
CI=0.99-1.03)
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pancreatic
cancer in a
prospective
cohort study.
Cancer
epidemiology
, biomarkers
&
prevention355

and glucose were associated
with pancreatic cancer risk
Free fructose
HRQ5VSQ1=1.29, 95%
CI=1.04-1.59, P trend=0.004
Glucose (Q5 VS Q1)
HRQ5VSQ1=1.35,95%
CI=1.10-1.67, P trend=0.005

Alcohol

Jiao L et al.
(2009)
Alcohol use
and risk of
pancreatic
cancer: the
NIH-AARP
Diet and
Health Study.
American
journal of
epidemiology

Total alcoholic drinks per
day (>=6 drinks/day vs light
drinkers who take 0-0.99
drinks/ day)
RR=1.55, 95% CI=1.132.13, P-trend=0.004;
Total alcoholic drinks >=3
drinks/day vs 0-0.99 drinks/
day
RR=1.45, 95% CI=1.17,
1.80, P-trend = 0.002
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Liquor use (>=3 drinks/day
vs >0-0.99 drinks/day)
RR=1.62, 95% CI=1.242.10, P trend=0.001

Coffee

Guertin KA
et al. (2015)
A prospective
study of
coffee intake
and
pancreatic
cancer:
results from
the NIHAARP Diet
and Health
Study. Br J
Cancer274

Dietary
pattern

Arem H et al.
(2013) The
Healthy
Eating Index
2005 and risk
for pancreatic
cancer in the
NIH-AARP
study. J Natl
Cancer Inst281
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Significant association
between total alcohol and
liquor drink was only
observed among men not
women.
Beer or wine use was not
associated with the risk.
No association between
total, caffeinated, or
decaffeinated coffee intake
and pancreatic cancer, and
the observed null association
was consistent across all
examined strata (sex,
smoking status and prevalent
diabetes)

Pancreatic cancer risk
comparing exposure Q5 vs
Q1:
HEI-2005
Men and women
HR=0.85, 95% CI= 0.740.97, P-trend=0.003
Men and women had similar
HR, but association was not
statistically significant
among women

Among men, P interaction
by BMI=0.03
HR=1.21, 95% CI=0.88 1.67, P-trend=0.23 (normal
weight men
HR= 0.72, 95% CI = 0.590.88, P-trend<0.001
(overweight/obese men)

Jiao L et al.
(2009) A
combined
healthy
lifestyle score
and risk of
pancreatic
cancer in a
large cohort
study.
Archives of
internal
medicine282
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Health diet quality vs.
unhealthy diet quality (5–8
points for aMDS excluding
alcohol vs 0–4 points)
HR=0.92, 95% CI=0.81-1.05

CHAPTER 3
3
METHODS
3.1

Statement of research aims and hypotheses
The overall aims of the dissertation were to examine the association between the

inflammatory potential of diet measured by the DII and pancreatic risk in the PLCO and
NIH-AARP cohorts, to assess effect measure modification by sex and inflammationrelated lifestyle factors including BMI, cigarette smoking, alcohol drinking, diabetes
history and NSAIDs, as well as to investigate the mediated effect of type-2 diabetes in the
association of E-DII and pancreatic cancer. Specifically, for Aim 1, we investigated if the
inflammatory potential of diet impacted pancreatic cancer in the PLCO, and examined
how sex and BMI modified the association. For Aim 2, we examined the association
between E-DII and pancreatic cancer risk in the NIH-AARP, and examined effect
modification by sex, BMI, smoking status, history of diabetes, alcohol drinking and
NSAIDs use. With Aim 3, we conducted a causal mediation analysis to explore the
mediated effect of type-2 diabetes in the association between E-DII to pancreatic cancer
in the PLCO and NIH-AARP separately and in a pooled analysis after demonstrating that
between-study heterogeneity was not significant.
Our hypothesis was that greater inflammatory potential of diet would be
associated with higher risk of pancreatic cancer in both studies, inflammation-related
lifestyle conditions (overweight or obese individuals, individuals with previous smoking
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history, high level of alcohol drinking, those who had presence of diabetes history, or less
NSAIDs use frequency) could act jointly with E-DII to increase pancreatic cancer risk,
and that type-2 diabetes mediated the E-DII and pancreatic cancer association (i.e.,
dietary inflammatory potential has indirect effect on pancreatic cancer through increasing
risk of type-2 diabetes).
3.2

Description of the study population

3.2.1

Participants from PLCO Cancer Screening Trial
PLCO is a large population-based randomized controlled trial with the aim to

assess the effects of prostate, lung, colorectal and ovarian cancer screening tests on
cancer-related mortality and secondary endpoints in men and women aged 55 to 74 years.
A detailed description of the PLCO study design was published elsewhere.43 Briefly, a
total of 154,897 eligible participants (76,682 men and 78,215 women), aged 55–74, were
enrolled into the trial from 1993 to 2001 from ten screening centers across US and
randomized based on sex and age group into either a control arm where usual care was
received, or an intervention arm where screening exams for prostate, lung, colorectal or
ovarian cancers were received. Participants included in the intervention arm received
screening during their first 6 years in the trial: women had chest x-rays, flexible
sigmoidoscopy, cancer antigen (CA)-125 blood tests, and transvaginal ultrasound and
men received chest x-rays, flexible sigmoidoscopy, prostate-specific antigen (PSA) blood
tests, and digital rectal exams and all the participants in the intervention arm were
subsequently followed up for at least 7 additional years. The screening component of the
trial was completed in 2006. Participants in the control arm were followed for 13 years
after enrollment.44
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Participants in PLCO were uncompensated volunteers recruited from the general
population in the geographic area of each of the screening centers. They were excluded
from the study if they met any of the following criteria44: (1) underwent cancer treatment
at the time of randomization (excluding basal-cell and squamous-cell skin cancer); (2)
had known prior cancer of the colon, rectum, lung, prostate (men only) or ovary (women
only), including primary or metastatic PLCO cancers; (3) before October 1996, women
with previous surgical removal of both ovaries were excluded from the trial, and
beginning in October 1996, these women were not excluded; (4) participated in another
cancer screening or cancer primary prevention trial; (5) males who had taken
Proscar/Propecia/finasteride in the 6 months before randomization; (6) before April 1,
1999, women were excluded from the trial if they currently took or had taken Tamoxifen
or Evista\Raloxifene in the 6 months prior to randomization; after April 1, 1999, women
who had been or currently took Tamoxifen or Evista\Raloxifene were not excluded; (7)
males who had more than one PSA blood test in the three years prior to randomization;
(8) individuals who had a colonoscopy, sigmoidoscopy, or barium enema in the three
years prior to randomization; (9) individuals who were unwilling or unable to sign the
informed consent form.
In general, a majority of recruited participants were non-Hispanic white, married
or living as married, had higher education level than some college, overweight at
baseline, and above 85% of female participants were postmenopausal.45 A selfadministered baseline questionnaire, which included questions on demographic factors,
medical history and health-related behaviors was collected from all subjects at the time of
randomization. Dietary data were collected with the use of a self-administered FFQ, the
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Diet History Questionnaire (DHQ), version 1.0 (National Cancer Institute, 2007), which
was introduced to the intervention and control arms between 1998 and 2005.357
Depending on the time a subject was recruited into study, only a small portion of subjects
in the control arm completed DHQ at randomization while most subjects returned back
the form at their third to five years after randomization.44 The DHQ queried frequency
and portion size of 124 food items consumption during the past year.358 A supplemental
questionnaire was introduced to all subjects in 2006 to update information that may have
changed since completion of baseline questionnaire, which included medication use,
demographic factors, and updated healthy history. The study was approved by the
Institutional Review Boards of the National Cancer Institute and each of the centers that
participated.
3.2.2

Participants from NIH-AARP Diet and Health Study
The NIH-AARP Diet and Health Study is the largest prospective cohort study of

diet and health ever conducted in US and it was initiated in 1995 to 1996 when a baseline
questionnaire asking information on demographic characteristics, medical history, dietary
intake and health behaviors was mailed to 3.5 million AARP members with the goal to
examine a number of important diet and cancer relationship hypotheses.359 The scientific
rationale and study design of the cohort was described previously.46 The initial study
population of this cohort was 617,119 females and males who responded to the baseline
questionnaire with a response rate of 17.6%. Study exclusion criteria included: (1)
responses on the questionnaire were not reliable (i.e., unknown sex, skipped everything,
skipped facing page that provided personal information and date when they completed
the questionnaire, deceased or proxy respondent, more than 10 recording errors and less
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than 10 foods consumed); (2) respondents asked to be dropped from cohort; (3) died or
moved before entry; (4) those with duplicate representation of the questionnaire.46
Participants in the NIH-AARP were 50 to 71 years old with mean age of 62 years at
baseline and lived in one of six states (California, Florida, Pennsylvania, New Jersey,
North Carolina, or Louisiana) or two metropolitan areas (Atlanta, Georgia or Detroit,
Michigan).46 Participants were predominantly white, have higher education level and
lower percentage of current smokers than the general US population.46,360 The selfadministered NCI-developed DHQ included in the baseline questionnaire assessed
participants’ usual frequency of intake and portion size on 124 food items over the past

year. It also included 21 additional questions on food choices and cooking practices, and
four supplement intake questions.361 One year after the baseline questionnaire, a risk
factor questionnaire was sent out in 1996 to 1997 to collect information of some common
lifestyle or risk factors such as cooking practices in the past year, physical activity, family
history of cancer, diet habit during young adulthood and other health behaviors. In 2004,
a follow-up questionnaire was sent out to members to record their cancer status and other
non-cancer endpoints as well as update medical use and other demographic
information.359 The study was approved by the National Cancer Institute Special Studies
Institutional Review Board.
3.3

Diet assessment

3.3.1

Diet data from PCLO and NIH-AARP
The main exposure variable in this dissertation was the derived E-DII score

calculated based on dietary responses from the DHQ in PLCO and NIH-AARP (both
studies employed the NCI-developed DHQ but with different templates) with linkage to

66

the corresponding inflammatory effect score designated in the DII. The DHQ in both
studies was used to assess the frequency and portion size of 124 food items during the
past year among cohort participants. Participants in both studies were asked to choose
from 10 frequency categories ranging from “never” to “>=6 times/d” for beverages, from
“never” to “>=2 times/d” for solid foods and three categories of portion sizes.362,363 In the
PLCO DHQ, from one to seven additional embedded questions are asked about related
factors such as seasonal intake, food type (e.g., low fat, fat-free, lean, caffeine free),
and/or fat uses or other additions use on 44 out of the 124 foods.362 Daily nutrient intake
was calculated by the DietCalc software, which links responses of food frequency,
portion size, and other relevant responses from the DHQ with a nutrient database based
on national dietary data (USDA's 1994-96 Continuing Survey of Food Intakes by
Individuals and supplemented by the Nutrition Data Systems for Research from the
University of Minnesota).364 Three studies were conducted to evaluate the PLCO DHQ’s
measurement performance. The first study used a checklist and showed that most of the
cognitive improvements incorporated in the PLCO DHQ resulted in better measure of
frequency than was 1992 NCI Block questionnaire.365 The second validation, which
compared the DHQ to two widely used FFQs (the 1995 Block FFQ and the Willett FFQ),
showed the DHQ performed best overall among the three instruments for estimating
absolute intake of most nutrients.363 However, the third validation study, the Observing
Protein and Energy Nutrition (OPEN) study, which compared intake of energy and
protein estimated based on the DHQ with unbiased biomarkers, doubly labeled water for
energy and urinary nitrogen for protein among 484 healthy adult men and women living
in Maryland, suggested significant underreporting by both men and women for protein
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and total energy366 and measurement error on the DHQ which may lead to severe
attenuation in estimated disease relative risks.367 We obtained diet data of 35 food
parameters out of the 45 food parameters in the DII from PLCO to calculate the E-DII
score for each individual, which included alcohol, vitamin B12, vitamin B6, betacarotene, caffeine , carbohydrate , cholesterol, food energy, total fat, total dietary fiber,
folate , iron, magnesium, monounsaturated fatty acids, poly-unsaturated fatty acids,
niacin, onions, protein, riboflavin, saturated fatty acids, selenium, thiamin, total transfatty acids, vitamin A, vitamin C, vitamin E , vitamin D, zinc, tea, flavan-3-ols, flavones,
flavonones, anthocyanidin, isoflavone , and peppers.
The DHQ used in the NIH-AARP allowed for variation in eating patterns in
different parts of the country because it contained some regional and ethnic groupspecific foods. To assess relative validity and reliability, the baseline DHQ was compared
to two nonconsecutive 24-hour dietary recalls (randomly assigned by day of the week
with a median of 21 days apart) and a second FFQ among 1,415 participants who
responded to baseline DHQ in the NIH-AARP. After adjusting for random within-person
error, the energy-adjusted correlation coefficient ranged from 0.40 (vitamin E) to 0.76
(saturated fat) among men, and from 0.36 (vitamin E) to 0.70 (vitamin B6) among
women.361 NIH-AARP study respondents were found to consume less fat and red meat
but more fruits and vegetables than comparably aged general US adults.353 Responses
from the DHQ were linked to the US Department of Agriculture’s (USDA) Continuing
Survey of Food Intakes of Individuals (CSFII) survey databases (1989–91 initially, and
1994–96 as it became available), in order to estimate intake values of nutrients, foods,
and food group intakes.364 Thirty-four out of the 45 food parameters were available in the
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NIH-AARP dataset. These include the following: calories; carbohydrates; protein; total
fat; saturated, monounsaturated, and polyunsaturated fat; trans-fat; alcohol; fiber;
cholesterol; vitamins B1, B2, B6, B12, A, C, D, and E; niacin; iron; magnesium; zinc;
selenium; folic acid; beta-carotene; anthocyanidins; flavan-3-ols; flavones; flavonones;
isoflavones; caffeine; green peppers; and tea. To calculate flavonoid classes, DHQderived daily fruits and vegetables intake in grams will be linked to the US Department
of Agriculture (USDA)’s Database for Flavonoid Content from Selected Foods (Release
3.1, December 2013) by matching foods with the USDA’s 5-digit nutrient database
number. Once linked, the content levels of each flavonoid class will be applied to each
fruit and vegetable in the DHQ and summed to provide a total value for each flavonoid
class.34
3.3.2

E-DII score calculation

The DII is a literature-derived, population-based index used to measure individual’s diet
in terms of inflammatory potential. The development22 and construct
validation23,24,26,27,29,30,188 of the DII have been described previously. The goal in
developing the DII was to create a score that could assess the overall quality of diet with
regard to its inflammatory potential. A total of about 6,500 research articles published
through December 2010 on the effect of dietary parameters on six well-established
inflammatory markers (CRP, IL-1β, IL-4, IL-6, IL-10, TNF-α) were screened for
inclusion in the DII scoring algorithm. CRP, IL-1β, IL-6 and TNF-α are considered proinflammatory biomarkers while IL-4 and IL-10 are considered anti-inflammatory
cytokines. A total of 1,943 research articles were reviewed and scored based on 45 proand anti-inflammatory food parameters identified in the search. One of three possible
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values was assigned to each article based on the effect of the food parameter on
inflammation: “+1” was assigned if the effects were pro-inflammatory (significantly
increased IL-1 β, IL-6, TNFα, or CRP or decreased IL-4 or IL-10); “-1” if the effects
were anti-inflammatory (significantly decreased IL-1β, IL-6, TNFα, or CRP or increased
IL-4 or IL-10) and “0” if the food parameter had no relationship with the inflammatory
marker. Sometimes, foods had differential effects in a study (have both anti-inflammatory
and pro-inflammatory effects), then this article was scored separately, assigning ‘−1’ for
its anti-inflammatory effect and ‘+1’ to the same article for its pro-inflammatory effect.
Articles were first weighted by study design, with clinical trials receiving the highest
weight and cell culture studies receiving the lowest weight. Using these weights, the proand anti-inflammatory fractions for each food parameter were calculated. The “food
parameter-specific overall inflammatory effect score” was then calculated by: 1) dividing
the weighted pro- and anti-inflammatory articles by total weighted number of articles and
2) subtracting the anti-inflammatory fraction from the pro-inflammatory fraction. A cut
point of 236, the median of the total weighted number of articles across all the food
parameters, was chosen to indicate an optimally robust pool of literature. All food
parameters with a weighted number of articles ≥236 were assigned the full value of the
score which was regarded as the food parameter-specific raw inflammatory effect score.
Foods and constituents with a weighted number of articles <236 were adjusted as
follows: (1) number of weighted articles was divided by 236; (2) the fraction was then
multiplied by the food parameter-specific raw inflammatory effect score.22 To avoid the
arbitrariness as a result of simply using raw intake amounts, having consequence of
different units of measurement for various nutrients which could exert large influences on
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the overall score, the DII was standardized to a representative range of global dietary
intake based on actual human consumption. This was accomplished by constructing a
composite database representing a wide range of dietary intake consumed among
populations living in countries in different regions in the world.22 Authors of articles
reporting dietary data from nutrition surveys were contacted to request access to complete
datasets. A total of 11 such datasets were identified and used in developing the composite
worldwide dietary database with the detailed methods described in the reference.22 Thus,
this representative world diet database provided an energy-adjusted mean intake and
standard deviation for each food parameter as a reference to standardize the E-DII score.
To calculate the overall E-DII score for each participant in a given study, dietary data
from each study were first energy adjusted to take into account the difference in total
energy intake and linked to the world composite database. By subtracting the standard
global energy-adjusted mean from the energy-adjusted intake reported by the individual
and dividing this value by its standard deviation, we obtained the multipliers to express
an individual's exposure relative to the ‘global mean’ as a Z-score. To minimize the effect
of “right skewing,” this value was converted to a percentile score. To achieve a
symmetrical distribution with values centered on 0 (null) and bounded between -1
(maximally anti-inflammatory) and 1 (maximally pro-inflammatory), each percentile
score was doubled and then 1 was subtracted. The centered-percentile value for each food
parameter was then multiplied by its respective food parameter-specific inflammatory
effect score to obtain a food parameter-specific E-DII score. Finally, all of the food
parameter-specific E-DII scores were summed to create the overall E-DII score for an
individual.22 This approach both ‘anchors’ an individual's exposure to a robust range of
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diet habits in a variety of countries and obviates completely the problem of noncomparability of units because the Z-scores and percentiles are independent of the units
of measurement (refer to Figure 3.1 for the E-DII score calculation flow chart). More
positive scores represent a more pro-inflammatory diet, whereas more negative scores
represent a more anti-inflammatory diet. When DII scores were calculated based on the
composite global dietary database, the DII score was between +7.98 for maximally proinflammatory diet, to −8.87 for the maximally anti-inflammatory diet and the median was
+0.23.22 E-DII scores from food plus supplement were calculated as exposures in each
cohort. The DII score, calculated from multiple different dietary assessment instruments,
were found to be associated with higher levels of IL-6,24 TNF-α receptor 2,24 hsCRP23,27
and homocysteine.25
3.4

Covariates assessment
Based on the comprehensive literature review about risk factors for pancreatic

cancer stated in Chapter 2 and the directed acyclic graph (DAG) (Figure 3.2) which
described the relationship among all the considered variables in the association between
DII and pancreatic cancer, potential covariates to be included in both PLCO and NIHAARP studies were age at baseline (continuous), sex (male and female), race/ethnicity
(Hispanic, Non-Hispanic Black, Non-Hispanic White, Others, missing), BMI
(underweight, normal, overweight, obese, missing), alcohol consumption (continuous,
grams/day), screening arm of PLCO (screening arm or control arm) , total energy intake
(kcal/day, continuous), physical activity (never/rarely, 1–3times per month, 1–2times per
week, 3–4times per week, or >=5times per week), past medical disease history including
chronic pancreatitis, gallstone, cholecystectomy, gastric or duodenal ulcer, gastrectomy,
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periodontal disease, venous thromboembolic events, HBV and HCV infection (yes or no),
first-degree family history of pancreatic cancer (yes/no), first-degree family history of
prostate cancer (yes/no), cigarette smoking status (never smoker, former smoker, current
smoker), pack-years of cigarette smoking (continuous), number of years of smoking
cessation among former smokers since stopped smoking (1, 1–5, 5–10, or >10 years
before baseline), ever used other tobacco products (yes or no), self-reported history of
diabetes (yes or no), and NSAIDs use frequency (none,1-3times/month, 1-2times/week,36 times/week, >=7 times/week). These covariates were all self-reported on baseline
questionnaires in PLCO and NIH-AARP except that physical activity over the past year
was not assessed at baseline in the PLCO but was assessed on the supplemental
questionnaire and NSAIDs use information was collected from the risk factor
questionnaire in the NIH-AARP. BMI was calculated as weight (kg)/height(m)2 and
categorized based on the World Health Organization criteria.368
3.5

Effect measure modifiers assessment
Due to smaller case number in PLCO compared to NIH-AARP, in the NIH-

AARP, sex and inflammation-related lifestyle factors were examined as effect modifiers
while sex, BMI, diabetes history and smoking status were examined as effect modifiers in
the PLCO. As mentioned in section 3.5, these effect modifiers in both studies were all
self-reported at baseline or close to baseline (NSAIDs use was assessed in the NIHAARP at one year after baseline). We categorized alcohol intake into high and low level
by using 53.4g as the cut-off point in the interaction test in NIH-AARP given the
evidence in the 2012 American Institute for Cancer Research (AICR) CUP report for
pancreatic cancer that supported a nonlinear association between alcohol and pancreatic
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cancer risk with increased risk observed among those consuming 53.4g alcohol or more a
day.239 Based on previous evidence showing time may have a significant interaction with
dietary factors in pancreatic cancer etiology using a cutoff of 4 years of follow-up, 256,354
we also examined time (<4 and >=4 years) as effect modifier in both cohorts to be
comparable to the two previous studies.
3.6

Outcomes assessment
The outcome of interest for each aim was defined as incident adenocarcinoma of

the exocrine pancreas: International Classification of Diseases for Oncology, Third
Edition, codes C25.0-C25.3, C25.7- C25.9. In the PLCO, explicit diagnosis date with
confirmed cancer status (rather than death) of incident exocrine pancreatic cancer was
available, so we used this date as the outcome occurrence date. However, in the NIHAARP, they did not distinguish between pancreatic cancer death and incidence in the
pancreatic cancer diagnosis status variable. Thus, pancreatic cancer date of death was
compared to date of diagnosis to determine which subjects died of pancreatic cancer. A
sensitivity analysis was conducted where date of pancreatic cancer diagnosis was
imputed for those subjects who died from pancreatic cancer. Based on a literature review,
the median survival time of exocrine pancreatic cancer after diagnosis is four months,369
the value of date of diagnosis is the death date for pancreatic cancer minus four months,
since the unit of time we used in the analysis was years, we did not impute the date of
diagnosis using statistical method due to the very small values for the time variable. Our
case definition in both studies excluded endocrine tumors (histology types 8150–8155,
8240, 8246, and 8502) and some other rare histology types such as islet cell adenoma,
carcinoid tumor, sarcoma because these types and exocrine pancreatic cancer may have

74

different disease mechanisms and etiology.370 In the PLCO, pancreatic cancer cases were
ascertained through a mailed annual questionnaire in which subjects were asked if they
had been diagnosed with cancer by a health care provider. They were then asked to
provide information on the type of cancer.371 Additional sources for identification of
pancreatic cases included state registries, death certificates, physician reports, and reports
from next of kin (for deceased subjects).371 These cases were then confirmed by
abstraction from medical records.371 We calculated the person-years of follow up for each
individual from the date of DHQ to the date of first incident pancreatic cancer diagnosis,
to censoring at the date of death, study withdrawal or the end of data collection for the
study which was the first of either 13 years after randomization or 12/31/2009, whichever
came first.44
In the NIH-AARP, participants were followed up yearly by using the National
Change of Address database (U.S. Postal Service) and MaxCoA (Anchor Computer Inc.).
Approximately 4% of participants were lost to follow-up.249 Vital status was ascertained
by annual linkage to the Social Security Administration Death Master File.249 Incident
pancreatic cancer cases were identified by linkage to 11 state cancer registries (the 8
original states where participants were recruited as well as Arizona, Nevada, and Texas),
and mortality cases were identified by linkage to the National Death Index.249 Similar to
PLCO, the person-years of follow up for each individual was calculated from the date of
response to baseline questionnaire to the date of first incident exocrine pancreatic cancer
diagnosis, or to censoring at the date of death, or move out from the study area, or the end
of study which was December 31, 2011, whichever came first.
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3.7

Statistical analysis

3.7.1

Statistical methods for specific aim 1 and 2

3.7.1.1 Primary aim analysis: relationship between E-DII and pancreatic cancer risk
Among the eligible study population in each study, we further excluded participants with
any cancer history at baseline and with extreme total energy intake and those with
implausible BMI. E-DII score was adjusted for total energy intake using the energy
density model372 and categorized to various quantiles (tertiles, quartiles, quintiles, and
deciles) first to examine the trend. The decision of which quantile to use in final models
was made based on the trend results and distribution of E-DII and case number in each
category, as well as the result after examination of the proportional hazards assumption.
In both studies, we categorized E-DII into quintiles, and the trend in other quantiles were
similar with quintiles of E-DII. In the NIH-AARP, we treated E-DII as both a categorical
and a continuous variable. The lowest E-DII category served as the referent group.
Potential confounding variables in our analysis include those listed in section 3.5 above.
Confounding variables were assessed using two methods: (1) 10% rule method where
covariates were added to the crude model individually and ≥10% changes in the risk
estimate for the highest compared to lowest E-DII quintile was regarded as confounding;
(2) covariates which were both related to E-DII (categorical or continuous) and
pancreatic cancer risk were regarded as confounders. Covariates determined to be
confounders using either aforementioned method and effect modifiers were retained in
the final multivariable-adjusted models. 249 We checked the Spearman rank correlation
coefficient between each two continuous variables included in the final model to make
sure there was no collinearity indicated by statistically significant large coefficient
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(>=0.7) and P value<=0.05.373 Descriptive baseline demographic and lifestyle
characteristics of the study population were generated, including means and standard
errors (SE) for the continuous variables and frequencies and proportions for the
categorical variables. Analysis of variance (ANOVA) was used to test the difference
across E-DII quintiles for continuous variables, and Chi-square test was performed to test
the difference for categorical variables. To estimate and compare the risk of pancreatic
cancer by quintiles of E-DII score, multivariable Cox proportional hazards regression
with person-year as the underlying time metric was fitted to estimate the age- and energyadjusted and multivariable-adjusted hazard ratios HRs and 95% CIs with subjects in the
lowest E-DII quintile (the most anti-inflammatory score) as the referent. Proportional
hazard (PH) assumption was examined using the Schoenfeld residual test.374
Stratification or interaction of time and covariate was used for those covariates that did
not meet the PH assumption. Linear trend test was performed by using the continuous EDII variable and in the multivariable-adjusted models. Continuous HR and 95% CIs also
were calculated and reported for each one unit of standard deviation increase of E-DII
score after the restricted cubic spline test indicated the linear assumption was sufficient in
the NIH-AARP.375 In the NIH-AARP, we presented sex-specific E-DII and pancreatic
cancer association given that men and women had different distributions of the E-DII
score and other covariates, although the interaction by sex was not statistically
significant.
All data analyses were conducted using SAS statistical software (SAS Institute,
Cary, NC). All statistical tests were two-sided, and P values less than 0.05 were
considered as statistically significant.
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3.7.1.2 Secondary aim analyses: effect modification examination
Interaction tests were conducted to examine if the association between E-DII and
pancreatic cancer risk was consistent among strata of variables including sex and BMI in
the PLCO, and sex and inflammation-related lifestyle factors in the NIH-AARP. An
interaction test was performed by including each interaction term (product of quintile EDII score and categorical effect modifier) one at a time in the final multivariable-adjusted
model and conducting -2 log likelihood ratio test. If any interaction was significant (P
value from -2 log likelihood ratio test <=0.1),376 we stratified the effect modifier and
reported the E-DII and pancreatic cancer association in each stratum of the effect
modifier separately, otherwise, we only reported the combined result.
3.7.1.3 Sensitivity analyses
Several sensitivity analyses to examine the robustness of our results under
different scenarios were conducted. In the first sensitivity analysis, we excluded
participants with follow-up<5 years to avoid potential subclinical disease which may
affect usual diet habit to result in reverse causality. A second sensitivity analysis was
conducted to exclude all the participants who self-reported history of diabetes because
there was evidence showing diabetes may be a preclinical indictor of pancreatic
cancer.377 We also restricted the outcome to primary pancreatic cancer only, and in the
NIH-AARP, we added pancreatic cancer death cases to both primary pancreatic cancer
outcomes and the total incident outcomes using the imputed incidence time. We
performed the main analysis and the interaction analyses described in section 3.7.1 in
these sensitivity analyses.

78

3.7.2

Statistical methods for specific aim 3

Based on the analytical cohort of PLCO and NIH-AARP, we further excluded
participants who did not have valid supplemental questionnaire in PLCO or follow-up
questionnaire in NIH-AARP, which contained follow-up data on diabetes, and those who
had baseline diabetes, the remaining subjects constituted the mediation cohort for PLCO
and NIH-AARP separately. Causal mediation analysis approach under the counterfactual
framework was used to first assess the study-specific mediated effect of type-2 diabetes
in the association between E-DII and pancreatic cancer.378 A SAS macro developed by
Valeri and Vanderweele379 was used to calculate the study-specific mediation parameters:
natural direct effect (NDE), natural indirect effect (NIE), and marginal total effect (MTE)
of E-DII on pancreatic cancer risk with type-2 diabetes as a mediator. Briefly, mediation
parameter estimates were obtained in three steps: 1) type-2 diabetes (mediator variable)
was regressed on E-DII using the logistic regression with inclusion of the study-specific
set of confounding variables except that diabetes history at baseline was removed; 2)
pancreatic cancer was regressed on type-2 diabetes and E-DII with inclusion of the E-DII
and type-2 diabetes interaction and the same set of confounders as in 1) using a logistic
regression model, if the interaction was not statistically significant, it was then be
removed from the model; 3) based on the specified comparison levels of exposure,
parameters derived from these two logistic models gave way to essential mediator
parameters through a series of mathematical calculations.379
The incident follow-up type-2 diabetes data was retrieved from the supplemental
questionnaire in the PLCO and from the follow-up questionnaire in the NIH-AARP. Both
questionnaires asked participants whether they have been diagnosed with diabetes and the
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timing when they were diagnosed (choices were several categories of years of diagnosis
or age ranges at diagnosis). Because we excluded participants with baseline diabetes in
the mediation analysis, the study-specific responses to the two above-mentioned diabetes
questions could be used to identify incident diabetes that occurred during follow-up. The
mediator subsequently was coded as a categorical variable with three levels: “yes”, “no”
and “missing” using the following method: 1) if subjects answered they were never
diagnosed with diabetes on the study-specific follow-up questionnaire, these subjects
were assigned “no”; 2) if subjects reported they were ever diagnosed with diabetes, we
further compared their ages at first diagnosis of diabetes using the median value of each
category of the variable indicating diabetes occurrence time on the study-specific followup questionnaires, with their ages at pancreatic cancer diagnosis, and coded mediator as
“yes” if diabetes occurred before pancreatic cancer or no pancreatic cancer occurred,
“no” if diabetes occurred after pancreatic cancer (because mediator as defined should
occur before the occurrence of outcome of interest), or “missing ” if no information on
age at first diagnosis of diabetes; and 3) if subjects did not report whether they were
diagnosed with diabetes, these subjects were assigned “missing” as their mediator level.
In the study-specific mediation analysis, we calculated the NDE, NIE, and MTE
of E-DII on pancreatic cancer risk for subjects in each higher E-DII quintile (i.e., quintile
2, quintile 3, quintile 4, quintile 5) compared to those in the lowest quintile with type-2
diabetes as mediator. We also centered each E-DII value to the mean to report the
mediation effect of a one-unit increase in centered E-DII on pancreatic cancer with type-2
diabetes as mediator. The Z-score of E-DII was calculated by dividing the centered value
by the standard deviation, and used in the mediation model to report the mediation effect
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of type-2 diabetes on the association of one standardized unit increment of E-DII with
pancreatic cancer risk. For all these mediation analysis, we also calculated the mediation
proportion by type-2 diabetes using the equation as follows: proportion of mediation by
type-2 diabetes= NDE x (NIE – 1)/ (NDE x NIE – 1)
A random effects model was used to pool each study-specific mediation effect
(i.e., NDE, NIE, MTE) on pancreatic cancer comparing each higher E-DII quintile to the
lowest quintile, and the study-specific mediation effect on pancreatic cancer associated
with each one unit increment of centered E-DII value and z-score of E-DII, across two
studies. Between-studies heterogeneity was evaluated using the Q statistic 380,381 and I2
statistic.382 If between-study heterogeneity was not significant, we combined primary data
from two cohorts into one dataset by harmonizing categories for the categorical
covariates which were shared in both studies as potential confounders and performed the
mediation analyses as stated above in the pooled mediation cohort of PLCO and NIHAARP. We reassessed the confounders in the pooled cohort using the two methods as
stated in the section 3.7.1.1 and used these confounders in the mediation analysis
procedures.
All statistical tests were two-sided and all data analyses were conducted using
SAS statistical software (SAS Institute, Cary, NC).
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1)1943 articles identified on 45 food
parameters, reviewed and scored
based on inflammation effect

5) Calculate energy-adjusted world
mean and standard deviation for each
of the 45 food parameters using the
world composite database for
45 food parameters based on diet
data from 11 countries

2) Weight articles by study design and
calculate pro- and anti-inflammation
fractions
Energyadjusted
dietary
intake
calculated
from a
given study

3) Adjust scores if total weighted
articles are<236

6) Calculate z-scores and
centered percentiles for each of the
food parameters for each individual
in the study, based on the energyadjusted dietary data and world
mean and standard deviation.

4) Calculate food parameter-specific
overall inflammatory effect score

7) Multiply centered percentile by the inflammatory
effect score for each food parameter and sum across
all 45 food parameters to obtain overall E-DII score

Figure 3.1: Sequence of steps to calculate the energy-adjusted DII score in the
PLCO Cancer Screening Trial and NIH-AARP Diet and Health Study. (Adapted from
Shivappa, N., Steck SE, Hurley TG, Hussey JR, Hebert JR, Designing and Developing a
Literature-derived, Population-based Dietary Inflammatory Index. Public Health Nutr, 2013: p. 18.) Abbreviations: DII, dietary inflammatory index; PLCO, the Prostate, Lung, Colorectal and
Ovarian; NIH-AARP, the National Institute of Health Association of Retired Persons
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Figure 3.2 DAG that describes the relationships of each covariate with exposure DII
and with outcome pancreatic cancer in the PLCO Cancer Screening Trial and NIHAARP Diet and Health Study. Abbreviations: DAG, directed acyclic graph; DII, dietary
inflammatory index; PLCO, the Prostate, Lung, Colorectal and Ovarian; NIH-AARP, the
National Institute of Health Association of Retired Persons
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4.1

Abstract
Background: Inflammation plays a central role in pancreatic cancer etiology and

can be modulated by diet. We aimed to examine the association between the
inflammatory potential of diet, assessed with the Dietary Inflammatory Index (DIITM),
and pancreatic cancer risk in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer
Screening Trial prospective cohort. Methods: Our study included 101,449 participants
aged 52 to 78 years at baseline who completed both baseline questionnaire and a diet
history questionnaire. Energy-adjusted DII (E-DII) scores were computed based on food
and supplement intake. Cox proportional hazards models were used to estimate hazard
ratios (HRs) and 95% confidence intervals (CIs) with participants in the lowest E-DII
quintile (most anti-inflammatory scores) as referent. Results: After a median 8.5 years of
follow-up, 328 pancreatic cancer cases were identified. E-DII scores were not associated
with pancreatic cancer risk in the multivariable model (HRQ5vsQ1 =0.99; 95% CI=0.691.40; P-trend=0.31). Time significantly modified the association (P-interaction=0.02).
Among subjects with follow up <4 years, there was an inverse association between E-DII
and pancreatic cancer (HRQ5vsQ1=0.55; 95% CI=0.32-0.95; P-trend=0.15) while there was
a positive trend among those with ≥4 years of follow-up (HRQ5vsQ1 =1.36; 95% CI=0.852.17; P-trend=0.03). Similar results were observed for E-DII from food only.
Conclusion: Our study does not support an association between inflammatory potential
of diet and pancreatic cancer risk; however, heterogeneous results were obtained with
different follow-up times. Reverse causality owing to undetected disease may account for
the inverse association observed in the first four years of follow-up.
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4.2

Introduction
Pancreatic cancer, the majority (~90%) of which is ductal adenocarcinoma of the

exocrine pancreas, has the highest case-fatality rate of any major cancer.1,383 Despite low
incidence, it is the fourth leading cause of cancer death among both men and women in
the United States, with a 5-year relative survival rate of only 8% for all stages combined.1
Although the etiology of pancreatic cancer is not fully understood, inflammation may
play a pivotal role in the pathogenesis of this malignancy, as manifested by the fact that
inflammatory states are etiologically linked to well-recognized risk factors for pancreatic
cancer, including chronic pancreatitis, cigarette smoking, obesity, and diabetes.58,384
Dietary factors could affect cancer risk through modulation of inflammation,385,386
realized mainly by dietary impact on visceral obesity,387 oxidative damage78 and insulin
resistance.387 Therefore, understanding the effect of dietary inflammatory potential on the
development of pancreatic cancer may guide dietary intervention strategies aimed at the
primary prevention of this lethal malignancy. A number of epidemiological studies have
reported inconsistent results regarding the relationship between pancreatic cancer risk and
inflammation-modulating nutrients or foods, such as fruits and vegetables and associated
vitamins,388,389 fat and fatty acids,390 fiber,391 whole grains,392 and flavonols.393,394
A typical human diet consists of both pro-inflammatory and anti-inflammatory
foods and nutrients. Therefore, a dietary pattern approach, which takes into account the
complex interactions among dietary components, has advantages over individual foods or
nutrients when being studied for associations with disease risk.13 Assessing the overall
inflammatory potential of the diet may provide better insight on the effect on pancreatic
cancer risk than assessing only a select set of nutrients or individual foods. To date, two
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case-control studies have used the DII to assess the association between dietary
inflammatory potential and pancreatic cancer risk; both studies reported a significant >2fold increased risk in the most pro-inflammatory diet group.38,39 However, case-control
studies are susceptible to recall and selection biases, which may distort the true
associations.395 Therefore, a large prospective cohort study in which exposure
information has been collected before the cancer diagnosis is advantageous for examining
the role of diet in pancreatic cancer etiology. The objective of this study was to examine
the association between inflammatory potential of diet, assessed using the DII, and
pancreatic cancer risk with data from the PLCO Cancer Screening Trial prospective
cohort.
4.3

Materials and methods

4.3.1

Study design
The PLCO was a multi-center population-based randomized trial designed to

assess effects of screening tests for prostate, lung, colorectal and ovarian cancers on
mortality and secondary endpoints. Details of this study have been described elsewhere.43
Briefly, between 1993 and 2001, a total of 154,897 eligible participants (76,682 men and
78,215 women), aged 55–74 years, were enrolled into the trial from ten screening centers
across the United States. Participants were randomized by sex and age group into a
control arm, where usual medical care was received, or intervention arm where screening
exams for PLCO cancers were received.44 PLCO eligibility criteria excluded a previous
personal history of PLCO cancers, ongoing cancer treatment (excluding basal-cell and
squamous-cell skin cancer), participation in another cancer screening or cancer primary
prevention trial, and a recent screening test for prostate or colorectal cancer.43,358
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Participants in the intervention arm received their screening tests during their first six
years in the trial and were subsequently followed up for at least seven additional years;
participants in the control arm also were followed for 13 years after enrollment.44
4.3.2

Study population
In our analyses, we further excluded 11,874 participants who had a cancer (except

non-melanoma skin cancer) diagnosed before completing the DHQ; 4,920 participants
who did not return baseline questionnaires; 36,268 participants who did not have valid
DHQ responses (i.e., valid DHQ responses were defined as having DHQ completion
date; alive at DHQ completion; <8 missing DHQ responses; and plausible caloric intake
defined as within the sex-specific first and last percentiles of total energy); 220
participants who reported unreasonable BMI (i.e., BMI was considered unreasonable if
one of the followings occurred: weight<60 pounds; height<48 inches; height>78 inches
for females; height>84 inches for males; BMI<15 kg/m2) and 166 participants without
follow-up data. After these exclusions, the analytical cohort included 101,449
participants (49,347 men and 52,102 women). The study was approved by the
institutional review boards of the National Cancer Institute and each of the centers that
participated. Informed consent was obtained from each eligible participant in the study.
4.3.3

Dietary assessment
Diet was assessed by a self-reported FFQ, the DHQ version 1.0 (National Cancer

Institute, 2007), which was introduced in 1998 to both control and intervention arms
within a median of three years after randomization in the trial.396 On the DHQ,
participants reported their frequency of intake and portion size of 124 food items and
supplement use over the previous year.396 Daily nutrient intake was calculated by the
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DietCalc software, which links responses of food frequency, portion size, and other
relevant responses from the DHQ with a nutrient database based on national dietary data
(USDA's 1994-96 Continuing Survey of Food Intakes by Individuals and supplemented
by the Nutrition Data Systems for Research from the University of Minnesota).364 The
DHQ has been validated against four 24-hour dietary recalls (one in each season) among
1,640 nationally representative participants in the Eating at America's Table Study where
the energy-adjusted correlation coefficients for dietary factors ranged from 0.51 for
vitamin E to 0.78 for magnesium among women and from 0.41 for sodium to 0.83 for
thiamin among men.363
4.3.4

Energy-adjusted DII score calculation
The E-DII score for each participant was calculated based on the reported nutrient

and food intake from the DHQ with linkage to the corresponding inflammatory effect
scores designated in the DII.22 The DII is a literature-derived, population-based index
designed to estimate the overall inflammatory potential of an individual’s diet. The
details of the development of the DII have been published previously.22 Briefly, 1,943
eligible peer-reviewed primary research articles published through 2010 on the effect of
dietary factors on six inflammatory markers (IL-1β, IL-4, IL-6, IL-10, tumor necrosis
TNF-α, and CRP) were identified and scored to derive the component-specific
inflammatory effect scores for 45 dietary factors (i.e. components of DII), which
comprised macronutrients, micronutrients and some foods or bioactive components such
as spices and tea.22
Ten DII components including ginger, turmeric, garlic, oregano, rosemary,
eugenol, saffron, n-3 fatty acids, n-6 fatty acids and flavonols were not available from the
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DHQ. Therefore, the remaining 35 components were used for E-DII score calculation in
our analysis. The food and nutrient consumption estimated from the DHQ was first
adjusted for total energy per 1000 calories to account for the difference in individual
energy intake. To avoid the arbitrariness as a result of simply using raw intake amounts,
the energy-adjusted dietary intake was subsequently standardized to a composite dietary
database representing energy-adjusted dietary intake from 11 populations living in
different countries across the world.22 The energy-adjusted standardized dietary intake
was then multiplied by the literature-derived inflammatory effect score for each DII
component, and summed across all components to obtain the overall E-DII score.22
Higher E-DII scores represent more pro-inflammatory diets while lower (i.e., more
negative) E-DII scores indicate more anti-inflammatory diets. The DII score has been
construct-validated and found to be associated with higher levels of inflammatory
biomarkers including IL-6,24 TNF-α receptor 2,24 and hsCRP.23 Because a majority of the
partipants (79%) in the PLCO consumed supplements, and many dietary factors used in
supplements have anti-inflammatory properties,397 we reported E-DII scores from food
plus supplements and E-DII scores from food only as exposures to quantify the
association between the inflammatory potential of diet, with and without supplements, in
relation to pancreatic cancer risk.
4.3.5

Assessment of other covariates
Baseline characteristics, which included demographic information, personal

medical history, family history, and health behaviors, were self-reported through the
baseline questionnaire within three months of randomization in the PLCO. BMI was
calculated as weight (kg)/height(m)2 and categorized based on the World Health
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Organization criteria.368 Information on physical activity over the past year was not
assessed at baseline, but was assessed on the supplemental questionnaire which was
introduced at a median of nine years after randomization in the trial.
4.3.6

Pancreatic cancer case ascertainment
Incident pancreatic cancer cases were identified through an annual study update

questionnaire in which participants reported if they had been diagnosed with any cancer
by a healthcare provider, the type of cancer, date of diagnosis, and location of diagnosis.
State registries, death certificates, and physician reports also were used as additional
sources for identification of pancreatic cancer cases. All reports of pancreatic cancer were
followed-up and medical records were abstracted and reviewed for case ascertainment. In
this analysis, pancreatic cancer case was defined as primary incident adenocarcinoma of
the exocrine pancreas (International Classification of Diseases for Oncology, Third
Edition, codes C25.0-C25.3, C25.7- C25.9). Our case definition excluded pancreatic
endocrine tumors and other rare histology types of pancreatic cancer (histology type
8150, 8154, 8240,8245, 8246, 8550) as etiology may differ,248,370 and we censored these
types of pancreatic cancer at the date of diagnosis.
4.4

Statistical analysis
The baseline characteristics of the study population were presented by quintiles of

E-DII from food plus supplements with cut-off points determined from the distribution of
the entire cohort. Means and SE for continuous variables and frequencies and
percentages for categorical variables were calculated. Participants were followed up from
the date of DHQ completion to the date of diagnosis of pancreatic cancer, death from any
cause, study withdrawal, or the end date of study follow-up (the first of either 13 years
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after randomization or 12/31/2009), whichever came first. Cox proportional hazards
regression, with person-year as the underlying time metric, was used to estimate the HRs
and 95% confidence intervals (CIs) for higher E-DII quintiles compared to the lowest EDII quintile (the most anti-inflammatory score) as referent. To test the linear trend of
pancreatic cancer risk across E-DII score, a continuous E-DII variable was used.
Variables were considered as confounders if they were associated with both pancreatic
risk and E-DII (in either continuous or categorical format), or they changed the crude risk
estimate by more than 10% in bivariate analyses. Although BMI did not meet these
criteria, we included it as a confounder because BMI is an established risk factor for
pancreatic cancer and is also related to diet.239 In the multivariable models, we adjusted
for age at DHQ completion, sex (male or female), BMI (underweight, normal,
overweight, obese, missing), pack-years categories within smoking status (never smoker,
former smoker with<18 pack-years, former smoker with 18-41 pack-years, former
smoker with >41 pack-years, current smoker with <18 pack-years, current smoker with
18-41 pack-years, current smoker with >41 pack-years, missing), history of diabetes (yes,
no, missing), and total energy intake (kcal/day). The proportional hazards (PH)
assumption was examined using the Schoenfeld residual test.374 There was no evidence
that E-DII or any covariate violated the PH assumption.
Effect modifications by sex, BMI, history of diabetes, smoking status were
examined by adding the cross-product of each effect modifier with E-DII quintile in the
multivariable-adjusted model with P value smaller or equal to 0.10 as an indicator of
significant interaction.376 We also examined effect modification by follow-up time in our
analysis given the possibility of latent pancreatic cancer affecting recent dietary intake.354
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Previous PLCO analyses with diet and pancreatic cancer suggested significant time
interaction with dietary fat and available carbohydrate using a cutoff of 4 years of followup.256,354 Among the effect modifiers of interest, only follow-up time was found to be
significant. Therefore, we performed the stratified analyses by two distinct time intervals,
with cut-off point at 4 years of follow-up, to be comparable with the other PLCO
analyses.256,354
Two sensitivity analyses were performed. First, subjects who self-reported
diabetes history at baseline were removed from analyses because diabetes may be a
preclinical indictor of pancreatic cancer and diet modification may have occurred after
diagnosis of diabetes.377,398 Secondly, as we excluded a large number of participants, we
compared the demographic characteristics and pancreatic cancer risk factors between our
included sample and excluded subjects to examine how results could have been affected
by excluding these subjects in our analyses.
Identical analyses, including sensitivity analyses, were performed for E-DII from
food only in relation to pancreatic cancer risk. All statistical analyses were conducted
using SAS® (version 9.4, Cary, NC). All tests were two-sided, with p values <0.05
considered statistically significant unless otherwise noted.
4.5

Results
After a median of 8.5 years of follow-up, 328 incident pancreatic cancer cases

occurred. E-DII scores from food and supplements ranged from -8.43 to 6.38. Compared
to participants who had the most anti-inflammatory E-DII scores from food and
supplement (i.e., E-DII quintile 1), participants consuming a more pro-inflammatory diet
had higher BMI and who smoked more heavily at baseline, were younger at the time of
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DHQ completion, consumed more alcohol and total calories, and were more likely to be
male, Black non-Hispanic or Hispanic, current smokers, have below-college education
level, a family history of pancreatic cancer in a first-degree relative, and have a personal
history of diabetes (Table 4.1).
HRs for pancreatic cancer risk across E-DII quintiles from food plus supplement
are presented in Table 4.2. After controlling for confounders, there was no significant
association between E-DII scores and pancreatic cancer risk (HRQ5vsQ1 =0.99, 95%
CI=0.69-1.40, P-trend=0.31). After excluding subjects with a history of diabetes at
baseline (n=7,319), the multivariable-adjusted HRs changed only slightly.
In stratified analyses by sex, BMI category, history of diabetes, smoking status,
and follow-up time (<4 and >=4 years), only follow-up time had a statistically significant
interaction with E-DII scores (P-interaction=0.02). Analyses stratified by follow-up time
of <4 years and ≥4 years produced divergent results (Table 4.3). Among 8,977
individuals with <4 years of follow-up, those consuming the most pro-inflammatory diets
had a statistically significant 45% lower risk of pancreatic cancer compared with
individuals with the most anti-inflammatory diets although the trend was not significant
(multivariable HRQ5vsQ1 =0.55, 95% CI=0.32-0.95, P-trend=0.15). However, a significant
positive trend was seen among individuals with follow-up time of ≥4 years, although the
HR comparing two extreme quintiles was not statistically significant (multivariable
HRQ5vsQ1 =1.36, 95% CI=0.85-2.17, P-trend=0.03). We performed the stratified
association by follow-up time <4years and ≥4 years in the sensitivity analysis (i.e.,
excluding subjects with diabetes history), and the results did not change (data not shown).
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Similar patterns of associations were observed when analyses were performed
with E-DII from food only. In the multivariable analyses, E-DII from food only was not
associated with pancreatic cancer risk and similar HRs were observed in the sensitivity
analyses (Table 4.4). None of the covariates, except follow-up time, significantly
modified the observed results (data not shown). A similar but nonsignificant association
was observed for E-DII from food only among subjects with less than four years of
follow up (HRQ5vsQ1=0.60, 95% CI=0.33-1.07, P-trend=0.30) and there was a borderline
significant positive trend among those with longer follow-up (HRQ5vsQ1=1.28, 95%
CI=0.80-2.06, P-trend=0.05) (Table 4.5).
Compared to subjects included in analyses, excluded subjects tended to have less
healthy behaviors or characteristics that are likely associated with increased risk of
pancreatic cancer, including male, Black or Hispanic, heavier smoking, a more proinflammatory diet, older age, diabetes history, lower education attainment (Table 4.6).
4.6

Discussion
This is the first prospective cohort study investigating the association between

dietary quality with respect to inflammatory potential and pancreatic cancer risk. Overall,
no association was found between inflammatory potential of diet and pancreatic cancer
risk. However, there was significant effect modification by follow-up time. In the
stratified analysis, we observed a significant increased trend of risk associated with a proinflammatory diet among those with follow-up longer than four years, whereas evidence
of risk reduction was seen among subjects diagnosed with pancreatic cancer in the first
four years of follow-up. These divergent results may indicate the presence of reverse
causality in the short-term, where decreases in dietary inflammatory potential may be a

95

consequence, rather than a cause, of pancreatic cancer or a well-known precursor
condition, pancreatitis.399 We observed similar results for E-DII from food plus
supplements and E-DII from food only. Because supplements may be the preferred
choice for people with subclinical disease, this also may reflect issues of appetite control.
Two case-control studies, with one conducted in the U.S.39 and the other in
Italy,38 previously reported positive associations between E-DII scores from food and
pancreatic cancer risk. Both studies found an approximate 2.5-fold increased risk of
pancreatic cancer in the highest compared to the lowest quintile of the E-DII group (U.S.:
ORQ5vsQ1 =2.54, 95% CI=1.87-3.46, P-trend<0.0001;39 Italy: ORQ5vsQ1=2.48, 95%
CI=1.50-4.10, P-trend=0.00238). Evidence of effect modification by smoking status and
BMI was documented in the Italian case-control study where a significant positive
association was observed among never and past smokers but not among current smokers,
and among normal and overweight rather than obese subjects, respectively.38 In the U.S.
case-control study using a joint effect approach, Antwi et al. demonstrated that dietary
inflammatory potential may act synergistically with cigarette smoking and diabetes to
increase the risk of pancreatic cancer beyond the risk of any of these factors alone.39
Compared to these two case-control studies, a significant association was not observed in
the PLCO and the magnitude of the association was much weaker, even after excluding
the subjects who may have changed diet due to symptoms associated with latent
pancreatic cancer in the early follow-up period. There are differences between the
prospective cohort design we utilized and a case-control design which are important to
note. Differential misclassification of exposure is minimized in a cohort design because
exposure is measured before the outcome develops, but after the outcome has occurred in
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a case-control design, possibly resulting in differential recall. In addition, there may be
biased selection of cases and controls in a case-control study which may induce selection
bias and thus biased associations.400
We did not observe evidence of effect modification in our study except for
follow-up time which, as noted above, may reflect subclinical disease. Although many
pancreatic cancer studies have performed lag time analysis by excluding subjects with
short follow-up time in order to alleviate concerns about changes in diet driven by preclinical symptoms of pancreatic cancer (or precursor conditions, especially pancreatitis),
few studies have examined the time interaction with dietary exposure. Our study finding
of significant time interaction with E-DII were consistent with two previous analyses of
diet and pancreatic cancer in the PLCO cohort, of which both found time was the only
significant effect modifier.256,354 In the study by Arem et al, higher total fat and saturated
fat intake (both strongly pro-inflammatory) were associated with significant reduced
pancreatic cancer risk among subjects with less than four years of follow-up, and
associations became weaker and nonsignificant after excluding these subjects.256 In the
other PLCO study examining dietary glycemic load and available carbohydrates as well
as fat (also pro-inflammatory), the positive association of pancreatic cancer with
glycemic load and available carbohydrate and inverse association with saturated fat were
observed only in the first four years, but not subsequently.354 Pancreatic cancer patients
may present with severe, though nonspecific symptoms such as impaired glucose control,
fatigue, jaundice, abdominal pain, nausea, blunted appetite, and vomiting before actual
diagnosis, which is usually at a late stage because there exists no accurate method for
early detection.401 Thus, assessment of dietary intake in pancreatic cancer studies, which
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typically query diet in the past 12 months, may capture disease-related diet changes (or
those related to precursor conditions), rather than intake prior to cancer symptoms.354 In
our study, subjects may choose to eat healthier or more anti-inflammatory food or less
amount of total food (i.e., fewer calories) due to symptoms associated with latent diseases
in the early time period, which resulted in lower E-DII scores. Although prospective
studies are less susceptible to reverse causation bias, such bias can occur in prospective
studies of pancreatic cancer, given the cancer's unknown latency and the fact that it and
its precursor conditions have profound effects on digestion. Differences in associations
by follow-up time should be considered in future prospective studies assessing dietary
intake and pancreatic cancer. Unlike the previous PLCO studies on fat intake, we
observed a significant positive trend among subjects with longer follow up. Differences
in results between these investigations may be explained by the different exposure we
used that measured the total inflammatory potential from multiple foods and nutrients
rather than dietary intake of a single macronutrient.
Five studies investigating a priori dietary patterns other than DII in relation to
pancreatic cancer risk have been published, including variants of MDS,17,282,402 the HEI2005,48 and dietary total antioxidant capacity score.403 Results from these studies all
suggested better diet quality, was associated with lower pancreatic cancer risk, with effect
estimates ranging from 0.4417 to 0.92282 comparing the highest with the lowest dietary
quality group. However, our study suggested a nonsignificant association with total
inflammation potential of diet. The different findings may be, to some extent, explained
by the differences in dietary patterns under study, the nature of FFQs, study design, study
population, sample size, or timing from dietary data collection to diagnosis.
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It is well-recognized that pro-inflammatory states foster a cellular environment
that supports the development of genetic mutations and the initiation of pancreatic
carcinogenesis.58 Inflammation associated with diet may contribute to pancreatic
malignancy through the increased level of inflammatory cytokines (e.g., TNF-α; IL-6, IL8 and interferon-γ), reactive oxygen species and mediators in the inflammatory pathway
(e.g., NF-кB and cyclooxygenase-2), leading to increased cell cycling, loss of tumor
suppressor function, and stimulated oncogene expression, all of which may induce
modifications of key cancer-related proteins, and ultimately, tumorigenesis.57,58
Major strengths of our study include its prospective cohort design, which
conceptually minimizes the possibility of recall bias. The long follow-up in the PLCO
cohort among a large study population allowed for an in-depth evaluation of effect
modification by time from the DHQ to cancer diagnosis. Detailed information on a
comprehensive list of covariates allowed for careful adjustment in the analyses. The EDII, a construct-validated tool which takes into account the whole diet instead of single
nutrients or foods and is based on the entire literature on inflammation, provided a
comprehensive assessment of dietary inflammatory potential. It has major advantages
over other a priori dietary patterns as it was developed specifically to reflect diet’s effect
on inflammation that plays a central role in pancreatic cancer etiology. In addition, the
use of a validated FFQ which covered major foods and nutrients consumed by
Americans, and application of majority of DII components to calculate the E-DII scores
helped to create a large contrast of E-DII scores in this study population. This is the first
study to investigate whether dietary inflammatory potential is associated with pancreatic
cancer risk in a prospective manner. The significant time interaction identified in our
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study and the inverse association between proinflammatory diet and pancreatic cancer
within <4 years of follow up, confirmed the previous PLCO findings on diet and
pancreatic cancer.
This study also presents several limitations. First, it is likely the case number was
not large enough in some stratified analyses so that we lacked statistical power to observe
significant associations. Exclusion criteria resulted in exclusion of over 50,000 subjects,
and differences were noted between excluded and included participants by various
pancreatic cancer risk factors. This may have introduced selection bias and resulted in
underestimation of the association. The FFQ is prone to response set bias, including
social approval and social desirability, leading to measurement error in FFQ data as
another unavoidable limitation, which may have resulted in some misclassification of the
E-DII score.404Although follow-up data were available on most covariates, the large
amount of missing information impeded our ability to use these data. Evaluation of the
E-DII at a single time point could result in non-differential misclassification of exposure
given diet may change over time. However, we previously found DII scores were
relatively stable over a long timeframe in postmenopausal women who were of
comparable ages as ours.405 Another limitation of the study is that data were only
available on 37 out of the 45 DII components used to calculate the E-DII scores;
however, the range of DII scores may rely more on the amount of foods actually
consumed rather than the number of available DII components.406 While we adjusted for
important potential confounders, residual or unmeasured confounding
cannot be ruled out.
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4.7

Conclusion
In conclusion, this study does not support an association between inflammatory

potential of diet and pancreatic cancer risk in the PLCO cohort. However, time
significantly modified the association. There was evidence of an inverse association
between E-DII and pancreatic cancer in the first four years of follow up, suggesting
dietary changes due to undiagnosed disease (or a precursor condition) might affect
appetite and food choices to lower the E-DII scores in the early stage, while a positive
association was suggested by a significant trend after excluding subjects with follow-up
time <4years. Future prospective cohort studies assessing dietary factors and pancreatic
cancer risk should consider differences in associations by follow-up time. Additional
cohort studies with large number of cases are warranted to examine effect modification of
E-DII and pancreatic cancer by important lifestyle risk factors.
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Table 4.1 Baseline characteristics of 101,449 subjects in the PLCO Cancer
Screening Trial cohort by quintiles of E-DII from food plus supplement
Most antiinflammatory
diet
E-DII
Quintile 1
(-8.43, -5.32)

Most proinflammatory
diet
E-DII
Quintile 3
(-4.25, 3.03)
20290

E-DII
Quintile 4
(-3.02, 1.22)
20290

E-DII
Quintile 5
(-1.21, 6.38)

20290

E-DII
Quintile 2
(-5.31, 4.26)
20290

Mean (SE)

Mean (SE)

Mean (SE)

Mean (SE)

Mean (SE)

Age at DHQ
completion (y)

65.8 (0.04)

65.8 (0.04)

65.6 (0.04)

65.5 (0.04)

64.9 (0.04)

BMI at baseline
(kg/m2)

26.4 (0.03)

27.0 (0.03)

27.3 (0.03)

27.7 (0.03)

28.1 (0.03)

Pack-years of
cigarette at
baseline

13.5 (0.2)

14.8 (0.2)

16.5 (0.2)

19.5 (0.2)

25.0 (0.2)

Alcohol
consumption
(g/d)

8.2 (0.1)

7.1 (0.1)

7.7 (0.1)

9.9 (0.2)

14.8 (0.3)

N (%)a

N (%)a

N (%)a

N (%)a

N (%)a

Sex
Male

6476 (31.9)

7653 (37.7)

9505 (46.9)

11531 (56.8)

14182 (69.9)

Female

13814 (68.1)

12637
(62.3)

10785
(53.1)

8759 (43.2)

6107 (30.1)

Trial arm
Intervention

10361 (51.1)

10253
(50.5)

10302
(50.8)

10460 (51.6)

10290 (50.7)

Control

9929 (48.9)

10037
(49.5)

9988 (49.2)

9830 (48.4)

9999 (49.3)

Race/ Ethnicity
White nonHispanic

18124 (89.3)

18413
(90.8)

18615
(91.8)

18655 (91.9)

18452 (91.0)

Black nonHispanic
Hispanic

525 (2.6)

618 (3.0)

674 (3.3)

651 (3.2)

873 (4.3)

239 (1.2)

290 (1.4)

278 (1.4)

316 (1.6)

367 (1.8)

Others

1402 (6.9)

969 (4.8)

723 (3.5)

668 (3.3)

597 (2.9)

4291 (21.1)

5328 (26.3)

5736 (28.3)

6471 (31.9)

7867 (38.8)

2267 (11.2)

2554 (12.6)

2648 (13.1)

2760 (13.6)

2887 (14.2)

N

Education level
High school or
below
Post high school
training other
than college
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20289

Some college
College
Postgraduate
Missing

4482 (22.1)
4134 (20.4)
5077 (25.0)
39 (0.2)

4419 (21.8)
3778 (18.6)
4154 (20.5)
57 (0.3)

4466 (22.0)
3564 (17.6)
3850 (19.0)
26 (0.1)

4273 (21.0)
3401 (16.8)
3349 (16.5)
36 (0.2)

4112 (20.3)
2922 (14.4)
2457 (12.1)
44 (0.2)

Never smoked

10396 (51.2)

10357
(51.0)

10175
(50.2)

9357 (46.1)

8116 (40.0)

Past smoker
Current smoker

8916 (44.0)
978 (4.8)

8667 (42.7)
1260 (6.2)

8484 (41.8)
1627 (8.0)

8822 (43.5)
2107 (10.4)

8770 (43.2)
3399 (16.8)

First-degree
pancreatic
cancer family
history
Yes
No

562 (2.8)
19194 (94.6)

496 (2.4)
19138
(94.3)
516 (2.5)
140 (0.7)

514 (2.5)
19044 (93.9)

450 (2.2)
18949 (93.4)

560 (2.8)
172 (0.9)

724 (3.6)
166 (0.8)

Smoking status
at baseline

Probable
Missing

389 (1.9)
145 (0.7)

569 (2.8)
19134
(94.3)
431 (2.1)
156 (0.8)

History of
diabetes
Yes

1160 (5.7)

1313 (6.5)

1481 (7.3)

1532 (7.5)

1299 (6.4)

19025 (93.8)

18869
(93.0)
108 (0.5)

18711
(92.2)
98 (0.5)

18631 (91.8)

18894 (93.1)

127 (0.6)

96 (0.5)

No
Missing

105 (0.5)

Abbreviations: SE, standard error
a
Sum of percentages may not add up to 100% because of rounding or missing.

103

Table 4.2 Association between E-DII from food plus supplement and pancreatic
cancer risk among 101,449 subjects in the PLCO Cancer Screening Trial cohort
Most antiinflammatory
diet
E-DII
Quintile 1
(-8.43, -5.32)

Cases (n)
Sample size
Age and
energyadjusted HR
(95% CI)
Multivariableadjusted HR
(95% CI)b

Most proinflammatory
diet
Ptrenda

E-DII
Quintile
3
(-4.25, 3.03)
59

E-DII
Quintile
4
(-3.02, 1.22)
71

E-DII
Quintile 5
(-1.21, 6.38)

67

E-DII
Quintile
2
(-5.31, 4.26)
56

20290

20290

20290

20290

20289

1.00

0.85
(0.601.22)

0.92
(0.651.30)

1.12
(0.801.57)

1.25 (0.891.76)

0.01

1.00

0.82
(0.571.17)

0.83
(0.581.18)

0.97
(0.691.36)

0.99 (0.691.40)

0.31

1.10
(0.761.59)

1.07 (0.731.56)

0.18

75

After excluding subjects with diabetes history at baseline
Multivariableadjusted HR
(95% CI)c

1.00

0.83
(0.561.23)

0.93
(0.641.37)

a

Continuous DII score was used to determine P for trend
Adjusted for age at time of DHQ completion, sex (male and female), body mass index at baseline
(underweight, normal, overweight, obesity and missing), history of diabetes (no, yes, missing), packyears
within smoking status at baseline (never smoker, former smoker with<18 pack-years, former smoker with
18-41 pack-years, former smoker with>=41 pack-years, current smoker with<18 pack-years, current
smoker with 18-41 pack-years, current smoker with>=41 pack-years, missing), total energy intake (kcal/d)
c
Model included 94,130 subjects and was adjusted for covariates listed in b.

b
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Table 4.3 Stratified analyses of E-DII from food plus supplement and pancreatic
cancer risk by follow-up time (i.e. <4 and >=4 years) among 101,449 subjects in the
PLCO Cancer Screening Trial cohort
Most antiinflammat
ory diet

Most proinflammato
ry diet

E-DII
E-DII
E-DII
Quintile 1 Quintile 2 Quintile 3
(-8.43, (-5.31, (-4.25, 5.32)
4.26)
3.03)
Participants with follow-up time<4 years
Cases (n)

E-DII
Quintile 5
(-1.21,
6.38)

Ptrend
a

34

25

24

30

25

Sample size

1539

1711

1768

1903

2056

Age and
energyadjusted HR
(95% CI)

1.00

0.66 (0.401.11)

0.58 (0.340.98)

0.69
(0.421.13)

0.58 (0.340.98)

0.16

Multivariabl
1.00
0.65 (0.39e-adjusted
1.09)
HR (95%
CI)c
Participants with follow-up>=4 years

0.56 (0.330.95)

0.65
(0.391.09)

0.55 (0.320.95)

0.15

Cases (n)

a

E-DII
Quintile 4
(-3.02, 1.22)

33

31

35

41

50

Sample size

18757

18579

18522

18387

18233

Age and
energyadjusted HR
(95% CI)

1.00

0.96 (0.591.57)

1.11 (0.691.79)

1.33
(0.842.10)

1.70 (1.082.67)

0.001

Multivariabl
e-adjusted
HR (95%
CI)c

1.00

0.93 (0.571.52)

1.03 (0.641.66)

1.17
(0.731.87)

1.36 (0.852.17)

0.03

Pinter
actio
nb

0.02

Continuous DII score was used to determine P for trend

b

P-value for interaction was calculated by adding the cross-product of the E-DII quintiles and binary variable of time
(<4 years and >=4 years) in the multivariable-adjusted model
c

Adjusted for age at time of DHQ completion, sex (male and female), body mass index at baseline
(underweight, normal, overweight, obesity and missing), history of diabetes (no, yes), packyears within
smoking status at baseline (never smoker, former smoker with<18 pack-years, former smoker with 18-41
pack-years, former smoker with>=41 pack-years, current smoker with<18 pack-years, current smoker with
18-41 pack-years, current smoker with>=41 pack-years, missing), total energy intake (kcal/d)
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Table 4.4 Association between E-DII from food only and pancreatic cancer risk
among 101,449 subjects in the PLCO Cancer Screening Trial cohort
Most antiinflammatory
diet
E-DII Q1
(-7.58, -3.82)

Most proinflammatory
diet
E-DII Q5
(0.38, 6.89)

Ptrenda

64

E-DII Q2
(-3.81, 2.60)
52

E-DII Q3
(-2.59, 1.30)
65

E-DII Q4
(-1.29,
0.37)
78

Sample size

20291

20289

20290

20289

20290

Age and
energyadjusted HR
(95% CI)

1.00

0.82 (0.571.19)

1.06 (0.751.49)

1.32 (0.941.84)

1.22 (0.861.73)

0.009

Multivariableadjusted HR
(95% CI)b

1.00

0.79 (0.551.14)

0.97 (0.681.37)

1.13 (0.811.59)

0.97 (0.671.39)

0.26

After excluding subjects with diabetes history at baseline
1.00
0.70 (0.47- 0.90 (0.61Multivariable1.06)
1.32)
adjusted HR
(95% CI)c

1.21 (0.841.73)

0.97 (0.661.43)

0.17

Cases (n)

a

69

Continuous DII score was used to determine P for trend
Adjusted for age at time of DHQ completion, sex (male and female), body mass index at baseline
(underweight, normal, overweight, obesity and missing), history of diabetes (no, yes, missing), packyears
within smoking status at baseline (never smoker, former smoker with<18 pack-years, former smoker with
18-41 pack-years, former smoker with>=41 pack-years, current smoker with<18 pack-years, current
smoker with 18-41 pack-years, current smoker with>=41 pack-years, missing), total energy intake (kcal/d)
c
Model included 94,130 subjects and was adjusted for covariates listed in b

b
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Table 4.5 Association between E-DII from food only and pancreatic cancer risk by
follow-up time (i.e. <4 and >=4 years) among 101,449 subjects in the PLCO Cancer
Screening Trial cohort
Most antiinflammato
ry diet
E-DII Q1
(7.58, 3.82)

E-DII Q2
(-3.81, 2.60)

Most proinflammat
ory diet
E-DII Q5
(0.38,6.89)

E-DII Q3
(-2.59, 1.30)

E-DII Q4
(-1.29,
0.37)

35

30

22

1825
0.98
(0.611.60)

1959
0.77
(0.461.28)

1979
0.60 (0.341.05)

0.96
(0.581.56)

0.76
(0.451.28)

0.60 (0.331.07)

Ptrend
a

Pintera
ctionb

Subjects with follow up <4 years
Cases (n)

31

20

Sample size
1563
1651
1.00
0.64 (0.36Age and
1.12)
energyadjusted
HR (95% CI)
Multivariabl
1.00
0.63 (0.36e-adjusted
1.10)
HR (95%
CI)c
Subjects with follow up>=4 years
Cases (n)

a

0.29

0.30

33

32

30

48

47

0.01

Sample size

18728

18638

18465

18330

18311

Age and
energyadjusted
HR (95% CI)
Multivariabl
e-adjusted
HR (95%
CI)c

1.00

0.98 (0.611.60)

0.95
(0.581.55)

1.57
(1.012.46)

1.61 (1.022.54)

0.002

1.00

0.95 (0.591.55)

0.88
(0.541.45)

1.38
(0.872.17)

1.28 (0.802.06)

0.05

Continuous DII score was used to determine P for trend

b

P-value for interaction was calculated by adding the cross-product of the E-DII quintiles and binary variable of time
(<4 years and >=4years) in the multivariable-adjusted model
c
Adjusted for age at time of DHQ completion, sex (male and female), body mass index at baseline
(underweight, normal, overweight, obesity and missing), history of diabetes (no, yes), packyears within
smoking status at baseline (never smoker, former smoker with<18 pack-years, former smoker with 18-41
pack-years, former smoker with>=41 pack-years, current smoker with<18 pack-years, current smoker with
18-41 pack-years, current smoker with>=41 pack-years, missing), total energy intake (kcal/d)
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Table 4.6 Comparison of important demographic and lifestyle characteristics
between study sample and excluded sample in the PLCO Cancer Screening Trial
cohort
P-valuea

Study population
(n=101,449)

Excluded subjects
(n=53,448)

Mean (SE)

Mean (SE)

Age at DHQ (years)

65.5 (0.02)

66.8 (0.04)

<.0001

Pack-years of cigarette at
baseline

17.8 (0.08)

21.8 (0.1)

<.0001

E-DII from food and
supplement

-3.2 (0.01)

-3.0 (0.02)

<.0001

E-DII from food only

-1.7 (0.01)

-1.5 (0.02)

<.0001

N (%)b

N (%)b

Sex
Male
Female

49347 (48.6)
52102 (51.4)

27335 (51.1)
26113 (48.9)

Trial Arm
Intervention
Control

51666 (50.9)
49783 (49.1)

25778 (48.2)
27670 (51.8)

Race/Ethnicityc
White non-Hispanic
Black non-Hispanic
Hispanic
Others

92259 (90.9)
3341 (3.3)
1490 (1.5)
4359 (4.3)

40320 (83.2)
4367 (9.0)
1328 (2.7)
2477 (5.1)

29693 (29.3)
13116 (13.0)

15782 (32.7)
5711 (11.8)

21752 (21.5)
17799 (17.6)
18887 (18.6)

10940 (22.6)
7545 (15.6)
8341 (17.3)

Education levelc
High school or below
Post high school training
other than college
Some college
College
Postgraduate

<.0001

<.0001

<.0001

Smoke status at baselinec
Never smoked
Past smoker
Current smoker

<.0001

<.0001
48401 (47.7)
43659 (43.0)
9371 (9.2)

20871 (43.0)
20958 (43.2)
6684 (13.8)
<.0001

First-degree pancreatic
cancer family historyc
Yes
No
Probable

2591 (2.6)
95459 (94.8)
2620 (2.6)

1208 (2.5)
45308 (94.1)
1616 (3.4)

History of diabetesc
Yes
No

6785 (6.7)
94130 (93.3)

4744 (9.9)
43364 (90.1)

<.0001
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a

P value was calculated from independent t-test for continuous variables and from Chi-Square test for
categorical variables.
b
The sum of percentages for some categorical variables may not add up to 100% because of rounding.
C
the proportion was calculated after excluding missing because there were 9% excluded participants did
not return baseline questionnaire which contained these variables
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CHAPTER 5
5
INFLAMMATORY POTENTIAL OF DIET, INFLAMMATIONRELATED LIFESTYLE FACTORS AND RISK OF PANCREATIC
CANCER: RESULTS FROM THE NIH-AARP DIET AND HEALTH
STUDY
5.1

Abstract
Background: Chronic inflammation is an underlying pathophysiological

foundation for many cancers, including pancreatic cancer. Diet is a strong moderator of
chronic inflammation. Other inflammation-related lifestyle factors such as smoking and
obesity may act synergistically with inflammatory potential of diet, to affect pancreatic
cancer risk. We aimed to use data from NIH-AARP Diet and Health Study which
includes so far the largest number of pancreatic cancer cases in the US, to prospectively
examine the association between dietary inflammatory potential and pancreatic cancer
and the association by cancer severity, and also examine the effect modifications by
important inflammation-related lifestyle factors including body mass index, cigarette
smoking, diabetes history, alcohol drinking and frequency of use of non-steroidal antiinflammatory drugs. Methods: Our final analytical cohort consisted of 533,286
participants (314,162 men and 219,124 women) aged between 50 to 71 at baseline.
Energy-adjusted DII (E-DII) scores were computed based on food and supplement intake.
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Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95%
confidence intervals (CIs) with participants in the lowest E-DII quintile (most antiinflammatory scores) as referent. Effect modifications were examined by adding crossproduct of each effect modifier as a categorical variable with E-DII quintile in the
multivariable-adjusted model. Results: After a median 13.4 years of follow-up, a total of
3,338 pancreatic cancer cases occurred. After controlling for confounders, there was no
significant association between E-DII scores and pancreatic cancer risk among both men
and women. Inflammatory potential of diet was not associated with pancreatic cancer by
cancer stage or grade. The E-DII and pancreatic cancer association was not modified by
any of the inflammation related lifestyle factors. Conclusion: Our study did not support
an association between inflammatory potential of diet and pancreatic cancer and no
significant effect modifications between diet-associated inflammation and other lifestyles
related to inflammation on pancreatic cancer etiology were detected.
5.2

Introduction
Inflammation, a critical function of the innate immune system, protects against

pathogens and initiates specific immunity.49 Acute inflammation is not regarded as a risk
factor for the development of neoplasia, but frequent acute inflammation results in
unresolved wound healing with consequent chronic inflammation.50 Chronic
inflammation has been identified as an underlying pathophysiological foundation for
many chronic diseases, including cancers.407,408 Chronic inflammation also plays a pivotal
role in the development of pancreatic cancer, as exemplified by the fact that both
hereditary and sporadic forms of chronic pancreatitis are associated with an increased risk
of pancreatic cancer.57,59,409,410 Due to lack of early detection approaches and limited
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effective treatments, pancreatic cancer has the highest case-fatality rate of any major
cancer.1,370,411 It is the fourth leading cause of cancer death among both men and women
in the United States, even with low incidence rates.1
Diet is a strong moderator of chronic inflammation, mainly through its impact on
visceral obesity,387 oxidative damage,78 and insulin resistance.387 The DII was developed
to assess the inflammatory potential of diet.22 The use of a dietary index or patterns
approach has advantages over the use of individual inflammation-modulating nutrients or
foods, given the complex interaction and correlation among various dietary
components.412,413 Besides diet, other lifestyle factors are known to be associated with
inflammation, such as obesity, diabetes, smoking, alcohol intake, and frequency use of
NSAIDs.
To date, two case-control studies have examined the association between the DII
and pancreatic cancer risk with both studies reporting a more than 2-fold increased risk
among individuals consuming a pro-inflammatory diet. Both studies examined the
interaction between DII and some inflammation-related factors but with inconsistent
results.38,39 However, a cohort study using data from the PLCO Cancer Screening Trial
did not find an association between DII and pancreatic cancer, except when stratified by
follow-up time where a pro-inflammatory diet was associated with increased risk only in
those subjects with >4 years of follow-up (Zheng et al. unpublished data in chapter 4).
Therefore, the NIH–AARP Diet and Health Study, one of the largest diet and health
prospective cohort studies in the US (approximately 500,000 US adults), provides an
invaluable opportunity to examine and verify the relationship between the DII and
pancreatic cancer risk with a large number of cases. We also explored if important
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inflammation-related lifestyle factors including BMI, cigarette smoking, alcohol
drinking, NSAIDs use frequency, and history of diabetes modified the DII and pancreatic
cancer association. Additionally, the study examined the association between dietary
inflammatory potential and severity of pancreatic cancer (cancer grade and cancer stage).
5.3

Methods

5.3.1

Study population
The NIH-AARP Diet and Health Study is the largest prospective cohort study of

diet and health ever conducted in US with the goal to examine a number of important diet
and cancer hypotheses. Baseline data collection was initiated between 1995 and 1996
when a baseline questionnaire asking information on demographic characteristics,
medical history, dietary intake and health behaviors was mailed to 3.5 million AARP
members.359 The scientific rational and study design of the cohort was described
previously.46 The initial study population of this cohort was 617,119 females and males
who responded to the baseline questionnaire with a response rate of 17.6%. Subjects were
50 to 71 years old with mean age of 62 years at baseline and lived in one of six states
(California, Florida, Pennsylvania, New Jersey, North Carolina, or Louisiana) or two
metropolitan areas (Atlanta, Georgia or Detroit, Michigan).46 After excluding respondents
whose responses on the baseline questionnaire were not reliable with the following
reasons: 1) unknown sex, 2) skipped substantial portions of the questionnaire, 3) skipped
facing page that provided personal information and date when they completed the
questionnaire, 4) indicated they were not the intended respondent and did not complete
the rest of the questionnaire, 5) more than 10 recording errors and less than 10 foods
consumed, and respondents who asked to be dropped from cohort, who died or moved
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before entry and those with duplicate representation of the questionnaire, there remained
566,398 eligible study participants (339,666 men and 226,732 women).46 From the
eligible participants, we further excluded 15,760 subjects whose baseline questionnaires
were filled out by proxy, 8,828 subjects who had any registry-confirmed cancer diagnosis
at baseline (except for non-melanoma skin cancer), 4,261 subjects who had extreme daily
energy intake [i.e., 2 interquartile ranges (IQRs) below the sex-specific 25th percentile or
above the 75th percentile of log-transformed energy intake], 49 subjects who moved out
of the study area or died at or before processing of the baseline questionnaire, and 4,214
subjects who had implausible body mass index (BMI) values (2 IQRs below the sexspecific 25th percentile or above the 75th percentile of log-transformed BMI). Our final
analytical cohort consisted of 533,286 participants (n=314,162 men and n=219,124
women). The NIH–AARP Diet and Health Study was approved by the National Cancer
Institute Special Studies Institutional Review Board, and all participants gave informed
consent by virtue of completing and returning the questionnaire.
5.3.2

Dietary assessment and E-DII score calculation
The self-administered NCI-developed FFQ included in the baseline questionnaire

assessed participants’ usual frequency of intakes and portion sizes on 124 food items over
the past year, using 10 frequency categories ranging from “never” to “>=6 times/d” for
beverages and from “never” to “>=2 times/d” for solid foods. Each item has 3 options of
portion size.48 The FFQ also included 21 additional questions on food choices and
cooking practices, and four supplement intake questions.361 In the calibration study, the
performance of baseline FFQ was evaluated using two nonconsecutive 24-hour dietary
recalls by telephone which were randomly assigned by day of the week with a median of
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21 days apart among 1,953 subsample participants who responded to at least a baseline
FFQ and one 24-hour recall.361 After adjusting for random within-person error, the
energy-adjusted correlation coefficient ranged from 0.40 (vitamin E) to 0.76 (saturated
fat) among men, and from 0.36 (vitamin E) to 0.70 (vitamin B6) among women.361
Responses from the FFQ were linked to the USDA’s CSFII survey databases (1989–91
initially, and 1994–96 as it became available), in order to estimate individuals’ nutrients,
foods, and food group intakes.364
The DII is a literature-derived, population-based index designed to assess the
overall inflammatory potential of an individual’s diet. The details of the development of
the DII have been published previously.22 Briefly, 1,943 eligible peer-reviewed primary
research articles published up to 2010 on the effect of dietary factors on six inflammatory
markers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP) were identified and scored to derive
the component-specific inflammatory effect scores for 45 dietary factors (i.e. components
of DII), which comprised macronutrients, micronutrients and some bioactive components
such as spices and tea.22 Thirty-four baseline FFQ-derived food parameters in the NIHAARP study were used to calculate the E-DII score. These included the following:
calories; carbohydrates; protein; total fat; saturated, monounsaturated, and
polyunsaturated fat; trans-fat; alcohol; fiber; cholesterol; vitamins B1, B2, B6, B12, A, C,
D, and E; niacin; iron; magnesium; zinc; selenium; folic acid; beta-carotene;
anthocyanidins; flavan-3-ols; flavones; flavonones; isoflavones; caffeine; green peppers;
and tea. To calculate flavonoid classes, daily fruits and vegetables intakes in grams were
linked to the USDA’s Database for Flavonoid Content from Selected Foods (Release 3.1,
December 2013) by matching foods with the USDA’s 5-digit nutrient database number.
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The content levels of each flavonoid class from each fruit and vegetable were calculated
and summed to provide amount of consumption for each flavonoid class.48
The food and nutrient consumption estimated from the FFQ was first adjusted for
total energy per 1000 calories. The energy-adjusted dietary intake was subsequently
standardized to a composite dietary database representing average worldwide energyadjusted dietary intake from 11 populations in the world, to avoid the arbitrariness of
simply using raw intake amounts.22 The energy-adjusted standardized dietary intake was
then multiplied by the literature-derived inflammatory effect score for each of 34 DII
components, and summed across all components to obtain the overall E-DII score.22
Higher E-DII scores represent more pro-inflammatory diets while lower (i.e., more
negative) E-DII scores indicate more anti-inflammatory diets. The DII score, calculated
from multiple different dietary assessment instruments, has been construct validated and
found to be associated with higher levels of IL-6,24 TNF-α receptor 2,24 hsCRP23,27 and
homocysteine.25
A majority of the partipants (68%) in the NIH-AARP Study consumed
supplements, and most dietary supplements contain components which have antiinflammatory properties. Thus, we utilized intake data from food and supplements to
calcuate the E-DII and quantify the association between the inflammatory potential of
overall dietary exposures and pancreatic cancer risk.
5.3.3

Assessment of other covariates
Baseline characteristics, which included demographic information, personal

medical history, family history, and health behaviors such as smoking, alcohol drinking,
and physical activity were self-reported through the baseline questionnaire. BMI was
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calculated as weight (kg)/height(m)2 and categorized based on the World Health
Organization criteria.368 NSAIDs use information was collected from a risk factor
questionnaire which was sent to participants in 1996 to 1997.414
5.3.4

Cohort follow-up and pancreatic cancer case ascertainment
The NIH-AARP cohort are followed annually for change of address by matching

the cohort database to that of the National Change of Address (U.S. Postal Service). Vital
status was ascertained by annual linkage of the cohort to the Social Security
Administration Death Master File (SSA DMF) on deaths in the U.S., follow-up searches
of the National Death Index (NDI) for subjects that match to the SSA DMF, cancer
registry linkage, questionnaire responses and responses to other mailings. Incident cases
of pancreatic cancer were identified through linkage between the NIH-AARP cohort
membership and eight state cancer registry databases which are estimated to be 95%
complete within two years of cancer incidents. Uncertain matches underwent a final
manual review. A follow-up questionnaire sent out in 2004 to record participants’ cancer
status and other non-cancer endpoints was used as an additional resource. Mortality cases
were identified by linkage to the NDI. In our analysis, pancreatic cancer case was defined
as incident adenocarcinoma of the exocrine pancreas (International Classification of
Diseases for Oncology, Third Edition, codes C25.0-C25.3, C25.7- C25.9) and our case
definition excluded pancreatic endocrine tumors and other rare histology types (histology
type 8150, 8151, 8154, 8155,8160, 8240,8245, 8246, 8430, 8440, 8453, 8470, 8471,
8520, 8550, 8800, 8980) because they may differ etiologically from adenocarcinoma of
exocrine pancreas.248,370,383 We treated these cases as censored at the date of diagnosis.
Secondary pancreatic cancer cases (i.e., non-primary pancreatic cancer) were excluded
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from outcome in the sensitivity analysis. There were cases who had pancreatic cancer
diagnosis at the time of death (diagnosis date=death date), so we imputed their diagnosis
date by subtracting 4 months from the death date (4 months is the median survival time
for exocrine pancreatic cancer) and we included these people in the outcome in one of the
sensitivity analyses.369
5.4

Statistical analysis
The baseline characteristics of the study population by quintiles of E-DII from

food plus supplement, with quintile cut-off points determined from the distribution of the
entire cohort, was described by calculating means and SE for continuous variables and
frequencies and percentages for categorical variables. ANOVA test was used to test the
difference across E-DII quintiles for continuous variables, and Chi-square test was
performed to test the difference for categorical variables. Participants were followed up
from the baseline questionnaire completion to the date of diagnosis of pancreatic cancer,
death from any cause, moved out of the study’s ascertainment area, or the end date of
study follow-up (12/31/2011), whichever came first. Multivariable Cox proportional
hazards regression with person-year as the underlying time metric was fitted to estimate
the age- and energy-adjusted and multivariable-adjusted hazard ratios (HRs) and 95%
confidence intervals (CIs) with subjects in the lowest E-DII quintile (the most antiinflammatory score) as the referent. Proportional hazard (PH) assumption was examined
using the Schoenfeld residual test.374 Only baseline age (continuous format) violated PH
assumption, so we fitted a stratified COX model by binary age group using the median
age of the cohort. To test the linear trend of pancreatic cancer risk across quintiles of EDII score, a continuous E-DII variable was used.415 We considered all variables in Table
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5.1 as potential confounders during model building and created parsimonious
(multivariable-adjusted) models that included variables if they were associated with both
pancreatic risk and E-DII (in either continuous or categorical format), or changed the
crude risk estimate by more than 10%. In the multivariable-adjusted models, we adjusted
for age group at entry (<62 or >=62 years old), sex (male and female), BMI
(underweight; normal; overweight; obese; missing), smoking status (nonsmoker;
quit>=10 years,<=20 cigs/day; quit>=10 years,>20 cigs/day; quit 5-9 years,<=20
cigs/day; quit 5-9 years,>20 cigs/day; quit 1-4 years,<=20 cigs/day; quit 1-4 years,>20
cigs/day; quit<1 year or current,<=20 cigs/day; quit<1 year or current,>20 cigs/day;
missing), alcohol intake (g/d), education levels (<=11 years; 12 years or completed high
school; post-high school, some college, college or post graduate; unknown), medical
history of diabetes (yes; no), and total energy intake (kcal/day). Continuous HR and 95%
CIs also were calculated for each one unit of standard deviation increase of E-DII score
after the restricted cubic spline test indicated the linear assumption was sufficient.375
Since men and women had different distributions of the E-DII score and other covariates,
we present the associations between E-DII and pancreatic cancer by sex using sexspecific E-DII quintile cut-off points, and among combined men and women.
Effect modifications by inflammation-related lifestyle factors including BMI,
smoking status, alcohol drinking , NSAIDs use frequency (i.e., aspirin and ibuprofen
products), and diabetes history were examined by adding cross-product of each effect
modifier as a categorical variable with E-DII quintile in the multivariable-adjusted model
with a P value ≤0.1 as an indicator of significant interaction.376 HRs and 95% CIs
comparing subjects in each higher E-DII group with lowest E-DII were reported for each
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stratum of a given effect modifier. According to the American Institute for Cancer
Research Continuous Update Project 2012 report for pancreatic cancer, there was
evidence of a nonlinear association between alcohol (as ethanol) and pancreatic cancer
risk with increased risk observed among those consuming 53.4g alcohol or more a day.239
Thus, we categorized alcohol intake into high and low level by using 53.4g as the cut-off
point in the interaction test. We did not find any difference in the significance of
interactions between males and females; thus, we presented the results of interactions
without stratifying by sex.
To examine whether associations varied by pancreatic cancer severity, we also
performed separate association analysis among cancer cases with different cancer stages
and cancer grades.
Multiple sensitivity analyses were performed. First, to alleviate concerns
regarding reverse causality (i.e., a biased association attributed to diet or a lifestyle
change as a result of latent pancreatic cancer), lag time analysis was performed by
excluding study subjects with follow-up <5 years as previously reported. Secondly,
subjects who self-reported diabetes history at baseline were removed from analysis as
diabetes may be a preclinical indictor of pancreatic cancer, and diet modification may
have occurred after diagnosis of diabetes.307,354,377,398 We also restricted the outcome to
primary pancreatic cancer only, and added death cases of pancreatic cancer to both
primary pancreatic cancer outcomes and the total incident outcomes using the imputed
incidence time.
All statistical analyses were conducted using SAS® (version 9.4, Cary, NC). All
tests were two-sided with p values<0.05 considered to be statistically significant if not
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otherwise noted.
5.5

Results
After a median 13.4 years of follow up, a total of 3,338 pancreatic cancer cases

occurred. E-DII scores ranged from -7.91 to 6.66, which was comparable to other US
cohorts.193,406 As shown in Table 5.1, compared to participants who had the most antiinflammatory E-DII scores (i.e. E-DII quintile 1), participants consuming a more proinflammatory diet (i.e., higher E-DII scores) were younger at baseline but with larger
BMI, consumed more alcohol and energy, and were more likely to be males, current
smokers or former smoker who smoked more than 20 cigarettes per day, Black nonHispanic or Hispanic race/ethnicities, have below-college education level, have history of
diabetes, but be less physically active, and report less frequent use of NSAIDs.
HRs for pancreatic cancer risk according to E-DII quintiles and continuous E-DII
are presented in Table 5.2. In the age- and energy-adjusted model, significantly increased
pancreatic cancer risk with E-DII quintile and continuous E-DII was seen among males
and among all subjects combined, but not among females. After controlling for
confounders, there was no significant association between E-DII scores and pancreatic
cancer risk among men (HRQ5vsQ1=1.03, 95% CI=0.89-1.18, P-trend=0.69), women
(HRQ5vsQ1= 0.98, 95% CI=0.82-1.17, P-trend=0.98), or all subjects combined
(HRQ5vsQ1=0.97, 95% CI=0.87-1.09, P-trend=0.87, P-interaction by sex=0.63)
Continuous HRs also were not significant among men or women or all (Table 5.2).
The E-DII and pancreatic cancer association was not modified by any of the
inflammation related lifestyle factors which consisted of BMI, smoking status, alcohol
drinking, NSAIDs use (i.e. aspirin and ibuprofen products), and diabetes history (Table
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5.3). Stratified by any effect modifier, no significant association was detected in any of
the strata comparing the highest to lowest E-DII group.
Stratified by cancer stage, localized pancreatic cancer made up the least
proportion, followed by regional and distant metastasized pancreatic cancers. However,
inflammatory potential of diet was not associated with pancreatic cancer in any cancer
stage (Table 5.4). Similarly, when stratified by cancer grade, the largest proportion of
pancreatic cancer was poorly differentiated or moderately well differentiated. We did not
identify any significant association with pancreatic cancer in any cancer grade (Table
5.5).
After excluding subjects with follow-up <5 years, the multivariable HRs did not
change materially (Table 5.6). Similar HRs were observed when primary pancreatic
cancer was treated as the outcome. After we added pancreatic cancer death cases to
outcomes (i.e., total incident pancreatic cancer cases and primary pancreatic cancer cases)
by using the imputed incidence time, results did not change (Table 5.7 and 5.8).
5.6

Discussion
The current analyses represent the largest cohort to date to examine the

association between dietary inflammatory potential and pancreatic cancer in a prospective
manner. No association was observed between the E-DII and pancreatic cancer risk. We
also did not observe evidence of effect modification by inflammation-related lifestyle
factors including BMI, smoking status, alcohol drinking, NSAIDs use, or history of
diabetes. Due to the large sample size, we were able to examine associations by disease
severity, but found no evidence of increased risk of pancreatic cancer with a more proinflammatory diet among different cancer stages or grades.
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Two case-control studies and one cohort study previously investigated the E-DII
and pancreatic cancer association. The finding of the present analysis was consistent with
our previous work where an overall null association was reported among 101,449 US
participants in the PLCO cohort (Zheng et al. unpublished data in Chapter 4). In the two
case-control studies from the US39 and Italy,38 both reported a more than 2-fold
significant increased risk of pancreatic cancer in the highest compared to the lowest
quintile of the E-DII group (US: OR Q5vsQ1 =2.54, 95% CI=1.87-3.46, P trend<0.000139;
Italy: OR Q5vsQ1=2.48, 95% CI=1.50-4.10, P-trend=0.00238). The different results between
our analysis and the case-control studies may be explained by the different study designs.
The prospective design utilized in the two studies with null associations serves to
minimize differential misclassification of exposure which can be present in case-control
studies due to recall bias.400,416 On the other hand, it is possible that a one-time dietary
assessment many years prior to diagnosis in cohort studies is not the most etiologicallyrelevant timeframe for assessing exposure. Of note, however, our group has reported
significant associations between the DII and colorectal cancer, another cancer
substantially influenced by inflammation, within the NIH-AARP Study.34 While there
was no evidence of a follow-up time interaction in the current study, previous analyses of
the PLCO cohort indicated the association between diet and pancreatic cancer may differ
by follow-up time. In that study, decreased risk with a more pro-inflammatory diet was
observed with shorter follow-up time, and increased risk was observed for longer followup time (Zheng et al. unpublished data in Chapter 4). Thus, the effect of preclinical
disease on dietary intake and recall should be further explored in cohort studies.
Previous studies of dietary indices other than the DII using a priori or data-driven
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methods for deriving dietary patterns have generally suggested healthier dietary quality
characterized by high consumption of fruit, vegetables, whole grains, white meat, fiber,
low-fat dairy products was associated with reduced pancreatic risk while patterns
characterized by greater intake of animal foods, refined grains, high-fat dairy products,
sweets and desserts were associated with increased risk of pancreatic
cancer,16,17,20,21,48,402,403 although the associations were stronger in case-control than
cohort studies.417 The differences in dietary patterns of interest, dietary assessment
instruments, study design and study population, number of cases or timing from dietary
data collection to diagnosis are important factors that may explain the different results
across studies.
No evidence of effect modification by inflammation-related lifestyle factors was
identified in the study and no significant association appeared in any stratum of an effect
modifier, which was consistent with our findings in the PLCO cohort where BMI, history
of diabetes, and smoking status were not effect modifiers. The Italian case-control study
reported effect modification by smoking status and BMI where a significant positive
association was observed among never smokers (OR Q5vsQ1=2.32, 95% CI=1.08-4.99; Ptrend=0.01) and past smokers (ORQ5vsQ1= 3.37, 95 % CI=1.22-9.35; P-trend=0.07), but
not among current smokers. Positive associations were observed among normal weight
(ORQ5vsQ1 =2.24, 95 % CI=1.03-4.86; P-trend=0.16) and overweight (ORQ5vsQ1=2.32,
95% CI=1.03- 5.21; P-trend=0.005), but not among obese subjects (P-interactions by
BMI and by smoking status were not reported in the study).38 In the US case-control
study, Antwi et al. did not find significant interaction between DII and BMI, diabetes
history or cigarette smoking using the statistical test for multiplicative interaction.
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However, the quantitative additive and multiplicative interactions calculated by
comparing the observed and expected ORs suggested that diet-associated inflammation
may act synergistically with cigarette smoking and diabetes to increase the risk of
pancreatic cancer beyond the risk of any of these factors alone.39
This is one of the first cohort studies to examine the association between a dietary
index and pancreatic cancer severity. Similar to the overall null association, we did not
find a differential association between inflammatory potential of diet and pancreatic
cancer in any cancer stage or grade. The only other study to examine DII in relation to
pancreatic cancer stage at diagnosis was the case-control study in the US which found a
positive association overall. They also did not find differential effects by stage, reporting
increased risk for cancers presenting with resectable (ORQ5vsQ1 = 2.36, 95% CI = 1.48–
3.75), locally advanced (ORQ5vsQ1 = 2.21, 95% CI = 1.41–3.46) or metastatic (ORQ5vsQ1 =
3.13, 95% CI = 1.85–5.29) tumors.39 Due to the rapid fatality rates of pancreatic cancer,
case-control studies are especially prone to biases with frequent proxy responses used
among cases, which in turn may produce more measurement error among cases than
controls.
Although no association was found between a pro-inflammatory diet and
pancreatic cancer, there is mechanistic support for the hypothesis. It is well accepted that
inflammatory states foster a cellular environment that supports the development of
genomic mutations and the initiation of pancreatic carcinogenesis.58 Dietary factors can
modify inflammation through multiple mechanisms including regulation of the proinflammatory cytokines, NF-κB pathway activation, changes in DNA methylation, and
influence on the antioxidant defense.79,73 Pro-inflammatory diets can increase insulin
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resistance, increase reactive oxygen species and mediators in the inflammatory pathway
(e.g., NF-kB and COX-2), leading to increased cell cycling, loss of tumor suppressor
function, and stimulated oncogene expression, genetic alterations and modifications of
key cancer-related proteins and ultimately cause malignancy.57,58,418,419 Antiinflammatory diets can have strong antioxidant and carcinogenesis-inhibition properties,
owing to healthy fatty acid profiles, large fiber content, high antioxidants and
phytochemicals from vegetables and fruits which help to reduce insulin resistance,
oxidative stress and damage, and inhibit tumor initiation and promotion.182,420
This study has several strengths. The NIH-AARP Diet and Health Study is a large
well- established prospective cohort study with diet and lifestyle factors assessed before
cancer diagnosis, which minimized the recall bias and selection bias that may be found in
a typical case-control study. A large number of pancreatic cancer cases has provided
sufficient statistical power to detect the main association and interaction by several
important inflammation-related lifestyle factors. Detailed information on a
comprehensive list of covariates allowed for careful adjustment in the analyses. This is
the first cohort study to examine whether inflammatory potential of diet could act
synergistically with other inflammation-related lifestyle factors to influence pancreatic
cancer risk. It is also the first cohort study to examine the association between a dietary
index and pancreatic cancer severity. The use of the DII, a construct-validated
measurement tool which takes into account the whole diet to assess dietary inflammatory
potential has major advantage over other a priori dietary patterns as it was developed
specifically for inflammation mechanism,22 which plays a central role in the pancreatic
cancer carcinogenesis.58,59
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Despite these strengths, study limitations also are noted. The number of cases in
certain cancer stage (localized pancreatic cancer) and grade (well-differentiated
pancreatic cancer and undifferentiated/anaplastic pancreatic cancer) categories and some
other stratified analyses was not large enough to infer valid associations. Measurement
error in FFQ data and other covariates is another unavoidable limitation, and a measure
of social desirability was not obtained in this study.421,422 Although follow-up data on
covariates were available in the risk factor or follow-up questionnaires, the large missing
percentage impeded the possibility to use these data. Diet was only assessed at baseline,
therefore, any changes in diet over follow up were not captured, which could result in
non-differential misclassification of exposure. However, we previously found DII scores
were relatively stable over a long timeframe in postmenopausal women where the study
participants were of comparable age as the NIH-AARP study.405 Another possible
limitation in our study was that only data on 34 components of the DII were available to
calculate the E-DII scores. However, the range of DII scores may rely more on the
amount of foods actually consumed rather than on the number of available DII
components.406 Although important potential confounders were adjusted for in our
analyses, residual or unmeasured confounding may still be a possibility.
5.7

Conclusion
In conclusion, there was no association between dietary inflammatory potential

and pancreatic cancer risk in this large cohort among both men and women.
Inflammation-related lifestyle factors including BMI, smoking status, alcohol drinking,
NSAIDs use, and history of diabetes did not modify the association. Dietary
inflammatory potential was not associated with pancreatic cancer risk by cancer stage or
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grade. Future large cohort studies are warranted to test the effect modification of E-DII
and cancer by inflammation-related lifestyle factors and test the association between EDII and severity of pancreatic cancer to confirm our findings. Future cohort studies
should also examine the difference in associations by follow-up time.
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Table 5.1 Baseline characteristics of 533,286 subjects in the NIH-AARP Diet and
Health Study by quintiles of E-DII
Most antiinflammato
ry diet

Most proinflammato
ry diet

E-DII Q1
(-7.91,-5.61)

E-DII Q2
(-5.60,4.51)

E-DII Q3
(-4.50,3.29)

E-DII Q4
(-3.28,-1.51)

E-DII Q5
(-1.50,6.66)

106658

106657

106657

106655

106659

Mean (SE)

Mean (SE)

Mean (SE)

Mean (SE)

Mean (SE)

Age at
baseline (y)

62.0 (0.02)

61.9 (0.02)

61.8 (0.02)

61.6 (0.02)

61.1 (0.02)

<.0001

Total energy
intake
(kcal/d)

1564.7 (1.8)

1722.9 (2.2)

1817.2 (2.4)

1937.7 (2.6)

2180.1 (3.1)

<.0001

BMI at
baseline
(kg/m2)

26.3 (0.01)

26.8 (0.01)

27.1 (0.01)

27.4 (0.01)

27.6 (0.01)

<.0001

Alcohol
consumption
(g/d)

8.9 (0.05)

9.1 (0.06)

10.1 (0.07)

12.5 (0.1)

22.7 (0.2)

<.0001

n (%)b

n (%)b

n (%)b

n (%)b

n (%)b

N

<.0001

Sex
Male

48772 (45.7)

56695
(53.2)

62315
(58.4)

69005 (64.7)

77375
(72.5)

Female

57886 (54.3)

49962
(46.8)

44342
(41.6)

37650 (35.3)

29284
(27.5)

Race/
Ethnicity
White nonHispanic
Black nonHispanic
Hispanic
Other races
Unknown
Education
level
less than or
equal to 11
years
High school
completion

Pvaluea

<.0001
98311 (92.2)

97681
(91.6)

97094
(91.0)

97170 (91.1)

97249
(91.2)

3249 (3.1)

3915 (3.7)

4359 (4.1)

4319 (4.1)

4532 (4.3)

1675 (1.6)
2170 (2.0)
1253 (1.2)

1901 (1.8)
1873 (1.8)
1287 (1.2)

2114 (2.0)
1709 (1.6)
1381 (1.3)

2195 (2.1)
1457 (1.4)
1514 (1.4)

2015 (1.9)
1353 (1.3)
1510 (1.4)
<.0001

3689 (3.5)

5050 (4.7)

6106 (5.7)

7429 (7.0)

9593 (9.0)

16655 (15.6)

19182
(18.0)

20309
(19.0)

22155 (20.8)

25819
(24.2)
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Post high
school
training other
than college

9548 (9.0)

10032 (9.4)

10336 (9.7)

10810 (10.1)

11630
(10.9)

Some college

25274 (23.7)

25051
(23.5)

24514
(23.0)

24577 (23.0)

24331
(22.8)

College and
postgraduate

48561 (45.5)

44210
(41.5)

42193
(39.6)

38555 (36.2)

32090
(30.1)

2931 (2.8)

3132 (2.9)

3199 (3.0)

3129 (2.9)

3196 (3.0)

Missing
Smoking
status and
dose
combined
Never
smoked

<.0001

41415 (38.8)

40371
(37.9)

38425
(36.0)

35937 (33.7)

29965
(28.1)

Quit, <=20
cigs/d

33914 (31.8)

31148
(29.2)

29957
(28.1)

28543 (26.8)

24776
(23.2)

Quit, >20
cigs/d
Current
smoker,
<=20 cigs/d

20853 (19.6)

22738
(21.3)
7870 (7.4)

23947 (22.5)

5219 (4.9)

21904
(20.5)
6790 (6.4)

25782
(24.2)
12256
(11.5)

Current
smoker, >20
cigs/d

1443 (1.4)

2615 (2.5)

3621 (3.4)

5182 (4.9)

9571 (9.0)

Unknown

3814 (3.6)

3829 (3.6)

4046 (3.8)

3976 (3.7)

4309 (4.0)

9070 (8.5)

Physical
activity
frequency in
the past year
Never

2379 (2.2)

3493 (3.3)

4402 (4.1)

5529 (5.2)

8127 (7.6)

Rarely

9316 (8.7)

12124
(11.4)

13962
(13.1)

16348 (15.3)

20676
(19.4)

1-3 time per
month

11280 (10.6)

13170
(12.4)

14412
(13.5)

15631 (14.7)

17353
(16.3)

1-2 times per
week
3-4 times per
week
5 or more
times per
week

21867 (20.5)

23070
(21.6)
31369
(29.4)
22408
(21.0)

23192
(21.7)
28947
(27.1)
20555
(19.3)

23503 (22.0)

22817
(21.4)
21085
(19.8)
15213
(14.3)

1020 (1.0)

1187 (1.1)

Unknown

<.0001

34950 (32.8)
25974 (24.4)

892 (0.8)

History of
diabetes

26253 (24.6)
18184 (17.1)

1207 (1.1)

1388 (1.3)
<.0001
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No

98693 (92.5)

Yes

8019 (7.5)

Aspirin
products use
frequency
No use

96906
(90.9)
9751 (9.1)

96102
(90.1)
10555 (9.9)

95788 (89.8)
10867 (10.2)

97567
(91.5)
9092 (8.5)
<.0001

17070 (16.0)

16650
(15.6)
19139
(17.9)

16996
(15.9)
19267
(18.1)

16914 (15.9)

1-3
times/month

19527 (18.3)

1-6
times/week

11384 (10.7)

11272
(10.6)

10466 (9.8)

10226 (9.6)

9259 (8.7)

>=1 time/day

17982 (16.9)

17057
(16.0)
42539
(39.9)

16267
(15.3)
43661
(40.9)

14956 (14.0)

12750
(12.0)
47684
(44.7)

Unknown
Ibuprofen
products use
frequency
No use

40695
(38.15)

19542 (18.3)

16801
(15.8)
20165
(18.9)

45017 (42.2)

<.0001

26408 (24.8)

27366
(25.7)
20563
(19.3)
8339 (7.8)

27690 (26.0)

9463 (8.9)

26659
(25.0)
21333
(20.0)
9033 (8.5)

8057 (7.6)

27911
(26.2)
18403
(17.3)
6957 (6.5)

1-3
times/month
1-6
times/week
>=1 time/day

22739 (21.3)

19646 (18.4)

7133 (6.7)

6899 (6.5)

6519 (6.1)

5994 (5.6)

5459 (5.1)

Unknown

40195 (38.4)

42733
(40.1)

43870
(41.1)

45268 (42.4)

47929
(44.9)

Abbreviations: SE, standard error
a
Statistical analyses were performed by ANOVA test for continuous variables and by Chi-Square test for
categorical variables.
b
Sum of percentages may not add up to 100% because of rounding or missing.
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Table 5.2 Hazard ratios of pancreatic cancer by quintiles of E-DII score among
533,286 subjects in the NIH-AARP Diet and Health Study
E-DII
Q1

E-DII
Q2

E-DII
Q3

E-DII
Q4

E-DII
Q5

Ptrend
a

Continuous
HR and
95%CIb

Pinteractio
nc

Total subjects
Total sample

10665
8

10665
7

10665
7

10665
5

10665
9

Number of
cases

666

618

683

660

711

Age and
energyadjusted
model HR
(95% CI)

1.00

0.94
(0.841.05)

1.05
(0.951.17)

1.03
(0.921.15)

1.14
(1.021.27)

0.001

1.06 (1.031.10)

Multivariable
- adjusted
model HR
(95% CI)d

1.00

0.91
(0.811.01)

0.99
(0.891.10)

0.94
(0.841.04)

0.97
(0.871.09)

0.78

1.01 (0.971.04)

Total sample

62833

62833

62833

62830

62833

Number of
cases
Age and
energyadjusted
model
HR (95% CI)

422

413

435

407

448

1.00

1.00
(0.871.14)

1.07
(0.931.22)

1.01
(0.881.16)

1.15
(1.011.32)

0.02

1.05 (1.011.10)

Multivariable
- adjusted
model HR
(95% CI)d

1.00

0.97
(0.851.12)

1.02
(0.891.17)

0.95
(0.831.09)

1.03
(0.891.18)

Total sample

43826

43822

43827

43824

43825

Number of
cases
Age and
energyadjusted
model HR
(95% CI)
Multivariable
- adjusted
model HR
(95% CI)d

254

237

211

253

258

1.00

0.94
(0.791.13)

0.85
(0.711.02)

1.04
(0.871.23)

1.00

0.93
(0.781.11)

0.82
(0.680.98)

0.98
(0.821.17)

Males

0.63
0.69

1.01 (0.971.06)

1.09
(0.921.30)

0.16

1.04 (0.981.10)

0.98
(0.821.17)

0.98

1.00 (0.941.06)

Females

a.

P-trend was calculated using the continuous E-DII score in the model
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b.

The continuous HR and associated 95% CI for one standard deviation increase of E-DII score
P-interaction was calculated with the cross-product of sex and E-DII quintile in the multivariable adjusted
COX model
d.
Model was adjusted for age group(<62 and >=62 years old), sex (male or female), body mass index
category (underweight, normal, overweight, obese, missing), smoking, quit and dose combined
(nonsmoker, quit>=10 years,<=20 cigs/day, quit>=10 years,>20 cigs/day, quit 5-9 years,<=20 cigs/day,
quit 5-9 years,>20 cigs/day, quit 1-4 years,<=20 cigs/day, quit 1-4 years,>20 cigs/day, quit<1 year or
current,<=20 cigs/day, quit<1 year or current,>20 cigs/day, missing), total energy(kcal/day), alcohol from
alcoholic drinks(g/d), diabetes history(yes/no), education level (<=11 years, 12 years or completed high
school, post-high school, some college, college and post graduate, unknown).
c.
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Table 5.3 Hazard ratios* of pancreatic cancer by quintiles of E-DII score among
533,286 subjects in the NIH-AARP Diet and Health study, stratified by
inflammation-related lifestyle factors
Q1

Q2

Q3

Q4

Q5

HR

HR
95%CI

HR
95%CI

HR
95%CI

HR
95%CI

Ptrenda

BMI

0.29
1.00

Underweight
Normal

1.00

Overweight

1.00

Obese

1.00

Smoking
status
Never
smokers

Pinteractionb

1.60
(0.465.53)
0.91
(0.761.10)
0.89
(0.751.05)
0.86
(0.671.09)

1.95
(0.596.43)
1.09
(0.911.31)
1.01
(0.861.19)
0.75
(0.590.97)

0.41
(0.072.29)
0.86
(0.711.05)
0.95
(0.801.12)
0.88
(0.701.12)

0.84
(0.213.36)
0.94
(0.771.15)
1.01
(0.851.19)
0.86
(0.671.09)

0.50

0.73

0.54

0.53

0.48
1.00

Former
smokers

1.00

Current
smokers

1.00

Alcohol
level
Low

1.00

High

1.00

0.81
(0.680.98)
0.96
(0.821.12)
0.95
(0.671.34)

0.84
(0.701.01)
1.04
(0.891.22)
1.18
(0.851.63)

0.86
(0.711.04)
1.03
(0.881.21)
0.88
(0.631.23)

0.88
(0.721.07)
1.05
(0.891.24)
1.09
(0.801.49)

0.59

0.26

0.61

0.92

Frequency
of use of
aspirin
products
No use

1.00

Monthly use

1.00

0.90
(0.811.01)
0.95
(0.501.77)

0.98
(0.881.09)
1.22
(0.682.19)

0.93
(0.831.04)
1.10
(0.621.95)

0.96
(0.861.08)
1.14
(0.661.96)

0.89

0.74

0.23

0.78
(0.591.03)
0.84
(0.641.11)

0.95
(0.731.23)
1.15
(0.901.49)

0.87
(0.661.14)
0.97
(0.751.27)
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0.99
(0.761.31)
0.89
(0.681.17)

0.53

0.42

Weekly
and daily
use
Frequency
of use of
ibuprofen
products
No use

1.00

1.01
(0.821.25)

0.93
(0.751.16)

1.21
(0.971.51)

0.10

0.92

1.00

Monthly
use

1.00

Weekly
and daily use

1.00

Selfreported
diabetes
history
No

1.07
(0.871.31)

0.97
(0.781.20)
0.88
(0.691.13)
0.90
(0.681.20)

1.15
(0.931.41)
1.03
(0.811.31)
0.87
(0.651.17)

0.98
(0.791.21)
0.93
(0.721.19)
0.86
(0.631.16)

1.09
(0.881.36)
1.07
(0.821.38)
0.94
(0.681.29)

0.71

0.20

0.93

0.50

1.00

0.92
1.02
0.93
0.99
0.83
(0.82(0.91(0.83(0.881.04)
1.14)
1.05)
1.11)
Yes
1.00
0.79
0.79
0.93
0.86
0.90
(0.57(0.58(0.68(0.621.09)
1.09)
1.26)
1.21)
*The model was adjusted for age group, sex, body mass index category, smoking status with quit and dose
combined, total energy(kcal/day), alcohol intake (g/d), diabetes history, education level while adding the
cross-product term of the quintile E-DII and each effect modifier in the model.
a. P-trend was calculated using the continuous E-DII score in the model
b. P-interaction was calculated with the cross-product of the effect modifier and E-DII quintile in the
multivariable-adjusted COX model
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Table 5.4 The association between E-DII quintiles and risk of pancreatic cancer by
cancer stage in the NIH-AARP Diet and Health Study
Q1
Localized pancreatic cancer
Sample size
106658
Number of cases
25
Age and energy
1.00
adjusted model
HR (95% CI)
Multivariable1.00
adjusted model
HR (95% CI)b
Regional pancreatic cancer

Q2

Q3

Q4

Q5

106657
33
1.35 (0.802.27)

106657
31
1.29 (0.762.20)

106655
22
0.94 (0.531.67)

106659
37
1.66 (0.982.79)

1.31 (0.782.21)

1.23 (0.722.09)

0.87 (0.491.57)

1.48 (0.862.53)

Ptrenda

0.03

0.11

Number of cases

137

126

136

123

138

Age and calorie
adjusted model
HR (95% CI)
Multivariableadjusted model
HR (95% CI)b

1.00

0.93 (0.731.19)

1.02 (0.811.30)

0.94 (0.731.20)

1.10 (0.861.40)

0.30

1.00

0.91 (0.711.16)

0.97 (0.761.23)

0.87 (0.681.11)

0.96 (0.751.24)

0.91

Distant metastasized pancreatic cancer
Number of cases

214

180

200

215

227

Age and energy
adjusted model
HR (95% CI)

1.00

0.85 (0.701.03)

0.95 (0.791.16)

1.03 (0.851.25)

1.12 (0.921.36)

0.01

Multivariableadjusted model
HR (95% CI)b

1.00

0.81 (0.660.99)

0.87 (0.721.06)

0.91 (0.751.10)

0.90 (0.741.10)

0.82

a.

P-trend was calculated using the continuous E-DII score in the model
Model was adjusted for age group(<62 and >=62 years old), sex (male or female), body mass index
category (underweight, normal, overweight, obese, missing), smoking, quit and dose combined
(nonsmoker, quit>=10 years,<=20 cigs/day, quit>=10 years,>20 cigs/day, quit 5-9 years,<=20 cigs/day,
quit 5-9 years,>20 cigs/day, quit 1-4 years,<=20 cigs/day, quit 1-4 years,>20 cigs/day, quit<1 year or
current,<=20 cigs/day, quit<1 year or current,>20 cigs/day, missing), total energy(kcal/day), alcohol from
alcoholic drinks(g/d), diabetes history(yes/no), education level (<=11 years, 12 years or completed high
school, post-high school, some college, college and post graduate, unknown).

b.
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Table 5.5 The association between E-DII quintiles and risk of pancreatic cancer by
cancer grade in the NIH-AARP Diet and Health Study
Q1

Q2

Q3

Q4

Grade 1 or well-differentiated pancreatic cancer
Sample size
106658
106657
106657
106655
Number of cases
35
31
29
37
Age and energy1.00
0.91 (0.56- 0.87 (0.53- 1.13 (0.71adjusted model
1.48)
1.43)
1.81)
HR (95% CI)
Multivariable1.00
0.86 (0.53- 0.79 (0.48- 0.99 (0.62adjusted model
1.40)
1.31)
1.59)
HR (95% CI)b
Grade II or moderately well differentiated pancreatic cancer
Number of cases
105
94
106
93

Q5

106659
24
0.77 (0.451.32)
0.64 (0.371.10)

Ptrenda

0.69

0.25

112

Age and energy1.00
0.91 (0.69- 1.04 (0.80adjusted model
1.20)
1.37)
HR (95% CI)
Multivariable1.00
0.89 (0.67- 0.99 (0.76adjusted model
1.17)
1.31)
HR (95% CI)b
Grade III or poorly differentiated pancreatic cancer

0.93 (0.701.23)

1.16 (0.881.52)

0.26

0.86 (0.651.14)

1.00 (0.751.33)

0.99

Number of cases

123

123

121

103

110

Age and energy1.00
0.86 (0.66- 0.94 (0.72- 1.06 (0.82adjusted model
1.12)
1.21)
1.36)
HR (95% CI)
Multivariable1.00
0.83 (0.64- 0.88 (0.68- 0.97 (0.75adjusted model
1.08)
1.14)
1.25)
HR (95% CI)b
Grade IV or undifferentiated/anaplastic pancreatic cancer

1.09 (0.851.42)

0.08

0.94 (0.721.23)

0.60

Number of cases

9

6

7

10

9

Age and energyadjusted model
HR (95% CI)
Multivariableadjusted model
HR (95% CI)b

1.00

0.67 (0.241.90)

0.79 (0.292.14)

1.14 (0.462.85)

1.06 (0.412.74)

0.79

1.00

0.64 (0.231.79)

0.72 (0.271.95)

0.99 (0.392.51)

0.86 (0.322.32)

0.87

a.

P-trend was calculated using the continuous E-DII score in the model
Model was adjusted for age group(<62 and >=62 years old), sex (male or female), body mass index
category (underweight, normal, overweight, obese, missing), smoking, quit and dose combined
(nonsmoker, quit>=10 years,<=20 cigs/day, quit>=10 years,>20 cigs/day, quit 5-9 years,<=20 cigs/day,
quit 5-9 years,>20 cigs/day, quit 1-4 years,<=20 cigs/day, quit 1-4 years,>20 cigs/day, quit<1 year or
current,<=20 cigs/day, quit<1 year or current,>20 cigs/day, missing), total energy(kcal/day), alcohol from
alcoholic drinks(g/d), diabetes history(yes/no), education level (<=11 years, 12 years or completed high
school, post-high school, some college, college and post graduate, unknown).

b.
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Table 5.6. Multivariable-adjusted HRs of lag time analysis of DII and pancreatic
cancer risk after excluding subjects with follow-up<5 years
Q1
Q2
Q3
Subjects with follow-up >=5 years (N=489,744)

Q4

Q5

Sample size

99008

98407

97799

97694

96836

Number of cases

515

489

514

495

539

Multivariableadjusted model
HR (95% CI)b

1.00

0.94
(0.831.06)

0.98
(0.861.11)

0.93 (0.821.05)

0.98 (0.861.11)

a.

P-trenda

0.75

P-trend was calculated using the continuous E-DII score in the model
The model was adjusted for age group, sex, body mass index category, smoking status with quit and dose
combined, total energy(kcal/day), alcohol from alcoholic drinks(g/d), diabetes history, education level

b.
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Table 5.7 Multivariable-adjusted HRs of sensitivity analysis of adding pancreatic
cancer death cases with imputed incident time to the first incident pancreatic cancer
Q1

Total subjects
Sample size
10665
8
Number of
803
cases
1.00
Multivariabl
e-adjusted
modeld

Q2

Q3

Q4

Q5

10665
7
759

10665
7
804

10665
5
791

10665
9
843

0.92
(0.841.02)

0.97
(0.871.07)

0.93
(0.841.03)

0.96
(0.861.06)

Ptrenda

Continuous
HR (95%
CI)b

0.84

1.00 (0.961.03)

Pinteraction
by sexc

Males
Sample size

62833

62833

62833

62830

62833

Number of
cases

533

502

513

489

535

Multivariabl
e-adjusted
modeld

1.00

0.94
(0.831.06)

0.95
(0.841.08)

0.90
(0.791.02)

0.97
(0.851.10)

43826

43822

43827

43824

43825

289

289

253

295

302

1.00

1.00
(0.851.18)

0.87
(0.731.03)

1.02
(0.871.21)

1.03
(0.871.22)

Females
Sample size
Number of
cases
Multivariabl
e-adjusted
modeld
a.

0.34
0.72

0.99 (0.951.04)

0.84

1.01 (0.951.06)

P-trend was calculated using the continuous E-DII score in the model
The continuous HR and associated 95% CI for one standard deviation increase of E-DII score
c.
P-interaction was calculated with the cross-product of sex and E-DII quintile in the multivariable adjusted
COX model
d.
Model was adjusted for age group, sex, body mass index category, smoking, quit and dose combined,
total energy(kcal/day), alcohol from alcoholic drinks(g/d), diabetes history, education level

b.
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Table 5.8 Multivariable-adjusted HRs of sensitivity analysis of adding pancreatic
cancer death cases with imputed incident time to incident primary pancreatic
cancer
Q1

Q2

Q3

Q4

Q5

Ptrend
a

Total subjects
Sample size
Number of
cases
Multivariable
- adjusted
modeld

10665
8
638

10665
7
599

10665
7
645

10665
5
627

10665
9
672

1.00

0.92
(0.821.03)

0.98
(0.881.10)

0.94
(0.841.05)

0.98
(0.871.10)

62833

62833

62833

62830

62833

410

385

412

375

416

1.00

0.94
(0.811.08)

1.00
(0.871.15)

0.90
(0.781.04)

0.99
(0.861.15)

43826

43822

43827

43824

43825

237

240

205

244

257

1.00

1.01
(0.841.21)

0.86
(0.711.03)

1.02
(0.851.23)

1.05
(0.871.26)

Continuous
HR (95%
CI)b

0.70

1.01 (0.971.05)

0.92

1.00 (0.961.05)

0.55

1.02 (0.961.08)

Pinteracti
on by
sexc

Males
Sample size
Number of
cases
Multivariable
- adjusted
modeld
Females
Sample size
Number of
cases
Multivariable
- adjusted
modeld

0.56

a.

P-trend was calculated using the continuous E-DII score in the model
The continuous HR and associated 95% CI for one standard deviation increase of E-DII score
c.
P-interaction was calculated with the cross-product of sex and E-DII quintile in the multivariable adjusted
COX model
d.
Model was adjusted for age group, sex, body mass index category, smoking, quit and dose combined,
total energy(kcal/day), alcohol from alcoholic drinks(g/d), diabetes history, education level

b.
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CHAPTER 6
6
MEDIATION EFFECT OF TYPE-2 DIABETES IN THE ASSOCIATION
BETWEEN DIETARY INFLAMMATORY POTENTIAL AND
PANCREATIC CANCER RISK: A POOLED ANALYSIS OF THE PLCO
CANCER SCREENING TRIAL AND NIH-AARP DIET AND HEALTH
STUDY
6.1

Abstract
Background: inflammation plays an important role in pancreatic cancer

pathogenesis and can be modulated by diet. Two case-control studies have reported a
significant positive association between dietary inflammatory index and pancreatic
cancer risk. However, little is known about the mechanism underlying the pathway from
dietary inflammatory potential to pancreatic cancer development. Given type-2 diabetes
is an inflammatory disease and a large amount of biological and epidemiological
evidence have suggested a strong positive association between type-2 diabetes and
pancreatic cancer, we aimed to investigate whether type-2 diabetes mediated the
association between dietary inflammatory potential and pancreatic cancer risk in a pooled
cohort of two similar large prospective cohorts in the US (PLCO Cancer Screening Trial
and NIH-AARP Diet and Health Study). Methods: A total of 74,826 participants from
the PLCO and 194,815 subjects from the NIH-AARP with age range from 50 to 74 years
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at baseline comprised the pooled mediation cohort which included a total of 269,641
subjects (144,999 men and 124,642 women). E-DII scores from food plus supplement
were calculated based on study-specific baseline diet questionnaire. Information on
incident diabetes occurrence status (i.e., mediator) during follow-up and the age/year of
first diagnosis was obtained through the follow-up questionnaires of both studies. Studyspecific primary incident adenocarcinoma of the exocrine pancreas was regarded as the
outcome of interest. Causal mediation approach under the counterfactual concept, was
used to calculate the study-specific natural direct effect (NDE), natural indirect effect
(NIE), and marginal total effect (MTE) on pancreatic cancer risk with type-2 diabetes as
a mediator by quintile E-DII while treating the lowest quintile as the reference.
Mediation effects of type-2 diabetes also were calculated for pancreatic cancer associated
with each unit increment of centered E-DII value and z-score of E-DII. Random effects
model was used to pool each mediation effect together, and since there was no significant
between-study heterogeneity, we further calculated and reported the pooled mediation
results using same approach. Results: In the pooled cohort, incident type-2 diabetes
significantly mediated associations between both categorical and continuous E-DII and
pancreatic cancer although the mediated effect was small. The overall effect of E-DII on
pancreatic cancer, averaged over direct and indirect effect with type-2 diabetes as a
mediator was not statistically significant. Conclusion: Incident type-2 diabetes may play
a mediator role in the association between dietary inflammatory potential and pancreatic
cancer development.
6.2

Introduction
Pancreatic cancer, the majority (~90%) of which is ductal adenocarcinoma of the
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exocrine pancreas, is one of the most rapidly fatal malignancies with the highest case
fatality rate among any major cancers.1,383 Despite its low incidence rate, pancreatic
cancer is the fourth leading cause of cancer mortality in the United States among both
men and women.4 Inflammation plays a critical role in the pathogenesis of this
malignancy, as manifested by the fact that inflammatory states are etiologically linked to
well-recognized risk factors for pancreatic cancer, including chronic pancreatitis,
cigarette smoking, obesity, and diabetes.58,384 Diet, an important modifiable lifestyle
factor, can modulate inflammation through its effect on visceral obesity,387 oxidative
damage,78 and insulin resistance.387 The DIITM was developed to assess the inflammatory
potential of an individual’s diet,22 which has the advantage over individual foods or
nutrients when being studied for associations with disease risk as it takes into account the
complex interactions among dietary components.13
To date, the association between the inflammatory potential of diet and pancreatic
cancer risk has been investigated and reported in two case-control studies and two cohort
studies. Both case-control studies identified a significant more than 2-fold increased risk
among individuals consuming a pro-inflammatory diet.38,39 As described in this
dissertation, no associations were observed overall in the two cohort studies (Zheng et al.,
unpublished data). Little is known about the mechanism underlying the pathway from
dietary inflammatory potential to pancreatic cancer development. Enhancing knowledge
about potentials in the pathway could provide scientific evidence for identifying
intermediate biomarkers to screen high risk populations for pancreatic cancer. It also
helps with the design and guidance of an effective dietary intervention to reduce risk of
pancreatic cancer. Given the large amount of biological and epidemiological evidence
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that suggests a strong positive association between type-2 diabetes and pancreatic cancer
and the inflammatory nature of diabetes, we hypothesized that type-2 diabetes may play a
role as a mediator linking dietary inflammatory potential to increased pancreatic cancer
risk.
Causal mediation analysis, under the counterfactual concept, could discover the
causal role of a mediator underlying the relation between an exposure and outcome by
quantifying the extent to which this relationship is mediated by the mediator.423 The
conventional mediation analysis approach proposed by Baron and Kenny424 could give
rise to biased estimates if there is any uncontrolled mediator-outcome confounding or if
an interaction between exposure and mediator exists, and could not be used to obtain
causal inference of the mediated effect. In contrast, causal mediation analysis, with the
clear no-unmeasured-confounding assumption, is able to be used to obtain unbiased
casual inference of direct and indirect effects under the counterfactual framework.
Therefore, we aimed to investigate whether the associations between dietary
inflammatory potential and pancreatic cancer are mediated by incident type-2 diabetes by
using the causal mediation approach, in the pooled analysis of two large, well-established
cohorts in the U.S., the PLCO Cancer Screening Trial and NIH-AARP Diet and Health
Study.
6.3

Methods

6.3.1

Study population
The PLCO is a population-based randomized trial aimed to assess the effects of

screening tests for prostate, lung, colorectal, and ovarian cancers on mortality and
secondary endpoints. A total of 154,897 eligible participants (76,682 men and 78,215
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women) with age range from 55 to 74 years, were enrolled into the trial at baseline
between 1993 to 2001 from different centers spanning across the United States.43
Participants were randomized into either a control arm, where usual medical care was
received, or intervention arm where PLCO cancers screening tests were received. The
whole PLCO cohort was followed up for 13 years after enrollment, and participants in the
intervention arm received their screening tests during their first six years in the trial.44
The NIH-AARP Diet and Health Study is the largest prospective cohort study of diet and
health ever conducted in the US with the goal to examine a number of important diet and
cancer hypotheses. The details of the study design were described previously.46 Briefly,
566,398 eligible AARP members living across the country (339,666 men and 226,732
women) with age of 50 to 71 years old, who responded to the baseline questionnaire,
were enrolled between 1995 and 1996. NIH-AARP participants were followed until the
end of 2011 for the current analysis. In general, although the NIH-AARP had
approximately 3.6 times more participants and slightly longer follow-up than PLCO,
these two cohorts share substantial similarities in terms of the characteristics of study
population, with similar age ranges at enrollment and similar proportions of racial/ethnic
groups and other health behavior factors. In addition, the two studies were initiated
during similar time periods and utilized similar diet questionnaires which included
similar lists of food items (diet questionnaires in both studies were developed based on
the NCI-developed DHQ but with different templates and a few different questions),396,361
and included comprehensive information on covariates and cancer outcomes.
Study-specific exclusions included 1) cancer (except non-melanoma skin cancer)
diagnosed before dietary measurement; 2) participants did not return diet questionnaire or
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did not have valid responses; 3) participants reported unreasonable BMI (in the PLCO,
BMI was considered unreasonable if one of the followings occurred: weight<60 pounds;
height<48 inches; height>78 inches for females; height>84 inches for males; BMI<15
kg/m2 ; in the NIH-AARP, implausible BMI was defined as 2 IQRs below the sexspecific 25th percentile or above the 75th percentile of log-transformed BMI) or calorie
intake (unreasonable calorie intake was defined as sex-specific first and last percentiles of
total energy in the PCLO and 2 IQRs below the sex-specific 25th percentile or above the
75th percentile of log-transformed energy intake in the NIH-AARP ); or 4) no follow-up
data. After exclusions, the analytical cohort of the PLCO included 101,449 participants
(49,347 men and 52,102 women) and the NIH-AARP had a final sample size of 533, 256
(314,139 men and 219,117 women). Therefore, the pooled analytical cohort of PLCO and
NIH-AARP has a total of 634,705 participants (363,486 men and 271,219 women).
In the analytical cohort of 101,449 PLCO participants, we further excluded
participants who did not have valid supplemental questionnaire, which contained followup data on diabetes and was introduced at a median of nine years after randomization into
the trial (n=22,046), and those who had baseline diabetes (n=4,577), leaving a total of
74,826 participants involved in the PLCO mediation analysis cohort. Similarly, after
excluding 321,377 participants who did not have follow-up questionnaire or the
questionnaire was filled out by proxy, and 17,064 people who had baseline diabetes,
194,815 subjects remained in the mediation analysis cohort of NIH-AARP. In the pooled
mediation cohort of PLCO and NIH-AARP, there were a total of 269,641 participants
(144,999 men and 124,642 women).
The PLCO was approved by the institutional review boards of the National
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Cancer Institute and each of the centers that participated, and the NIH-AARP was
approved by the National Cancer Institute Special Studies Institutional Review Board. All
participants from the two studies gave informed consent.
6.3.2

Dietary assessment and E-DII score calculation
Both PLCO and NIH-AARP used self-administered NCI-developed DHQ to

assess participants’ usual frequency of intakes and portion sizes on 124 food items over
the previous year, using multiple frequency categories ranging from “never” to “>=6
times/d” for beverages and from “never” to “>=2 times/d” for solid foods, and each item
has 3 options of portion size.48,363 Supplement intake questions also were included in
FFQs from both studies.396,361,363 In the PLCO, the DHQ was introduced to trial
participants within a median of three years after randomization,396 while the DHQ was
completed at baseline in the NIH-AARP. Responses from the DHQ were linked to the
USDA’s CSFII survey databases in both studies, in order to estimate individuals’
nutrients, foods, and food group intakes.364 Results from comparisons with multiple 24
hour recalls in both cohorts suggested moderate energy-adjusted correlation coefficients
for important dietary factors such as fat, total energy, fiber and micronutrients, which
generally exceeded 0.4.361,363
The DII, a literature-derived index designed to assess the overall inflammatory
potential of an individual’s diet, was used in each study to calculate the overall E-DII
score for each participant. The details of the development of the DII have been published
previously.22 Briefly, 1,943 eligible peer-reviewed primary research articles published
through 2010 on the effect of dietary factors on six inflammatory markers (IL-1β, IL-4,
IL-6, IL-10, TNF-α, and CRP) were identified and scored to derive the component-
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specific inflammatory effect scores for 45 dietary factors (i.e. components of DII), which
comprised macronutrients, micronutrients and some bioactive components such as spices
and tea.22 Thirty-five FFQ-derived dietary factors in the PLCO were used to calculate the
E-DII, and 34 components were used for E-DII score calculation in the NIH-AARP (refer
to table 6.1 footnote for details of the dietary components in each cohort for E-DII
calculation).
To calculate individual’s E-DII score in each study, the FFQ-derived food and
nutrient intake values were first adjusted for total energy intake and expressed per 1000
calories. The energy-adjusted dietary intake was subsequently standardized to a global
composite dietary database representing average energy-adjusted dietary intake from 11
populations living in different countries across the world, to avoid the arbitrariness of
simply using raw intake amounts.22,201 The energy-adjusted standardized dietary intake
was then multiplied by the literature-derived inflammatory effect score for each DII
component, and summed across all components to obtain the overall E-DII score. Higher
E-DII scores represent more pro-inflammatory diets and lower (i.e., more negative) E-DII
scores indicate more anti-inflammatory diets. The DII score has been construct validated
and found to be positively associated with several inflammatory biomarkers such as IL6,24 TNF-α receptor 2,24 high-sensitivity CRP23,27 and homocysteine.25
In both the PLCO and NIH-AARP, a majority of the partipants consumed
supplements. Given that most dietary supplements contain anti-inflammatory
components, we calcuated the E-DII from food plus supplement as the exposure in all
analyses to quantify the association between the inflammatory potential of overall dietary
exposures and pancreatic cancer risk with type-2 diabetes as the mediator.
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6.3.3

Mediator assessment
Information on incident diabetes occurrence during follow up was obtained

through the follow-up questionnaires of both studies. In the PLCO, participants were
asked on supplemental questionnaire whether or not they were ever diagnosed with
diabetes (yes, no, or missing), and at what age they were first diagnosed with diabetes.
Participants could choose their age of first-diagnosed diabetes at "< 50", "50-59", "6069", "older than 70" or can leave it blank. Participants in the NIH-AARP reported
whether they were ever diagnosed with diabetes (yes, no, unknown) and year of first
diagnosis of diabetes (no, before 1985, 1985-1994, 1995-1999, 2000 to present,
unknown) on follow up questionnaire. Because we excluded participants with baseline
diabetes in the mediation analysis, the study-specific responses to the two abovementioned diabetes questions on the follow-up questionnaires can be used to identify
incident diabetes that occurred during follow-up. The mediator was coded as a
categorical variable with three levels: “yes”, “no” and “missing” using the following
method: 1) if subjects answered they were never diagnosed with diabetes on the studyspecific follow-up questionnaire, these subjects were assigned “no”; 2) if subjects
reported they were ever diagnosed with diabetes, we further compared their ages at first
diagnosis of diabetes using the median value of each category of the variable indicating
diabetes occurrence time on the study-specific follow-up questionnaires, with their ages
at primary pancreatic cancer diagnosis, and coded mediator as “yes” if diabetes occurred
before primary pancreatic cancer or no primary pancreatic cancer occurred, “no” if
diabetes occurred after primary pancreatic cancer (because mediator as defined should
occur before the occurrence of outcome of interest), or “missing ” if no information on
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age at first diagnosis of diabetes; and 3) if subjects did not report whether they were
diagnosed with diabetes, these subjects were assigned “missing” as their mediator level.
Figure 6.1 illustrates this method used to code the mediator. We assume the incident
diabetes in our study is type-2 diabetes as type-2 diabetes accounts for 90%-95% of those
with diabetes, while the majority of type-1 diabetes which results from a cellularmediated autoimmune destruction of the β-cells of the pancreas, is typically a juvenileonset disease.425
6.3.4

Covariates assessment
Data on covariates were retrieved from study-specific self-reported baseline

questionnaires, which included demographic information, personal medical history,
family history, and health behaviors such as smoking and alcohol drinking. BMI was
calculated as weight (kg)/height(m)2 and categorized based on the World Health
Organization criteria.368 In PLCO, information on physical activity over the past year was
not assessed at baseline, but was assessed on supplemental questionnaire, while physical
activity was assessed in the baseline questionnaire in the NIH-AARP. We did not use
follow-up data of covariates in analyses because of the large missing proportion and
inconsistent assessment time.
6.3.5

Harmonization of potential confounders across two studies
In the aggregated analysis where data from two cohorts were combined into one

dataset, we created harmonized categories for the shared potential confounding variables
of the E-DII and pancreatic cancer association across two studies. Because the physical
activity variable was measured from essentially different questions and using different
units in the two studies (physical activity in NIH-AARP was measured as frequency but
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in PLCO it was measured using Met-hours), we excluded this variable as a potential
confounder in the aggregated analysis. Family history of pancreatic cancer also was
excluded because this variable was not available in the NIH-AARP. The other potential
confounders shared between the two studies were created with harmonized categories for
categorical variables, including age at baseline (continuous), sex (male or female), total
energy intake (kcal/day), race (White non-Hispanic; Black non-Hispanic; Hispanic;
Asian, Pacific Islander or American Indian/Alaskan Native; or unknown), BMI
(underweight, normal, overweight, obese, or missing), alcohol intake (g/day), diabetes
history at baseline (yes, no, or missing), combination of smoking status and years since
quitting smoking (never smoked, stopped 10 or more years ago, stopped 5-9 years ago,
stopped 1-4 years ago, stopped within last year, currently smoking, or missing), and
education levels (<=11 years, high school completion, post high school training other
than college, some college, college and postgraduate, or missing).
6.3.6

Pancreatic cancer case ascertainment
Incident pancreatic cancer cases in the PLCO were identified through an annual

study update questionnaire in which participants reported if they had been diagnosed with
any cancer, the type of cancer, and date of diagnosis. State registries, death certificates,
and physician reports were used as additional sources for identification of pancreatic
cancer cases. In the NIH-AARP, incident cases of pancreatic cancer were identified
through linkage between the NIH-AARP cohort membership and eight state cancer
registry databases. Uncertain matches underwent a final manual review. The follow-up
questionnaire used to record participants’ cancer status and other non-cancer endpoints in
the NIH-AARP was used as an additional resource. In the present analysis, pancreatic
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cancer case was defined as primary incident adenocarcinoma of the exocrine pancreas
(International Classification of Diseases for Oncology, Third Edition, codes C25.0-C25.3,
C25.7- C25.9). Our case definition excluded pancreatic endocrine tumors and other rare
histology types of pancreatic cancer in each study, as etiology may differ,248,370 and we
censored these types of pancreatic cancer at the date of diagnosis.
6.4

Statistical analysis
The baseline characteristics of the study population in the pooled mediation

analysis cohort combining PLCO and NIH-AARP (n=269,641) were presented by
quintiles of E-DII with cut-off points determined from the distribution of the entire
pooled cohort. Means and SE for continuous variables and frequencies and percentages
for categorical variables were calculated. ANOVA was used to test the difference across
E-DII quintiles for continuous variables, and Chi-square test was performed to test the
difference for categorical variables. Because we excluded a substantial amount of
individuals in the pooled mediation cohort, we assessed the difference of important
baseline characteristics between study population in the pooled mediation cohort and
those in the combined PLCO and NIH-AARP cohorts.
We first assessed the study-specific total, direct, and indirect effects of E-DII on
pancreatic cancer risk with type-2 diabetes as a mediator by using the causal mediation
approach in a counterfactual framework.378,423,426 In this approach, total effect can be
decomposed into direct effect (not mediated by type-2 diabetes) and indirect effect
(mediated by type-2 diabetes). A SAS macro developed by Valeri and Vanderweele379
was used to calculate the study-specific mediation parameters: natural direct effect
(NDE), natural indirect effect (NIE), and marginal total effect (MTE) of E-DII on
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pancreatic cancer risk with type-2 diabetes as a mediator. Briefly, mediation parameter
estimates were obtained using the causal mediation approach in three steps: 1) type-2
diabetes was regressed on E-DII using the logistic regression with inclusion of the set of
confounding variables which were the same as those we reported in the association
between E-DII and pancreatic cancer in each cohort except that diabetes history at
baseline was removed (Zheng et al. unpublished data in chapter 4 and 5); 2) pancreatic
cancer was regressed on type-2 diabetes and E-DII with inclusion of the E-DII and type-2
diabetes interaction and the same set of confounders as in 1) using a logistic regression
model; since the interaction was not statistically significant, we removed it from the
model; 3) based on the specified comparison levels of exposure, parameters derived from
these two logistic models gave way to essential mediator parameters through a series of
mathematical calculations.379 In the study-specific mediation analysis, we calculated and
reported the NDE, NIE, and MTE of E-DII on pancreatic cancer risk for subjects in each
higher E-DII quintile (i.e., quintile 2, quintile 3, quintile 4, quintile 5) compared to those
in the lowest quintile with type-2 diabetes as mediator, by using ordinal E-DII variable in
the model (compare 2,3,4,5 with 1, respectively). We also centered each E-DII value to
the mean to report the effect of a one-unit increase in centered E-DII on pancreatic cancer
with type-2 diabetes as mediator (1 and 0 were specified as two exposure levels of
comparison). The Z-score of E-DII was calculated by dividing the centered value by the
standard deviation, and used in the mediation model to demonstrate the mediation effect
of type-2 diabetes on the association of increment of one standardized unit of E-DII with
pancreatic cancer risk (1 to 0 were specified as two exposure levels of comparison). For
all these mediation analysis, we also calculated the mediation proportion by type-2
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diabetes using the equation as follows: Proportion of mediation by type-2 diabetes=
[NDE x (NIE – 1)]/ (NDE x NIE – 1)
The following four assumptions suffice to identify valid NDE and NIE from the
data: 1) there is no unmeasured exposure-outcome confounding given measured
covariates, 2) there is no unmeasured mediator-outcome confounding given measured
covariates and exposure, 3) there is no unmeasured exposure-mediator confounding given
measured covariates, and 4) there is no effect of the exposure that confounds the
mediator-outcome relationship.378 Under such assumptions, the NDE and NIE can be
conceptually evaluated as follows: NDE is the contrast between the counterfactual
outcome if all subjects were exposed at a higher E-DII quintile and the counterfactual
outcome if the same subjects were exposed at the lowest E-DII quintile, with probability
of having type-2 diabetes assuming the value at when E-DII quintile was at the lowest
level. The NIE is the contrast, having set the E-DII at each higher quintile, between the
counterfactual outcome if probability of developing type-2 diabetes assumed whatever
value it would have taken at a value of the higher E-DII quintile and the counterfactual
outcome if probability of developing type-2 diabetes assumed whatever value it would
have taken at the lowest E-DII quintile. The MTE was the average of the NDE and NIE
estimated at the population level. 426,427
Each study-specific mediation effect (i.e., NDE, NIE, MTE) for pancreatic cancer
comparing each higher E-DII quintile to the lowest quintile, weighted by the inverse of
the sum of their variance and the estimated between-studies variance component, was
pooled using a random effects model.428 The study-specific NDE, NIE and MTE for
pancreatic cancer associated with each one unit increment of centered E-DII value and z-
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score of E-DII with type-2 diabetes as the mediation factor, also were pooled using the
same method. 428 Between-studies heterogeneity was evaluated using the Q statistics380,381
and I2 statistics.382
There was no significant between-study heterogeneity on the mediation parameter
estimates as assessed using the random effects models, and diet and other covariates were
measured using comparable ways across two studies. Thus, we further combined primary
data from two cohorts to take advantage of differences in the distributions of the exposure
variable across studies and to increase number of pancreatic cancer cases to increase
power.429 In addition, we can directly calculate the mediation parameter estimates in the
pooled cohort instead of combining the results from separate studies with larger statistical
errors. In this aggregated dataset, we considered all variables listed in the section of
“Harmonization of potential confounders across two studies” as potential confounders
during model building and selected and added those as confounders in the model if they
were associated with both pancreatic risk and E-DII (in either continuous or categorical
format), or changed the crude risk estimate by more than 10%. We finally adjusted for
age at baseline, sex, total energy intake, BMI, education levels, alcohol intake, and the
combined variable of smoking status and years since quitting smoking in the mediation
analysis with aggregated data from PLCO and NIH-AARP mediation cohorts. The same
mediation analyses as performed in each study as stated above were conducted in this
pooled cohort.
We also conducted analysis of association between E-DII and pancreatic cancer
among the participants in the pooled mediation cohort since this subset of people may be
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different from the full cohort because they were survivors and chose to complete the
follow-up questionnaire of both studies.
All statistical analyses were conducted using SAS® (version 9.4, Cary, NC)
except that the assessment of between-studies heterogeneity was conducted in STATA
(release 14, College Station, TX). All tests were two-sided with p values <0.05
considered to be statistically significant if not otherwise noted.
6.5

Results
As shown in Table 6.1, the range of the E-DII in the pooled mediation cohort of

269,641 participants from the PLCO and NIH-AARP was from -8.43 to 6.66. Compared
to participants who had the most anti-inflammatory E-DII scores (i.e., E-DII quintile 1),
participants consuming a more pro-inflammatory diet (i.e., higher E-DII scores) were
younger at baseline but consumed more alcohol and energy, were more likely to develop
incident type-2 diabetes during follow-up, and more likely to be males, Black nonHispanic or Hispanic race/ethnicities, overweight or obese, current smokers or former
smoker who stopped smoking within last 9 years, and have below-college education
level, but there was no difference in developing pancreatic cancer comparing high to low
dietary inflammatory potential.
Table 6.2 presents the study-specific NDE, NIE and MTE of E-DII on pancreatic
cancer risk comparing subjects in each higher E-DII quintile to those in the lowest
quintile with type-2 diabetes as the mediator, using the ordinal E-DII variable. In each
study, when comparing risk of pancreatic cancer for subjects in each higher E-DII
quintile to the lowest group, we observed a similar NDE, NIE, MTE and mediation
proportion with type-2 diabetes as a mediator, and identified a similar P value of each
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effect across different comparisons. The mediated effect of type-2 diabetes was
significant in both studies although the effect was small (slightly over 1). The overall
mediation proportion by type-2 diabetes was larger in the NIH-AARP than in the PLCO.
The total effect of E-DII on pancreatic cancer averaged over NDE and NIE was not
significant for each higher level of E-DII quintile compared to the lowest quintile. In both
studies, the association between E-DII and pancreatic cancer was fully mediated by
incident type-2 diabetes. The NDE, which was the E-DII and pancreatic cancer
association that was not mediated through type-2 diabetes, was not significant. When
pooling the mediation effect estimates from two studies using random effects model,
significant between-study heterogeneity for NDE, NIE and MTE was not observed in any
comparison group (Pheterogeneity >0.5). The pooled results generally provide the same
information as suggested by the study-specific results. There was a significant although
small mediated effect of type-2 diabetes and the E-DII and pancreatic cancer association
was fully mediated through type-2 diabetes. No significant overall effect of E-DII on
pancreatic cancer was identified (Table 6.3).
Study-specific NDE, NIE, and MTE of one-unit increase in centered E-DII and EDII z-score on pancreatic cancer risk with type-2 diabetes as mediator are presented in
Table 6.4 along with the pooled results from two studies using the random effects model.
Similar to the categorical E-DII results, in both studies and pooled results, NDE, NIE and
MTE effects of continuous E-DII on pancreatic cancer still presented the significant
mediated effect of type-2 diabetes which was in a small magnitude. The continuous
association between E-DII and pancreatic cancer also was fully mediated through type-2
diabetes. But overall there was no significant total effect of centered E-DII value or a
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standard unit of E-DII (z score) averaged over NDE and NIE on pancreatic cancer risk.
Between-study heterogeneity on three mediation effects of these two continuous E-DII
variables was not observed. The mediation proportion by type-2 diabetes was larger when
using the continuous E-DII format than the categorical comparisons in the PLCO.
When we combined the primary data into a single dataset, we still identified the
significant though small mediated effect of type-2 diabetes (i.e., NIE was significant),
whether it was in the association for categorical E-DII or in the continuous association by
using the centered E-DII value or z-score of E-DII (Tables 6.5 and 6.6). However,
compared to the study-specific results and pooled analysis results using random effects
model, the aggregated analysis presented the attenuated MTE averaged over NDE and
NIE of E-DII on pancreatic cancer with point estimates less than 1 in both categorical and
continuous associations, but the association was not significant. In the aggregated
analysis, the NDE attenuated too with point estimate below 1, thus it was in an opposite
direction with NIE in both the categorical and continuous associations between E-DII and
pancreatic cancer, which impeded us from obtaining an interpretable mediation
proportion.
Compared to subjects included in the pooled mediation analyses, excluded
subjects tended to be younger at baseline and had baseline characteristics that were more
likely to be associated with higher risk of health outcome, including male, Black or
Hispanic, recent smoking, a more pro-inflammatory diet, more calories intake, more
alcohol consumption, lower education attainment. Excluded participants also had higher
pancreatic cancer incidence (Table 6.7).
In the pooled mediation cohort, we did not find an association between E-DII
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from food plus supplement and pancreatic cancer risk after adjusting for confounders
(OR Q5vsQ1=1.04, 95% CI=0.82-1.33; P-trend=0.86), which was consistent with the null
association we identified in the separate cohort of PLCO and NIH-AARP (Table 6.8).
6.6

Discussion
The present study is the first to use the causal mediation approach to evaluate the

mediation role of type-2 diabetes incidence in the relation between dietary inflammatory
potential and pancreatic cancer risk in two large well-established nationally
representative cohorts in the U.S. In the pooled mediation cohort of the PLCO and NIHAARP, incident type-2 diabetes significantly mediated both categorical and continuous
associations between E-DII and pancreatic cancer, although the mediated effect was
small. The E-DII and pancreatic cancer association was fully mediated by type-2 diabetes
with the aggregated data from two cohorts. We did not observe a statistically significant
association of E-DII on pancreatic cancer, averaged over direct and indirect effect with
type-2 diabetes as a mediator. In both studies and pooled analyses, we identified a null
MTE of E-DII on pancreatic cancer, which was consistent with the findings of the E-DII
and pancreatic cancer association we observed in each study (Zheng et al. unpublished
data in Chapters 4 and 5) and with similar point estimate of effect.
In our analyses, we found the E-DII and pancreatic cancer association was fully
mediated through incident type-2 diabetes. There was strong biologic and
epidemiological evidence of the positive link between inflammation and diabetes. The
leading hypothesized mechanisms to explain insulin resistance in type-2 diabetics
suggests oxidative stress, endoplasmic reticulum stress, amyloid deposition in the
pancreas, ectopic lipid deposition in the muscle, liver and pancreas, and lipotoxicity and
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glucotoxicity are each thought to either induce inflammation or to be exacerbated by or
associated with inflammation.42,430,431 Prospective studies have also found that elevated
levels of IL-1β, IL-6, IL-1 receptor antagonist (IL-1Ra) and CRP are associated with
type-2 diabetes. 226,432,433 Although only one study to date has reported an association
between the DII and fasting glucose, postload glucose or insulin resistance,434 there is a
substantial amount of research reporting a positive association between DII scores and
insulin-resistance-related conditions such as metabolic syndrome and various types of
cancers, 189,435,26,203 supporting our observed link between type 2 diabetes and the DII.
The strong and positive association of type 2 diabetes with pancreatic cancer risk has
been verified in a large number of studies. Recent data from five pooled analyses40,41,306308

have concordant findings, showing that diabetics have 40% to 90% increased

pancreatic cancer risk compared to non-diabetics, and the relative risk decreases with
duration of diabetes, though a significant excess risk was still evident 10 years
after diabetes diagnosis. Even in the absence of diabetes mellitus, higher fasting blood
sugar and blood glucose or impaired glucose tolerance are associated with higher
pancreatic cancer risk.285,309,310 However, it is still controversial whether type-2 diabetes
is a consequence or a cause of the pancreatic cancer.305,436,437
The significant mediated effect of type-2 diabetes in the E-DII and pancreatic
cancer association is well-supported by the biologic mechanism stated as consecutive
steps as follows: 1) Pro-inflammatory diets can increase insulin resistance through
multiple mechanisms including regulation of pro-inflammatory cytokines, NF-κB
pathway activation, changes in DNA methylation, increase in oxidative stress, and
influences on antioxidant defense;79,73 2) Defective response of body tissues to insulin,

160

i.e., reduced insulin sensitivity, increases demand on pancreatic islets to secrete higher
quantities of insulin, leading to hyperinsulinemia and subsequent type-2 diabetes
development;438,439 and 3) Locally elevated insulin supply coming from the endocrine
islets of pancreas, which acts as a potential growth factor in the promotion of cell
proliferation and angiogenesis,440 lead to increased loss of tumor suppressor function, and
stimulated oncogene expression which altogether form a malignant transformation of
pancreatic cells, predominantly the ductal epithelial cells of the exocrine pancreas, and
ultimately cause malignancy.58,419
Our study has some major strengths. First, the PLCO and NIH-AARP were very
similar in the measurement of diet and important covariates and in the characteristics of
their study populations related to many key risk factors for pancreatic cancer such as age,
BMI, education level, smoking behavior. Additionally, the two studies were initiated at
similar times and follow-up diabetes was measured at a similar length of follow-up
(about 9 years into each study) These similarities enabled us to combine primary data
from the two cohorts to increase the number of pancreatic cancer cases and incident type2 diabetes cases, as well as take advantage of differences in the distributions of the
exposure variable across studies. Second, there are several advantages of using PLCO
and NIH-AARP: the prospective cohort design of both studies minimizes the possibility
of recall bias and selection bias; the long follow-up in both cohorts among a large study
population accumulated a large number of pancreatic cancer cases, especially in the NIHAARP; and detailed information on a comprehensive list of covariates which were
assessed in a similar way in two cohorts allowed for harmonization with less
misclassification bias in the pooling analysis and also allowed for careful adjustment in
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the analyses. Third, the E-DII was a strength, as it was designed specifically related to the
biologic mechanism of inflammation which links the DII-diabetes-pancreatic cancer
pathway and it provided a comprehensive assessment of dietary inflammatory potential.
Fourth, the null MTE of E-DII on pancreatic cancer in each study and in the pooled
cohort further confirmed the lack of association in each study separately as reported
previously (Zheng et al. unpublished data). Finally, in all the mediation analyses of this
paper (no matter in study-specific mediation analysis or in pooled cohort, and whether we
conducted categorical or continuous mediation analyses), we consistently observed the
significant mediated effect of type-2 diabetes, which suggested type-2 diabetes played a
role as a mediator in the DII and pancreatic cancer association.
Despite these advantages, limitations of this study are also noted. When we
created the mediator variable, we compared the age at first diagnosis of diabetes and age
at incident primary pancreatic cancer if the subject had both diseases occur in the followup, using the median value of each category of the follow-up diabetes occurrence time
variable. As we cannot obtain the precise age at diabetes occurrence, it may cause nondifferential misclassification of mediator variable, but the measurement error as a result
of using mean value of range was estimated to be small, because in PLCO only 21
subjects and in NIH-AARP only 86 subjects undergone the comparison of diagnosis
times at two diseases. Although the two studies we combined were very similar in many
aspects and there was no significant between-study heterogeneity, there was still the
possibility that the assumption of pooling the primary data may not be fully met in that
differences in the measurement and distribution of covariates (i.e., different questions to
obtain data, different categories of a covariate, different units) and in the number of
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available DII components used to calculate the E-DII score were present; however, there
was no method to test the assumptions.429 The follow-up data on many covariates were
available in each study but the large missing percentage impeded our ability to use these
data. Diet was only assessed at baseline, therefore, any changes in diet over follow up
were not captured, which could result in non-differential misclassification of exposure.
However, we previously found DII scores were relatively stable over a long timeframe in
postmenopausal women where the study participants were of comparable age as our
study.405 Although important potential confounders were adjusted for in our analyses,
residual or unmeasured confounding may still be a possibility. In addition, we can only
calculate the mediation proportion when the NDE and NIE were in the same direction, so
in some situations in this paper we cannot derive an interpretable mediation proportion.
6.7

Conclusion
In conclusion, in the pooled cohort of PLCO and NIH-AARP, we identified a

significant though small mediated effect of incident type-2 diabetes in the association
between dietary inflammatory potential and pancreatic cancer with the use of causal
mediation approach. The association of inflammatory potential of diet with pancreatic
cancer was fully mediated through incident diabetes. No significant overall effect of EDII on pancreatic cancer, averaged over direct and indirect effect with type-2 diabetes as
a mediator, was observed. Future large cohort studies are warranted to test other possible
mediators in the pathway from dietary inflammatory potential to pancreatic cancer risk.
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Table 6.1 Baseline characteristics of 269,641 subjects by quintiles of E-DII in the
pooled mediation cohort of PLCO Cancer Screening Trial and NIH-AARP Diet and
Health Study
Most antiinflammato
ry diet

N

Most proinflammat
ory diet

E-DII
Q1
(-8.43, 5.57)
53929

E-DII Q2
(-5.56, 4.47)

E-DII Q3
(-4.46, 3.24)

E-DII Q5
(1.45,6.66)

53928

E-DII
Q4
(-3.23, 1.46)
53929

53927

Mean (SE)

Mean
(SE)
62.8 (0.02)

Mean
(SE)
62.6 (0.02)

Mean
(SE)
62.5 (0.02)

Mean
(SE)
62.2 (0.02)

Pvaluea

53928

Age at baseline
(y)

62.7 (0.02)

Total energy
intake (kcal/d)

1553.7 (2.4)

1675.1
(2.8)

1756.9
(3.0)

1874.1
(3.3)

2107.1
(4.0)

<.0001

9.3 (0.06)

9.0 (0.08)

9.7 (0.09)

11.7 (0.1)

19.9 (0.2)

<.0001

n (%)b

n (%)b

n (%)b

n (%)b

Alcohol
consumption
(g/d)
Incident
diabetes
Yes
No
Missing
Primary
pancreatic
cancer
Yes
No
Sex
Male
Female
Race/ Ethnicity
White nonHispanic
Black nonHispanic
Hispanic

n (%)b

<.0001

<.0001
3198 (5.9)

3835 (7.1)

4205 (7.8)

4696 (8.7)

45950
(85.2)
4781 (8.9)

45368
(84.1)
4724 (8.8)

45087
(83.6)
4636 (8.6)

44489
(82.5)
4744 (8.8)

5456
(10.1)
43839
(81.3)
4633 (8.6)
0.95

153 (0.3)

146 (0.3)

159 (0.3)

148 (0.3)

149 (0.3)

53776
(99.7)

53781
(99.7)

53769
(99.7)

53781
(99.7)

53779
(99.7)
<.0001

21886
(40.6)
32043
(59.4)

25020
(46.4)
28907
(53.6)

28048
(52.0)
25880
(48.0)

32290
(59.9)
21639
(40.1)

37755
(70.0)
16173
(30.0)
<.0001

50323
(93.3)
1173 (2.2)

50406
(93.5)
1274 (2.4)

50402
(93.5)
1388 (2.6)

50391
(93.4)
1454 (2.7)

50334
(93.3)
1636 (3.0)

645 (1.2)

722 (1.3)

765 (1.4)

813 (1.5)

783 (1.5)
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Asian, Pacific
Islander or
American
Indian/Alaskan
Native
Unknown
BMI
Underweight
Normal
Overweight
Obese
Missing
Education level
less than or equal
to 11 years
High school
completion
Post high school
training other
than college
Some college
College and
postgraduate
Missing
Smoking status
and years of
quit combined
Never smoked
Stopped 10 or
more years ago
Stopped 5-9
years ago
Stopped 1-4
years ago
Stopped within
last year
Currently
smoking
Missing

1434 (2.7)

1189 (2.2)

1023 (1.9)

927 (1.7)

803 (1.5)

354 (0.7)

336 (0.6)

350 (0.7)

344 (0.6)

372 (0.7)

453 (0.8)
24510
(45.5)
20701
(38.4)
7441 (13.8)
824 (1.5)

392 (0.7)
21778
(40.4)
21840
(40.5)
9135
(16.9)
782 (1.5)

402 (0.8)
20006
(37.1)
22711
(42.1)
10028
(18.6)
781 (1.5)

370 (0.7)
18086
(33.5)
23495
(43.6)
11167
(20.7)
811 (1.5)

347 (0.6)
15700
(29.1)
24196
(44.9)
12781
(23.7)
904 (1.7)

1197 (2.2)

1644 (3.1)

1869 (3.5)

2435 (4.5)

3382 (6.3)

7668 (14.2)

8990
(16.7)

9586
(17.8)

10608
(20.0)

12611
(23.4)

4801 (8.9)

5348 (9.9)

5585
(10.4)

5659
(10.5)

6459
(12.0)

12108
(22.5)
27311
(50.6)
844 (1.6)

12166
(22.6)
24929
(46.2)
850 (1.6)

11980
(22.2)
24101
(44.7)
807 (1.5)

11943
(22.2)
22499
(41.7)
785 (1.5)

11973
(22.2)
18717
(34.7)
786 (1.5)

<.0001

<.0001

<.0001

23526
(43.6)
21166
(39.3)
3125 (5.8)

23834
(44.2)
19919
(36.9)
3050 (5.7)

23425
(43.4)
19546
(36.2)
3018 (5.6)

22293
(41.3)
19154
(35.5)
3162 (5.9)

19297
(35.8)
18299
(33.9)
3320 (6.2)

1529 (2.8)

1623 (3.0)

1619 (3.0)

1779 (3.3)

2072 (3.8)

723 (1.3)

825 (1.5)

882 (1.6)

960 (1.8)

1202 (2.2)

2571 (4.8)

3527 (6.5)

4277 (7.9)

1289 (2.4)

1149 (2.1)

1161 (2.2)

5453
(10.1)
1128 (2.1)

8533
(15.8)
1205 (2.2)

Abbreviations: SE, standard error
a
Statistical analyses were performed by ANOVA test for continuous variables and by Chi-Square test for
categorical variables.
b
Sum of percentages may not add up to 100% because of rounding or missing.
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Table 6.2 Study-specific natural direct effect, natural indirect effect and marginal
total effecta of E-DIIb on pancreatic cancer risk with incident type-2 diabetes as
mediator
Natural direct
effect
Estimate
P
with
value
95% (CI)
Q5 vs Q1

Q4 vs Q1

Q3 vs Q1

Q2 vs Q1

Q5 vs Q1

Q4 vs Q1

Q3 vs Q1

Q2 vs Q1

a.
b.

c.

1.14
(0.592.17)
1.10
(0.681.79)
1.07
(0.771.47)
1.03
(0.881.21)

0.70

1.01
(0.791.30)
1.01
(0.841.22)
1.01
(0.891.14)
1.00
(0.941.07)

0.93

Natural indirect effect

Marginal total effect

Estimate
P value
Estimate
with 95%
with 95%
(CI)
(CI)
PLCO Cancer Screening Trial
1.02 (1.0020.03
1.16 (0.611.03)
2.21)

Mediation
Proportionc

P
value

0.66

13.0%

0.70

1.01 (1.001.03)

0.03

1.11 (0.691.81)

0.66

12.6%

0.70

1.01 (1.001.02)

0.03

1.07 (0.781.49)

0.66

12.3%

0.70

1.004 (1.001.01)

0.03

1.04 (0.881.22)

0.66

11.9%

0.88

46.2%

0.88

45.6%

NIH-AARP Diet and Health Study
1.009
0.001
1.02 (0.79(1.0041.31)
1.015)
0.93
1.007
0.001
1.02 (0.84(1.003-1.01)
1.23)
0.93

0.93

1.004
(1.0021.007)
1.002 (1.001.003)

0.001

1.01 (0.891.14)

0.88

45.1%

0.001

1.00 (0.941.07)

0.88

44.5%

Logistic models involved in the causal mediation approach to derive the mediation parameter estimates
were adjusted for study-specific confounders.
Ordinal E-DII format was used in the model to compare risk of pancreatic cancer for subjects in each
higher E-DII quintile to subjects in the lowest quintile with type-2 diabetes as mediator. E-DII score
was derived in the PLCO based on 35 dietary components: alcohol, vitamin B12, vitamin B6, betacarotene, caffeine , carbohydrate , cholesterol, food energy, total fat, total dietary fiber, folate , iron,
magnesium, monounsaturated fatty acids, poly-unsaturated fatty acids, niacin, onions, protein,
riboflavin, saturated fatty acids, selenium, thiamin, total trans-fatty acids, Vitamin A, Vitamin C,
Vitamin E , Vitamin D, zinc, tea, Flavan-3-ols, flavones, flavonones, anthocyanidin, isoflavone, and
peppers. E-DII score was derived in the NIH-AARP based on 34 dietary components: data on onions
were not included and the others are same as those in PLCO.
Mediation proportion of type-2 diabetes was calculated using the equation NDE x (NIE – 1)/ (NDE x
NIE – 1)
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Table 6.3 Pooled PLCO and NIH-AARP natural direct effect, natural indirect effect
and marginal total effecta of categorized E-DIIb on pancreatic cancer risk with
incident type-2 diabetes as mediator, using random effect model

a.
b.

c.
d.

Pooled mediation estimates from PLCO and NIH-AARP mediation analyses were obtained using the
random effects model.
DII was treated as an ordinal variable in the study-specific mediation model to compare risk of
pancreatic cancer for subjects in each higher E-DII quintile to subjects in the lowest quintile with type2 diabetes as mediator.
I2 statistic describes the percentage of total variation that is due to heterogeneity rather than chance;
0% represents no heterogeneity.
Pheterogeneity was calculated from test for between-studies heterogeneity using the random effect model.
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Table 6.4 Study-specific and random-effect model pooled natural direct effect,
natural indirect effect and marginal total effecta of one-unit increase in centered EDII and E-DII z-score on pancreatic cancer risk with type-2 diabetes as mediator
Natural direct effect

Natural indirect effect

I2 Phe Estim
Estim P
b
c
ate
val
ate
te
with
ue
with
95%
95%
(CI)
(CI)
PLCO Cancer Screening Trial
1.00
0.9 N N
1.002
one
(0.91- 6
A A
(1.00unit
1.004)
incre 1.10)
ase in
cente
red
E-DII
value
1.01
0.9 N N
1.006
one
(0.86
A A
(1.00unit
1.01)
incre 1.26)
ase in
E-DII
zscore
NIH-AARP Diet and Health Study

P
valu
e

I2

Phe

b

c

0.04

N
A

0.04

N
A

Marginal total effect

Phe

Estim
ate
with
95%
(CI)

P
val
ue

b

N
A

1.01
(0.911.10)

0.9
2

N
A

N
A

50%

N
A

1.01
(0.811.27)

0.9
2

N
A

N
A

50%

N
A

N
A

Not
interpret
ablee

N
A

N
A

Not
interpret
ablee

0
%

0.8
7

NA

te

1.00
0.9 N N
1.002 0.00 N N
1.001 0.9
one
(0.96- 7
A A
(1.00- 1
A A
(0.96- 7
unit
1.003)
1.04)
incre 1.04)
ase in
cente
red
E-DII
value
1.00
0.9 N N
1.004 0.00 N N
1.00
0.9
one
(0.91- 7
A A
(1.001 1
A A
(0.92- 7
unit
1.10)
incre 1.09)
1.005)
ase in
E-DII
zscore
Pooled estimates from PLCO and NIH-AARP using random effect model
1.00
0.9 0
1.0 1.002 0.00 0
1.0 1.00
0.9
one
(0.96- 9
%
(1.001 1
%
(0.97- 0
unit
1.04)
incre 1.04)
1.003
ase in
cente
red
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I2

Mediati
on
proporti
ond

te

c

E-DII
value
one
unit
incre
ase in
E-DII
zscore

1.00
(0.921.09)

0.9
8

0
%

0.9
4

1.004
(1.002
1.006)

<0.0
01

0
%

0.4
7

1.00
(0.921.09)

0.9
7

0
%

0.9
4

NA

Abbreviation: NA, not available
a. Logistic models involved in the causal mediation approach to derive the mediation parameter
estimates were adjusted for study-specific confounders.
b. I2 statistic describes the percentage of total variation that is due to heterogeneity rather than chance;
0% represents no heterogeneity.
c. Pheterogeneity was calculated from test for between-studies heterogeneity using the random effect model.
d. Mediation proportion of type-2 diabetes was calculated using the equation [NDE x (NIE – 1)]/ (NDE
x NIE – 1)
e. Because the direction of NDE and NIE is different, the mediation proportion is not interpretable
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Table 6.5 Natural direct effect, natural indirect effect and the marginal total effecta
of the categorized E-DIIb on pancreatic cancer mediated by type-2 diabetes using
primary data of 269,641 subjects from the PLCO and NIH-AARP

Q5 vs Q1

Natural direct effect
Estimate with
P value
95% (CI)
0.91 (0.72-1.15) 0.45

Q4 vs Q1

0.93 (0.78-1.11)

0.45

Q3 vs Q1

0.96 (0.85-1.07)

0.45

Q2 vs Q1

0.98 (0.92-1.04)

0.45

a.

b.

Natural indirect effect
Estimate with P
95% (CI)
value
1.009 (1.0040.0002
1.013)
1.006 (1.0030.0002
1.01)
1.004 (1.0020.0001
1.006)
1.002 (1.0010.0001
1.003)

Marginal total effect
Estimate with
P value
95% (CI)
0.92 (0.73-1.16) 0.49
0.94 (0.79-1.12)

0.49

0.96 (0.85-1.08)

0.49

0.98 (0.92-1.04)

0.49

Logistic models involved in causal mediation approach to derive the mediation parameter estimates
were adjusted for age at baseline (continuous), sex (male and female), total energy intake (kcal/day),
BMI (underweight, normal, overweight, obese, missing), alcohol intake (g/day), combination of
smoking status and years since quitting smoking (never smoked, stopped 10 or more years ago,
stopped 5-9 years ago, stopped 1-4 years ago, stopped within last year, currently smoking, missing),
education levels (<=11 years, high school completion, post high school training other than college,
some college, college and postgraduate, missing).
Ordinal E-DII format was used in the model to compare risk of pancreatic cancer for subjects in each
higher E-DII quintile to subjects in the lowest quintile with type-2 diabetes as mediator.
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Table 6.6 Natural direct effect, natural indirect effect and marginal total effecta of
one-unit increase in centered E-DII and E-DII z-score on pancreatic cancer risk
with type-2 diabetes as mediator using primary data of 269,641 subjects from the
PLCO and NIH-AARP

One unit
increment of
centered E-DII
value
One unit
increase of zscore of E-DII
a.

Natural direct effect
Estimate
P
with 95%
value
(CI)
0.98 (0.950.28
1.02)

1.001 (1.001.002)

0.0001

0.95 (0.881.04)

1.003 (1.0021.005)

0.0001

0.28

Natural indirect effect
Estimate with P
95% (CI)
value

Marginal total effect
Estimate
P value
with 95%
(CI)
0.98 (0.950.31
1.02)

0.96 (0.881.04)

0.31

Logistic models involved in causal mediation approach to derive the mediation parameter estimates
were adjusted for age at baseline (continuous), sex (male and female), total energy intake (kcal/day),
BMI (underweight, normal, overweight, obese, missing), alcohol intake (g/day), combination of
smoking status and years since quitting smoking (never smoked, stopped 10 or more years ago,
stopped 5-9 years ago, stopped 1-4 years ago, stopped within last year, currently smoking, missing),
education levels (<=11 years, high school completion, post high school training other than college,
some college, college and postgraduate, missing).
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Table 6.7 Comparison of important demographic and lifestyle characteristics
between study sample and excluded sample in the pooled PLCO Cancer Screening
Trial and NIH-AARP
P-valuea

Study population
(n=269,641)

Excluded subjects
(n=365,064)

Mean (SE)

Mean (SE)

Age at DHQ (years)
Total energy intake
(kcal/d)
Alcohol consumption
(g/d)

62.6 (0.01)
1793.4 (1.5)

62.1 (0.01)
1852.9 (1.4)

<.0001
<.0001

11.9 (0.06)

12.4 (0.06)

<.0001

E-DII from food and
supplement

-3.6 (0.004)

-3.3 (0.003)

<.0001

N (%)b

N (%)b

Primary pancreatic
cancer
Yes
No
Sex
Male
Female
Race/ Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic
Asian, Pacific Islander or
American Indian/Alaskan
Native
Unknown
BMI
Underweight
Normal
Overweight
Obese
Missing
Education level
less than or equal to 11
years
High school completion
Post high school training
other than college
Some college
College and postgraduate
Missing
Smoking status and years
of quit combined
Never smoked

<.0001
755 (0.3)
268886 (99.7)

2397 (0.7)
362667 (99.3)

144999 (53.8)
124642 (46.2)

218487 (59.9)
146577 (40.1)

251856 (93.4)
6925 (2.6)
3728 (1.4)
5376 (2.0)

327882 (89.8)
16789 (4.6)
7662 (2.1)
7508 (2.1)

1756 (0.7)

5223 (1.4)

<.0001

<.0001

<.0001
1964 (0.7)
100080 (37.1)
112943 (41.9)
50552 (18.8)
4102 (1.5)

2836 (0.8)
113802 (31.2)
152290 (41.7)
86200 (23.6)
9936 (2.7)
<.0001

10527 (3.9)

27456 (7.5)

49463 (18.3)
27852 (10.3)

78227 (21.4)
37619 (10.3)

60170 (22.3)
117557 (43.6)
4072 (1.5)

85316 (23.4)
124730 (34.2)
11716 (3.2)
<.0001

112375 (41.7)

122133 (33.5)
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Stopped 10 or more years
ago
Stopped 5-9 years ago
Stopped 1-4 years ago
Stopped within last year
Currently smoking
Missing

98084 (36.4)

130113 (35.6)

15675 (5.8)
8622 (3.2)
4592 (1.7)
24361 (9.0)
5932 (2.2)

26715 (7.3)
15881 (4.4)
7523 (2.1)
48641 (13.3)
14058 (3.9)

a

P value was calculated from independent t-test for continuous variables and from Chi-Square test for
categorical variables.
b
The sum of percentages for some categorical variables may not add up to 100% because of rounding.
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Table 6.8 Hazard ratios of pancreatic cancer by quintiles of E-DII score from food
and supplement in the pooled mediation cohort of 269,641 subjects
Most antiinflammato
ry diet

Cases (n)
Sample size
Age and
energyadjusted HR
(95% CI)
Multivariable
-adjusted HR
(95% CI)c

Most proinflammat
ory diet
Ptrenda

Continuous
HR (95%
CI)b

1.14
(0.911.44)

0.28

1.04 (0.971.12)

1.04
(0.821.33)

0.86

1.01 (0.931.09）

E-DII
Q1

E-DII
Q2

E-DII
Q3

E-DII
Q4

E-DII Q5

153

146

159

148

149

53929

53927

53928

53929

53928

1.00

1.02
(0.811.28)

1.14
(0.911.42)

1.08
(0.861.35)

1.00

1.00
(0.801.26)

1.11
(0.891.39)

1.03
(0.821.30)

a

Continuous DII score was used to determine P for trend
The continuous HR and associated 95% CI for one standard deviation increase of E-DII score
c
Adjusted for age at baseline (continuous), sex (male and female), body mass index at baseline
(underweight, normal, overweight, obesity and missing), years of quit and smoking status combined (never
smoked, stopped 10 or more years ago, stopped 5-9 years ago, stopped 1-4 years ago, stopped within last
year, currently smoking, unknown), total energy intake (kcal/d), education level (<=11 years, 12 years or
completed high school, post-high school, some college, college and post graduate, unknown), alcohol
intake (g/day)
b

174

Figure 6.1 Coding of mediator of type-2 diabetes on the association between E-DII
and pancreatic cancer risk in the pooled analysis of the PLCO and NIH-AARP.
Abbreviations: PanC, primary pancreatic cancer; D, mediator variable indicating
incident type-2 diabetes occurrence during follow-up; P, primary pancreatic cancer.
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CHAPTER 7
7
DIETARY INFLAMMATORY POTENTIAL AND PANCREATIC
CANCER RISK: DISCUSSION OF STUDY RESULTS OF
INTERACTION AND MEDIATION ANALYSES IN TWO
PROSPECTIVE COHORTS
7.1

Summary of results
This dissertation aimed to investigate the association between inflammatory

potential of diet and pancreatic cancer in the PLCO Cancer Screening Trial and the NIHAARP Diet and Health Study, and examine important inflammation-related lifestyle
effect modifiers in the association. In the pooled analysis with combined data from the
PLCO and NIH-AARP, we aimed to examine whether incident type-2 diabetes mediated
the association between inflammatory potential of diet and pancreatic cancer using the
causal mediation approach. Generally, we did not observe a significant association
between E-DII and pancreatic cancer after adjusting for confounders in both PLCO and
NIH-AARP cohorts. However, in the PLCO specifically, time (<4 and >=4 years) was
found to be the only significant effect modifier (P-interaction=0.02). Among subjects
with follow up <4 years, there was an inverse association between E-DII and pancreatic
cancer (HRQ5vsQ1=0.55; 95% CI=0.32-0.95; P-trend=0.15), while there was a positive
trend among those with ≥4 years of follow-up (HRQ5vsQ1 =1.36; 95% CI=0.85-2.17; P176

trend=0.03). Similar results were observed for E-DII from food only. In the NIH-AARP,
inflammation-related lifestyle factors including BMI, smoking status, alcohol drinking,
NSAIDs use, and history of diabetes did not modify the E-DII and pancreatic cancer
association. Dietary inflammatory potential was not associated with pancreatic cancer
risk by cancer stage or grade. Both study-specific and pooled mediation analysis using
combined data from both the PLCO and NIH-AARP confirmed the significant though
small mediated effect of incident type-2 diabetes on the association between E-DII and
pancreatic cancer. However, the overall effect of E-DII on pancreatic cancer averaged
over direct and indirect effects with type-2 diabetes as a mediator was not significant.
7.2

Comparisons of dissertation findings with findings from two case-control

studies
Findings from our dissertation did not confirm the significant positive
associations of the E-DII and pancreatic cancer reported in the two previously published
case-control studies.38,39 In both case-control studies, an approximate 2.5-fold increased
risk of pancreatic cancer in the highest compared to the lowest quintile of the E-DII
group was observed (U.S.: ORQ5vsQ1 =2.54, 95% CI=1.87-3.46, P-trend<0.0001;39 Italy:
ORQ5vsQ1=2.48, 95% CI=1.50-4.10, P-trend=0.00238). In addition to the primary
association results, both studies also identified evidence of effect modification by a few
inflammation-related factors including smoking, BMI, and diabetes history. The Italy
case-control study documented evidence of effect modification by smoking status and
BMI where a significant positive association was observed among never and past
smokers but not among current smokers, and among normal and overweight rather than
obese subjects, respectively.38 In the U.S. case-control study, using a joint effect
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approach, Antwi et al. demonstrated that dietary inflammatory potential may act
synergistically with cigarette smoking and diabetes to increase the risk of pancreatic
cancer beyond the risk of any of these factors alone.39 However, this dissertation using
data from two large well-established prospective cohorts in the US consistently
demonstrated the null overall E-DII and pancreatic cancer association and no significant
effect modification by inflammation-related factors, although a significant positive trend
was detected in the PLCO among participants with follow up>=4 years. The major
reasons for the inconsistent results may be owing to the strengths and limitations of the
different study designs utilized. Differential misclassification of exposure is minimized in
a cohort design but is inextricable in a case-control design as a result of recall bias and
selection bias. In addition, due to the high fatality of pancreatic cancer, case-control study
of pancreatic cancer is susceptible to measurement error induced by using proxy’s
responses, which also could distort the association. However, as observed in Aim 1
analyses, although prospective studies measured exposure before outcome occurrence
which may minimize reverse causality bias, such bias can occur in prospective studies
given the unknown latency of pancreatic cancer. In addition, its precursor conditions have
profound effects on digestion, implying that dietary changes may be made at the early
stage of cancer development.
7.3

Potential mechanisms of action
Chronic inflammation has been identified as an underlying pathophysiological

foundation for many chronic diseases, including cancers.407,408 Uncontrolled proinflammatory responses could create a chronic inflammatory state, promoting a tumorfavorable microenvironment that supports the development of genomic mutations and
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potentially triggers immune overactivation and initiation of pancreatic cancer.58,441 The
process for pro-inflammatory cytokines (e.g., tumor necrosis factor, IL-6, IL-11 or IL-22)
to trigger signaling cascades that activate key transcription factors directly or indirectly
which control cell-cycle, cell death, dedifferentiation, stemness, motility, and migration
have gone astray in chronic inflammation.442 In addition, inflammatory states are
etiologically linked to well-recognized risk factors for pancreatic cancer, including
chronic pancreatitis, cigarette smoking, obesity, and diabetes.58,384
Dietary factors could affect cancer risk through modulation of inflammation,385,386
mainly realized through their impact on visceral obesity,387 oxidative damage,78 and
insulin resistance.387 Multiple mechanisms are involved in this process, including
regulation of the pro-inflammatory cytokines, NF-κB pathway activation, changes in
DNA methylation and influence on the antioxidant defense.79,73 Dietary patterns, which
take into account the complex interaction between foods or nutrients, such as Western
type diet and the Mediterranean diet, have been found to affect inflammatory
biomarkers.6,443-445
Pro-inflammatory diets can increase insulin resistance, increase reactive oxygen
species, and influence mediators in the inflammatory pathway (e.g., NF-kB and COX-2),
leading to increased cell cycling, loss of tumor suppressor function, stimulated oncogene
expression, genetic alterations, and modifications of key cancer-related proteins,
ultimately causing malignancy.57,58,418,419 Diets high in red and processed meat may
contain high amount of nitrosamine and nitrate which may cause DNA damage.243 A
recent investigation also found a chemical contributed primarily from red meat
consumption (dietary Nϵ-(carboxymethyl) lysine (CML) glycation end products) had a

179

pancreatic cancer promoting effect.249An anti-inflammatory diet has strong antioxidant
and carcinogenesis inhibition properties, which could help to reduce insulin resistance,
oxidative stress and damage, and inhibit pancreatic tumor development.182,420
There are other lifestyle factors known to be associated with inflammation besides
diet and that may have an effect on pancreatic cancer development. Obesity and diabetes
are inflammatory conditions, and recent data have demonstrated that the plasma
concentration of inflammatory mediators, such as TNF-α and IL-6, are increased in the
insulin-resistant states of obesity and type-2 diabetes.217,385,446 Cigarette smoking has
been shown to augment the production of pro-inflammatory cytokines and decrease the
levels of anti-inflammatory biomarkers.447,448 Chronic alcohol exposure promotes proinflammatory immune responses, and also impairs anti-inflammatory cytokines.449,450 The
pro-inflammatory effects of high-level alcohol drinking also play a major role in the
pathogenesis of pancreatitis.449 Non-steroidal anti-inflammatory drugs (NSAIDs), which
include aspirin, piroxicam, ibuprofen and other COX-2 inhibitors, have shown the ability
to alter systemic inflammation, reduce tumor recurrence and improve moderate cancer
cachexia.235
7.4

Strengths and limitations
This dissertation has several major strengths. The use of two large, well-

characterized prospective cohorts with long follow-up and adequate numbers of
pancreatic cancer cases and incident type-2 diabetes cases provided us with ample power
to test our hypotheses in three aims. In the pooled analyses (Aim 3), the similarities
between the PLCO and NIH-AARP cohorts provided us a strong justification to combine
primary data from these two cohorts to increase outcome and mediator numbers as well
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as take advantage of differences in the distributions of the exposure variable across
studies, in order to better test the mediated effect of incident type-2 diabetes. With diet
and lifestyle factors assessed before cancer diagnosis, recall bias and selection bias that
are inevitable in a typical case-control study were minimized in our research. To the best
of our knowledge, we are among the first to test the dietary inflammatory potential and
pancreatic cancer association in a prospective manner and examine whether inflammatory
potential of diet acted synergistically with other inflammation-related lifestyle factors to
influence pancreatic cancer risk. Using the NIH-AARP, this also is the first prospective
investigation to examine the association between a dietary index and pancreatic cancer
severity. The other strengths included detailed information on a comprehensive list of
covariates which allowed for careful adjustment in the analyses, the use of a constructvalidated dietary index which was designed specifically on the inflammation mechanism
and provided a comprehensive assessment of inflammatory potential of an individual’s
entire diet, and the application of majority of DII components to calculate the E-DII
scores which created a large contrast of exposure. We obtained consistent results from
three aims to support the lack of overall association of E-DII and pancreatic cancer. In all
the mediation analyses of Aim 3, we consistently observed the significant mediated effect
of type-2 diabetes, which suggested type-2 diabetes may play a role as a mediator in the
DII and pancreatic cancer association.
Several limitations should be considered in the interpretation of the results. In
each study, we excluded a substantial number of participants based on exclusion criteria,
but differences of some pancreatic cancer risk factors may exist between excluded and
included participants which may have introduced selection bias and resulted in
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underestimation of the association. The FFQ and other questionnaires used in each study
were prone to measurement error as another unavoidable limitation, which may have
resulted in some misclassification of the E-DII score and covariates. Although follow-up
data were available on most covariates, the large amount of missing information impeded
our ability to use these data. Evaluation of the E-DII at a single time point could result in
non-differential misclassification of exposure given diet may change over time. However,
we previously found DII scores were relatively stable over time in postmenopausal
women who were of comparable ages as our study populations.405 Another limitation of
the study was that not all of the 45 DII components were available in both the PLCO and
NIH-AARP to calculate the E-DII scores. However, the range of DII scores may rely
more on the amount of foods actually consumed rather than the number of available DII
components,406 and a previous study found a significant association between the DII and
colorectal cancer using data from the NIH-AARP,34 suggesting that the smaller number
of DII components would not limit the ability to detect an effect. While we adjusted for
important potential confounders, residual or unmeasured confounding cannot be ruled
out. In the mediation analysis specifically (Aim 3), we cannot rule out the possibility that
the assumption of pooling the primary data may not be fully met in that differences in the
measurement and distribution of covariates (i.e., different questions to obtain data,
different categories of a covariate, different units) and in the number of available DII
components used to calculate the E-DII score were present; however, there was no
method to test the assumptions.429 We also were unable to report some of the mediation
proportion as the NDE and NIE were not in the same direction.
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7.5

Public health implications
Pancreatic cancer has a high case-fatality rate, and due to lack of reliable

screening method for early detection, it is usually diagnosed at an advanced stage with a
very low survival rate. Therefore, identifying modifiable factors, including diet, can help
reduce the burden of this malignancy. Findings from this dissertation had scientific,
clinical, and public health significance.
The null association identified from the PLCO and NIH-AARP between the DII
and pancreatic cancer suggested that the total dietary inflammatory potential may not be a
major contributor to pancreatic cancer risk, which implies that maybe other mechanisms,
other dietary factors, or only a portion of the DII components are associated with
pancreatic cancer. These possible explanations warrant future studies to test and confirm.
Since our studies obtained a null association conclusion with several limitations, future
studies that can overcome these limitations are needed to confirm our results.
Nevertheless, striving toward a more anti-inflammatory diet may have other potential
health benefits beyond pancreatic cancer prevention.
Providing evidence of inflammation-related effect modifiers on the dietary
inflammatory potential and pancreatic cancer relationship is informative to evaluate total
risk of pancreatic cancer while taking into account other common lifestyle factors,
especially for people who have a pro-inflammatory diet such as Western type diet.
However, we did not observe any significant effect modification in the association, which
could be due to the small numbers in some strata or because we only conducted
multiplicative interaction test in the COX model but did not use the joint effect approach
to test the multiplicative and additive interactions. Therefore, our results laid the
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groundwork for future studies without these limitations to confirm our findings. Even if
there is a lack of significant results from statistical tests, that does not actually mean no
biologic interactive effects.
The finding of the significant mediated effect of type-2 diabetes in the association
between dietary inflammatory potential and pancreatic cancer not only elucidated a
mechanism through which dietary inflammatory potential could lead to development of
pancreatic cancer, it also provides clinical evidence and guidance to identify possible
intermediate biomarkers related to type-2 diabetes mechanism such as insulin resistance
in order to indirectly identify high risk population for developing pancreatic cancer,
especially for those who consume a more pro-inflammatory diet. In addition, our findings
could help with the design and guidance of an effective dietary intervention to reduce risk
of pancreatic cancer through intervening on type-2 diabetes.
7.6

Implications for future research
Given the conclusion from the PLCO that time was a significant effect modifier

of the E-DII and pancreatic cancer association, future prospective cohort studies
assessing dietary factors and pancreatic cancer risk should consider differences in
associations by follow-up time. It is possible for future studies to investigate how diet has
been changed in the early period of pancreatic cancer diagnosis. Future large cohort
studies with repeated diet measurements are warranted to confirm our findings in this
dissertation. Studies that have follow-up data missing at a small percentage are also
needed to test our hypotheses and confirm the results. Large cohort studies are needed to
test the effect modification of E-DII and pancreatic cancer by important inflammationrelated lifestyle factors and the association between E-DII and severity of pancreatic
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cancer to confirm our findings in the NIH-AARP. Since age at diagnosis of diabetes
during the follow-up was not measured in a precise way in both the PLCO and NIHAARP, future prospective cohort studies with follow-up type-2 diabetes measured in
more details are needed to test and confirm our mediation analysis findings. Other
possible mediators in the pathway from dietary inflammatory potential to pancreatic
cancer risk may exist. Therefore, future studies could test other possible mediators in the
association and further investigate the relationship between multiple mediators in the DII
and pancreatic cancer association. Given the significant mediator role of type-2 diabetes
in the association between DII and pancreatic cancer, the inclusion of diabetes as a
covariate in future analysis of DII and pancreatic cancer is not recommended.
7.7

Conclusion
Both the PLCO and NIH-AARP did not support a significant association between

inflammatory potential of diet and pancreatic cancer risk. However, in the PLCO cohort,
time significantly modified the E-DII and pancreatic cancer association. An inverse
association between E-DII and pancreatic cancer in the first four years of follow up was
observed, suggesting dietary changes due to undiagnosed disease might have affected
appetite or food choices to lower the E-DII scores in the early stages. A positive
association, as hypothesized, was suggested by a significant trend after excluding
subjects with follow-up time <4years. In the NIH-AARP, inflammation-related lifestyle
factors including BMI, smoking status, alcohol drinking, NSAIDs use, and history of
diabetes did not modify the association. Dietary inflammatory potential was not
associated with pancreatic cancer risk by cancer stage or grade.
In the pooled analysis of the PLCO and NIH-AARP, we identified a significant
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though small mediated effect of incident type-2 diabetes in the associations between both
categorical and continuous DII and pancreatic cancer. The association of inflammatory
potential of diet with pancreatic cancer was fully mediated through incident type-2
diabetes. However, the overall effect of E-DII on pancreatic cancer, averaged over direct
and indirect effect with type-2 diabetes as a mediator, was not significant.
7.8
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